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Abstract 
 
Rare diseases are typically chronic medical conditions of genetic etiology characterized by 
low prevalence and high complexity. Patients living with rare diseases face numerous 
physical, psychosocial and economic challenges that place them in the realm of health 
disparities. Congenital hypogonadotropic hypogonadism (CHH) is a rare endocrine disorder 
characterized by absent puberty and infertility. Little is known about the psychosocial impact 
of CHH on patients or their adherence to available treatments.  
 
This project aimed to examine the relationship between illness perceptions, depressive 
symptoms and adherence to treatment in men with CHH using the nursing-sensitive Health 
Promotion Model (HPM). A community based participatory research (CBPR) framework was 
employed as a model for empowering patients and overcoming health inequities. The study 
design used a sequential, explanatory mixed-methods approach. To reach dispersed CHH 
men, we used web-based recruitment and data collection (online survey). Subsequently, three 
patient focus groups were conducted to provide explanatory insights into the online survey 
(i.e. barriers to adherence, challenges of CHH, and coping/support) 
 
The online survey (n=101) revealed that CHH men struggle with adherence and often have 
long gaps in care (40% >1 year). They experience negative psychosocial consequences 
because of CHH and exhibit significantly increased rates of depression (p<0.001). Focus 
group participants (n=26) identified healthcare system, interpersonal, and personal factors as 
barriers to adherence. Further, CHH impacts quality of life and impedes psychosexual 
development in these men. The CHH men are active internet users who rely on the web for 
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crowdsourcing solutions and peer-to-peer support. Moreover, they are receptive to web-based 
interventions to address unmet health needs.  
 
This thesis contributes to nursing knowledge in several ways. First, it demonstrates the utility 
of the HPM as a valuable theoretical construct for understanding medication adherence and 
for assessing rare disease patients. Second, these data identify a range of unmet health needs 
that are targets for patient-centered interventions. Third, leveraging technology (high-tech) 
effectively extended the reach of nursing care while the CBPR approach and focus groups 
(high-touch) served as concurrent nursing interventions facilitating patient empowerment in 
overcoming health disparities. Last, these findings hold promise for developing e-health 
interventions to bridge identified shortfalls in care and activating patients for enhanced self-
care and wellness.  
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Abrégé  
Les maladies rares sont généralement de maladies chroniques d'étiologie génétique 
caractérisées par une faible prévalence et une haute complexité de traitement. Les patients 
atteints de maladies rares sont confrontés à de nombreux défis physiques, psychosociaux et 
économiques qui les placent dans une posture de disparité et d’inégalités en santé. 
L’hypogonadisme hypogonadotrope congénital (CHH) est un trouble endocrinien rare 
caractérisé par l’absence de puberté et l'infertilité. On sait peu de choses sur l'impact 
psychosocial du CHH sur les patients ou leur adhésion aux traitements disponibles. 
 
Ce projet vise à examiner la relation entre la perception de la maladie, les symptômes 
dépressifs et l'observance du traitement chez les hommes souffrant de CHH. Cette étude est 
modélisée à l'aide du modèle de la Promotion de la santé de Pender (HPM). Le cadre de 
l’approche communautaire de recherche participative (CBPR) a aussi été utilisé. La 
conception de l'étude a reposé sur une approche mixte séquentielle. Pour atteindre les hommes 
souffrant de CHH, un recrutement et une collecte de données ont été organisées 
électroniquement. Par la suite, trois groupes de discussion ont été menées avec des patients 
experts impliqués au sein d’organisations reliés aux maladies rares. Ils ont été invités à 
discuter certains éléments additionnels dont, les obstacles à l'adhésion au traitement, les défis 
généraux de vivre avec un CHH, et l’adaptation à la maladie en tenant compte du soutien 
disponible. 
 
Le sondage en ligne (n = 101) a révélé que les hommes souffrant de CHH ont souvent de 
longues périodes en rupture de soins (40% > 1 an). Ils vivent des conséquences 
psychosociales négatives en raison du CHH et présentent une augmentation significative des 
taux de dépression (p <0,001). Les participants aux groupes de discussion (n = 26) identifient 
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dans l’ordre, les systèmes de soins de santé, les relations interpersonnelles, et des facteurs 
personnels comme des obstacles à l'adhésion. En outre, selon les participants, le CHH impacte 
négativement sur leur qualité de vie générale et entrave leur développement psychosexuel. 
Les hommes souffrant de CHH se considèrent être des utilisateurs actifs d'internet et comptent 
sur le web pour trouver des solutions pour trouver des ressources et y recherchent le soutien 
de leurs pairs (peer-to- peer support). En outre, ils se disent réceptifs à des interventions qui 
sont basées sur le web pour répondre aux besoins de santé non satisfaits. 
 
Cette thèse contribue à la connaissance des soins infirmiers de plusieurs façons. Tout d'abord, 
elle démontre l'utilité de la HPM comme une construction théorique utile pour comprendre 
l'adhésion aux traitements et pour l'évaluation des éléments de promotion de santé qui 
concernent les patients atteints de maladies rares. Deuxièmement, ces données identifient une 
gamme de besoins de santé non satisfaits qui sont des cibles pour des interventions infirmières 
centrées sur le patient. Troisièmement, méthodologiquement parlant, cette étude démontre que 
les méthodes mixtes sont appropriées aux études en soins infirmiers car elles allient les 
nouvelles technologies qui peuvent effectivement étendre la portée des soins infirmiers 
(« high–tech »), et l'approche CBPR par des groupes de discussion (« high-touch ») qui ont 
facilité la compréhension des difficultés que doivent surmonter les hommes souffrant de CHH 
pour diminuer les disparités en santé et augmenter leur responsabilisation dans la gestion de la 
maladie rare. Enfin, ces résultats sont prometteurs pour développer des interventions e-santé 
susceptibles de combler les lacunes dans les soins et l'autonomisation de patients pour une 
meilleure emprise sur les auto- soins et le bien-être. 
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Chapter I: Introduction 
What is a Rare Disease? 
Rare diseases are disorders that affect a small number of individuals. These so-called “orphan 
diseases” are often related to genetic determinants and can be life threatening or may result in 
chronically debilitating disease. These rare conditions pose challenges for patients as well as 
for the healthcare providers who care for them.  
 
There is no universally accepted definition of what makes a disease rare. In the European 
Union (EU), rare is considered as affecting no more than 1 in 2,000 individuals while the 
incidence is set at 1 in 1,250 in the United States (US) (van Weely & Leufkens, 2004). 
Remarkably, the World Health Organization (WHO) estimates that there are approximately 
5,000-8,000 rare diseases and the vast majority are much rarer than either EU or US 
definitions (Remuzzi & Garattini, 2008). Individually these conditions are infrequent, yet the 
cumulative effect is quite large as there are an estimated 30 million European rare disease 
patients, a figure roughly the same as the combined populations of the Netherlands, Belgium 
and Luxembourg (van Weely & Leufkens, 2004).  
 
Despite the differences in how governing bodies have defined rare, beyond low prevalence 
there is a general agreement of common themes related to these rare conditions including 
significant morbidity/mortality, inadequate treatment(s), and insufficient research on these 
disorders. In 1983, the US Congress passed the “Orphan Drug Act” which defined a rare 
disease as disease with a prevalence of <200,000 persons (Asbury, 1991). By this definition, 
there are more than 7,000 rare disorders, affecting, an estimated 25 million persons in the US 
(approximately 10% of the population) (Griggs et al., 2009). This legislation resulted from the 
recognition of the unique challenges faced by patients and families affected by rare diseases; a 
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lot of which are genetic, poorly understood, life-threatening or chronically debilitating, and 
without cure or effective treatment. Because of these combined factors and the low prevalence 
of these diseases, special combined efforts are required for nursing and health care in general 
to address them. 
Impact of Living with a Rare Disease: 
The WHO (2006) defines health as “a state of complete physical, mental and social well-
being and not merely the absence of disease or infirmity” and declares that “the enjoyment of 
the highest attainable standard of health is one of the fundamental rights of every human 
being without the distinction of race, religion, political belief, economic or social condition” 
(page 1) . This reminds us that beyond the statistical criteria defining a disease as rare, there is 
the patient who lives with the disease, and to whom it is a central part of life. Even for those 
rare conditions that may be less severe and not life-threatening, the sense of isolation, 
uncertainty about how the disease will progress, and the lack of effective treatment can have a 
significant impact on attaining the best possible standard of health (Cohen & Biesecker, 2010; 
Institute of Medicine (IOM), 2010; van der Kloot et al., 2010) Accordingly, the impact of 
having a rare condition extends beyond the disease-specific effect on physical health and 
includes affects on psychosocial wellbeing and the socioeconomic implications of having a 
rare disorder (Wastfelt, Fadeel, & Henter, 2006). The general consensus shared by patients 
and health authorities alike is that patients affected by rare diseases are faced with similar 
challenges including: (1) lack of scientific knowledge of their disease, (2) lack of access to 
correct diagnosis, (3) delays in diagnosis, (4) lack of appropriate multidisciplinary healthcare, 
(5) lack of quality information and support at the time of diagnosis, (6) negative social 
consequences, (7) inequities and difficulties in access to treatment, rehabilitation and care, 
(8) dissatisfaction with and loss of confidence in medical and social services and, (9) rejection 
by health professionals (EURORDIS, 2009).  
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The European Organization of Rare Diseases (EURORDIS) utilized existing patient 
organizations to conduct extensive surveys (EurordisCare2 and EurordisCare3) examining the 
experiences of patients with 16 rare diseases across 22 European nations. The results were 
published in a report entitled “The Voice of 12,000 Patients” and revealed a number of 
poignant observations such as the following. In order to arrive at an accurate diagnosis, 18% 
of patients reported often having to seek out answers on their own, with little help from the 
health-care system and 25% stated they had to wait more than 3 years for the correct 
diagnosis. Notably, 41% of patients were initially misdiagnosed, 7% of whom were told that 
their condition was psychosomatic. Further, when a proper diagnosis was identified, 35% of 
patients felt the method of communicating the diagnosis was unsatisfactory (i.e. having 
information given in hospital corridors, by telephone, or in writing alone). Overall, these 
experiences led to an erosion of confidence in the healthcare system as reported by 19% of 
survey participants. Additionally, nearly 1 in 5 patients (18%) stated having experienced 
rejection by a healthcare professional because of the complexity of the rare disease or its 
associated symptoms (EURORDIS, 2009).  
 
The EURORDIS report supports the notion that there is insufficient access to information and 
medical or nursing expertise in relation to rare diseases. Patients and families struggle to get 
appropriate healthcare with 26% reporting difficulty or inability to access care and services 
including lack of appropriate referral. Further, rare diseases and chronic and care often 
requires a multidisciplinary approach involving different medical services which patients 
report as often being poorly coordinated (EURORDIS, 2009). Disenfranchised by the rare 
nature of their diseases and the frustration with the healthcare system, many patients and 
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families express a desire to connect with others with a rare disease, either the same of a 
different condition (Huyard, 2009).  
Technology Connects Patients with Rare Diseases: 
For patients with rare diseases, finding disease specific information and creating community 
with others like themselves is daunting given the dispersed nature of specialized referral 
centers and affected individuals/families. However, over the past 30 years, advances in 
telecommunications have dramatically changed the way people seek and consume 
information (Lober & Flowers, 2011). The first personal computers were introduced in the 
early 1980s and the 1990s witnessed the dawning of the internet. Many users were drawn to 
the internet following the introduction of electronic mail (e-mail) in the early 1990s and 
virtual communities grew as online access became faster and more widely available. Indeed, 
internet hosts grew in number from approximately 9 million in 1995, to over 100 million by 
the late 2000s (Lober & Flowers, 2011). The increased internet access and more widely 
available hot-spots for wireless connection paralleled the development of mobile devices and 
the increased use of laptop computers, internet capable cellular phones, and small tablet 
devices (Figure 1).  
 
Figure 1. Advances in information and telecommunications technology.   
 
Introduction of significant products and services are depicted by arrows above the timeline.  
The gray arrows below the timeline denote trends including introduction of the internet the 
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increasing availability to internet access/wireless hot-spots and the emergence of internet 
enabled social networking. 
This evolving technology has both increased access to information and has facilitated new 
modes of communication. For rare disease patients, the ability to connect over vast distances 
has created a perceptual shift. The New York Times columnist Thomas L. Freidman, wrote 
about the change brought about in part by the internet referring to it as a “flattening of the 
world” (Freidman, 2005) wherein people have access to unprecedented amounts of 
information and potential for connectivity around the globe. This new media allows dispersed 
people to create virtual communities via social networks, bringing together people who would 
otherwise never meet face-to-face enabling interactivity and “crowdsourcing”, or taking 
advantage of the combined knowledge, talents, and problem solving abilities of a group 
(Howe, 2006). These so-called communities of knowledge, communities of practice or 
communities of sharing have simultaneously spread in the health care and nursing sectors. 
 
These technologic advances have been embraced by the rare disease community as evidenced 
by the 2011 Pew Report on the use of internet in peer-to-peer healthcare (Fox, 2011). In a 
survey of over 3,000 adults living in the US, the Pew Report demonstrated that one in almost 
five (18%) of internet users have gone online to find others who share similar health concerns. 
Further, while most people taking part in this survey turn to a healthcare professional such as 
a doctor or nurse for technical information, non-professionals and peers were favored for 
emotional support in dealing with a health issue and for seeking answers related to everyday 
health issues. Professionals and non-professionals were considered equally important for 
advice in coping with day-to-day health situations. A second part of this study included an 
internet survey of more than 2,000 individuals affected by a rare disease. The study identified 
individuals with chronic conditions or rare diseases as the most likely to augment professional 
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medical advice with online peer-to-peer connections. Further, patients and caregivers of those 
living with a rare disease reported drawing upon their peer network during their time of need 
even more so than those with a more common chronic health condition (Fox, 2011).  
Rare Diseases: Getting Organized  
As depicted in “The Voice of 12,000 Patients”, patients and families affected by rare diseases 
face challenges in finding accurate information about their condition and in accessing 
appropriate care (EURORDIS, 2009). Within the crucible of rare diseases, patients and 
families have begun to utilize technology and social media to expand their support network 
and cope with the unique challenges they face in dealing with exceedingly uncommon 
medical conditions. When the Orphan Drug Act was passed in 1983, there were relatively few 
rare disease patient organizations. However, working collectively, they provided crucial 
advocacy which promoted the passage of the landmark legislation. Shortly thereafter, the 
National Organization for Rare Disorders (NORD) was formed (Putkowski, 2010). It was one 
of the first organizations to promote awareness of rare diseases and providing public policy 
advocacy, patient friendly information and assistance programs.  
 
In 1986, the Genetic Alliance was established to focus attention on groups promoting 
advocacy for genetic conditions. In 1997, the EURORDIS created an alliance of patient 
associations committed to improving the quality of life of all those living with rare diseases. 
EURORDIS has been a leader in advocating for the European Regulation of Orphan Drugs 
(Parliament, 1999) and the forming of the European Union Committee of Experts on Rare 
Diseases (EUCERD) which develops and monitors programs to provide quality care for 
patients with rare diseases. Projects include developing European reference networks for rare 
diseases, promoting cross border healthcare to improve access to quality care for rare disease 
patients, improving the visibility and promoting awareness of rare diseases via the Orphanet 
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database, improving coding and classification of rare diseases including revisions to the 
International Classification of Diseases (ICD), improving better access to orphan drugs, and 
pooling European expertise on rare diseases, and developing metrics and health indicators for 
rare diseases (Holmes, 2012).  
 
Such groups have been critical in making rare diseases a growing priority for healthcare 
providers, public health authorities, and policy makers alike (Figure 2).  
 
 
Figure 2. Timeline of legislation and organizations related to rare diseases. The establishment 
of organizations and key programs related to rare diseases are depicted by arrows above the 
timeline.  Seminal legislative acts related to rare diseases are noted by arrows below the 
timeline.  The star depicts the first International Rare Disease Day. 
Inequalities for People Living with Rare Diseases 
Though rare diseases are numerous in total, the rarity of the individual conditions can result in 
patients and families feeling marginalized and the psychosocial impact of perceived 
invisibility, isolation, and feelings of powerlessness can have tremendous deleterious impact 
on quality of life (Cohen & Biesecker, 2010; Huyard 2009; Nettleton, Watt, O’Malley, & 
Duffy, 2005). While the adoption of several legislative acts have benefitted patients and 
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families affected by rare diseases (Figure 2), a confluence of conditions create disparity in 
access to quality care and in allocation of social support of rare diseases.  
 
Firstly, people with rare diseases have difficulty in finding diagnostic expertise causing delays 
in diagnosis and receiving quality care (Schieppati, Henter, Daina, & Aperia, 2008). 
Secondly, most rare diseases are genetic and have no identified cure creating an unusually 
high stress and burden on family and children at risk to inheriting the condition (Aubeeluck & 
Moskowitz, 2008). Thirdly, a universally acknowledged coding system is lacking to properly 
identify patients, enable international registries, thus preventing accurate assessment of the 
economic and social consequences associated with rare diseases. The development of novel 
therapies is inhibited by a lack of profit potential and payback for investment in drug 
development (Scheindlin, 2006), researchers and clinicians face both funding and training 
challenges in pursuing careers related to rare diseases (Griggs et al., 2009; Hampton, 2006), 
and attempts to establish best practices or evidence based strategies are hindered by small 
samples sizes and recruitment problems related to dispersed population (Kruer & Steiner, 
2008; Watson et al., 2008). Further, patients with rare diseases also face economic challenges 
related to chronic care needs as they often require frequent medical care related to long-term 
health problems, available treatments are often prohibitively expensive and there is significant 
concern regarding discrimination related to employment and health insurance (Bombard et al., 
2008; Penziner et al., 2008). As such, the physical, psychosocial and economic impact of 
living with a rare disease is to be viewed as a social determinant of health disparity 
(Holtzclaw Williams, 2011). Because of these inequalities, these patients can be characterized 
as underserved and vulnerable populations. However, little is known about what kind of 
approaches to care or nursing services these patients find most important and wish for. 
9 
 
Challenges to Health and Empowerment in Rare Diseases 
Patients affected by rare diseases are a community that faces numerous challenges to 
wellbeing. If we accept the WHO delineation of health as an inalienable human right, then by 
logical extension, we must also strive to remove disparities and seek to attain equality and 
health for all people (Starfield, 2007). Marginalized and disenfranchised communities often 
lack the power to take action to remove barriers in their lives. Accordingly, powerlessness is 
an acknowledged negative determinant of health (Wallerstein, 1992). To remove barriers and 
facilitate health requires empowerment, i.e. the process by which people individually or/and 
collectively gain control over the factors and transform decisions creating desired outcomes 
that shape their lives (WHO, 2009). Empowerment has been acknowledged as a critical 
component of shared decision making process, patient-centered care, and achievement of 
better health outcomes (Maizes, 2009; Stewart et al., 2000). Given the unique challenges 
faced by patients with rare diseases, from a nursing perspective, empowerment becomes a 
central issue for this community of patients (Ayme, Kole, & Groft, 2008).  
The Social Cost of Rare Diseases 
The past 30 years has witnessed the growing voice of patients in many disease-related 
experiences and the emergence of the patients’ movement which has led to the growing 
recognition that specifically, rare diseases are not only a medical issue, but an important 
social issue as well. The patients’ movement emerged from the recognition that patients are a 
distinct group of individuals facing similar obstacles who share common experiences. Further, 
the patients’ movement is based on the notion that patients have a knowledge base that is both 
distinct and separate from health professionals, and that patients are entitled to a legitimate 
say in making the decisions around their condition (Ayme et al., 2008). Activated patients 
have played important roles in drawing attention to rare disease issues and the legislation and 
increased government funding of rare disease initiatives emerged from the combined activities 
10 
 
of patient advocacy groups, academia (including the basic science and translational research 
investigators from universities and academic medical centers), and politicians (Figure 2). 
Indeed, the EURORDIS, Orphanet, and the European Commission projects (Orphanet, 2005) 
have helped raise awareness of the social justice issues related to rare diseases (Schieppati et 
al., 2008). As part of the patients’ movement, patients and families have embraced technology 
and emerging social media as a way to combat the marginalizing effects of being diagnosed 
with a rare disease by drawing on each other for both emotional support, experiences, and 
information (Denecke, 2009). This support system has helped patients and families affected 
by rare diseases become more engaged with the healthcare system and to take a more active 
role in the health-related decision making process (Ayme et al., 2008).  
 
This activism has addressed the lack of effective treatment for many rare diseases. Advocacy 
groups have spurred calls for international collaboration between governments and industry 
stakeholders to accelerate the pace of translational research discoveries by engaging patients 
and establishing patient registries to facilitate recruitment into clinical trials and help speed 
the process of brining novel therapies to market (Griggs et al., 2009; Kruer & Steiner, 2008; 
Watson et al., 2008). Additionally, political action has identified rare diseases as a growing 
priority (Figure 2) and legislation enacted in the US and EU to remove some of the financial 
disincentives related to rare disease drug development has helped entice investment from the 
pharmaceutical industry to develop rational new therapies and facilitate collaboration of a 
higher order. The landmark Orphan drug act (1984) also designated conditions as “rare” in the 
event that there is little expectation to recoup costs for developing and bringing to market a 
drug for a condition with limited number of effected individual.  Since approval, more than 
110 pharmaceutical companies in the U.S. have received marketing approval from the Food & 
Drug Administration (FDA) for an orphan product and a number biotechnology companies, 
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such as Genentech, Amgen, and Genzyme, had an orphan drug as their first product to receive 
market approval (Haffner, Whitley, & Moses, 2002). Legislation has changed the pace at 
which orphan drugs are brought to market. In the 10 years prior to the passing of the 1983 
Orphan Drug Act, only 10 treatments for rare diseases received FDA approval in contrast to 
the 280 receiving approval in the 14 years following the adoption of this legislation (Haffner, 
2006). Attention to rare diseases has changed over the past decades, yet with an estimated 250 
new rare diseases being identified each year (Wastfelt et al., 2006), much work remains to be 
done.   
 
In summary, patients affected by rare diseases represent a broad and diverse group of 
individuals and each rare condition has its own and unique set of health and social challenges. 
Accordingly, it is poignant to consider that in order to strive for a level of health (and 
healthcare) to which all should be entitled, these patients had little choice but to become 
amongst the most active and empowered members of the broader health community 
(EURORDIS, 2009). Patients, families, and advocacy groups have made tremendous strides 
in raising the awareness about rare diseases, and they have been joined by clinicians, 
academics, members of industry, and politicians alike in beginning to address the inequalities 
and health disparities faced by this community. Each of these groups has recognized on some 
level that patients affected by rare diseases do not exist in isolation, rather, rare diseases 
impact families, communities, the health care system, and the health care financing. The 
healthcare professionals such as nurses who care for these patients are often reminded of the 
gap between patient needs and our inability to address and meet these needs. Thus, the 
background reviewed to this point suggests that patients with rare diseases are faced with 
many unique challenges and that the approaches applied to date have been insufficient in 
addressing the needs of these patients.  
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The Role of Nursing in Rare Diseases Using a Health Promotion Perspective 
In a very broad sense, nursing involves working with individuals, families, and communities 
to create optimal conditions for the highest attainable level of health and well-being. Nursing 
interventions address physical, emotional, and spiritual needs of patients to promote goal-
directed actions, self-care, and satisfying relationships with others in striving for the highest 
attainable level of health. Nursing promotes coping, self-care, and adaption in meeting 
physiologic and relational needs, while maintaining emotional/spiritual integrity and 
supporting a positive self concept and an intact identity (Pender, Murdaugh, & Parsons, 
2010). This definition is regardless of current health status.  
 
Also, nursing and social justice are connected through a lengthy history dating back to 
Florence Nightingale, who is credited as the founder of modern professional nursing 
(Manthey, 2008). Nightingale’s approach to nursing is explicated in 1855 in her book “Notes 
on Nursing: What it is and what it is not” from which emerge the humanistic tenets of nursing 
including respect, care, and empowerment (Nightingale, 1992). Indeed, Nightingale 
recognized existing power structures, in her case between the nurse/carer and the patient, and 
comments on the importance of not talking “to” or “at” patients, but rather speaking “with” 
them. This goal oriented advice, aimed at deconstructing power-based barriers, mirror the 
writings of Paolo Freire, who described the concept of powerlessness over a hundred years 
later (Freire, 1970).  Freire used this term to describe when the individual assumes a passive 
role as an object, rather than an active subject, acting on the environment (Freire, 1970). 
Nightingale’s writings on respect for patients and nursing actions aimed at eliminating 
barriers provide a historical link between empowerment and nursing.  
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Importantly, an element that separates nursing from other health professionals is that nursing 
is not solely focused on ameliorating the illness but also is focused on the patient’s reaction to 
illness. The holistic, patient-centered approach of nursing provided in the context of the 
Health Promotion Model can therefore be utilized to: i) identify the unmet bio-psycho-social-
spiritual needs of patients with rare diseases, ii) identify the perceived barriers to health, and 
iii) develop targeted interventions and empowering patients to adopt health promoting 
behaviors. This holistic view has relevance for patients with rare diseases as it places the 
definition of health in the context of the individual - including those faced with severe 
disability or facing a life threatening illness. 
 
In summary, nursing’s role in addressing the needs of patients and families affected by rare 
diseases is relevant because the humanistic approach that nursing brings is at once 
empowering, and can be transformative by its very nature. It is so for rare diseases which are 
often genetic conditions that are poorly understood and often are without cure or effective 
treatment and have significant impact on patients and families. These are considered as 
chronic conditions that require care throughout life and nursing has played in important role 
in chronic disease management (Bodenheimer, MacGregor, & Stothart, 2005). Further, as 
nursing interventions have been effective in addressing health disparities as well as closing 
the gaps, cracks and shortfalls in the continuity of care for patients with chronic conditions, it 
would follow that nursing can make important contributions that will positively impact 
patients and families affected by rare diseases. Herein, the nursing’s Health Promotion Model 
has been considered the most useful for understanding and addressing the unmet needs of 
patients with rare diseases (Pender, Murdaugh, & Parsons, 2010).  
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Research General Objective 
Given these elements, this research project aims to examine the unmet health needs of patients 
with the specific rare condition of congential gonadotrpin-releasing hormone (GnRH) 
deficiency (resulting in congenital hypogonadotropic hypogonadism, CHH) using the nursing 
framework of Pender’s Health Promotion Model (Pender, Murdaugh, & Parsons, 2010). This 
nursing-based needs assessment study is the needed step to develop a program of innovative 
nursing interventions to enhance health promoting behaviors and to develop patient-focused 
approaches to care in order to improve nursing sensitive and health-related outcomes.  
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Chapter II: Literature Review 
 
The focus of this literature review is threefold: i) to provide an extensive presentation of the 
rare disease, congenital GnRH deficiency (CHH) presenting the clinical portrait and the 
pathophysiological characteristics of the disease as well as describing its impact on patients 
and families; ii) to describe the types of care programs that have been developed for such 
patients and carefully scrutinize the nursing components of these programs, as well as their 
expected or measured outcomes; and iii) to evaluate the framework of Pender’s Health 
Promotion Model in relation to roles nursing plays in empowering patients via education, 
advocacy, enhancing coping, developing self-care skills, and building self-efficacy.  
 
Therefore, the first search strategy used the keywords (synonymous terms) related to the 
condition such as “congenital GnRH deficiency”, “Kallmann syndrome”, “idiopathic 
hypogonadotropic hypogonadism”, and “isolated GnRH deficiency” upon which additional 
search terms “genetics”, “phenotype”, and “treatment” were mapped in order to identify 
relevant publications related to congenital GnRH deficiency. This NCBI PubMed search was 
narrowed using the filters past 10 years, humans, and English language yielding a total of 331 
publications (Appendix 1). After careful review, 65 citations were included in the literature 
review of congenital GnRH deficiency because of their high relevance, impact, and 
timeliness. Additionally, references of the selected articles were reviewed and historically 
important and seminal publications in the field were also included. 
The second search strategy investigated the types of care programs and nursing interventions 
used in this patient population. Searches of the NCBI PubMed, CINAHL, and PsychINFO 
databases were used to retrieving the best possible up-to-date evidence from the past 10 years 
(2002-2012). Multiple MeSH and free-word searches were performed combining disease 
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synonyms (i.e. “congenital GnRH deficiency”, “Kallmann syndrome”, “idiopathic 
hypogoandotropic hypogonadism”, and “isolated GnRH deficiency”) that were focused using 
Boolean syntaxes combined with the MeSH and free-word terms “nursing”, “intervention”, 
“needs assessment”, “patient centered”, “self care”, “adherence”, “medication”, “patient 
compliance”, “attitude to health” (Appendix 2). This wide search failed to yield any relevant 
publications. Accordingly the search was expanded by broadening the disease term to include 
“hypogonadotropic hypogonadism” a less specific MeSH term encompassing the condition 
yielding 282 citations. The vast majority of which related to age-related hypogonadism, 
however after careful scrutiny, 5 citations (including studies of patients with Klinefelter 
syndrome, and review articles on androgen therapy) were deemed relevant and were included. 
As congenital GnRH deficiency is a rare, genetic, reproductive endocrine disorder “rare 
disease” was also explored to seek additional relevant citations (n= 297) and after careful 
review identified 18 relevant citations. Lastly, additional relevant citations were sought using 
the MesH term “endocrine system diseases” that identified nearly 2,000 citations and as such 
additional filtering was needed to obtain a more reasonable list of potentially relevant 
citations (Appendix 2). In the final analysis 30 of these were included.  
 
In summary, no relevant care programs were identified specifically for congenital GnRH 
deficiency, and the articles retrieved for rare diseases primarily related to three central 
themes: empowerment, disparities, and multidisciplinary teams for care. In contrast to the 
very rare endocrine disorder of congenital GnRH deficiency, diabetes mellitus is a relatively 
common endocrine disorder yet both require chronic care. Due to the growing incidence and 
significant morbidity associated with type 2 diabetes a great deal of attention has been 
focused on this area. Therefore, I examined chronic care programs targeted at improving 
chronic care for diabetes to explore nursing’s role on providing comprehensive 
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interdisciplinary care and to identify successful models that could be applicable to patients 
with rare, chronic diseases. Lastly, a review of the literature identified 21 relevant citations 
form the past 10 years relating to Pender’s Health Promotion model. References cited in these 
publications were reviewed to include additional relevant citations as well as Pender’s most 
recent textbook explicating the HPM. 
Clinical Portrait of Congenital GnRH Deficiency 
Congenital GnRH deficiency is a genetic disorder which is clinically characterized by 
incomplete/absent puberty and infertility. Because it is a rare condition, incidence is difficult 
to assess (Seminara, Hayes, & Crowley, 1998) with published estimates range from 1 in 4,000 
to 10,000 in a study of French conscripts (Fromantin, Gineste, Didier, & Rouvier, 1973), to 
1/86,000 in a Sardinian military study (Filippi, 1986). Additionally, it is 2-5 times more 
frequent in males than females (Hu, Tanriverdi, MacColl, & Bouloux, 2003; Quinton et al., 
2001; Seminara et al., 1998). Most cases are sporadic, keeping with a condition which impairs 
fertility, yet approximately a third of cases display a familial pattern of inheritance (Quinton 
et al., 2001; Seminara et al., 1998). Congenital GnRH deficiency is clinically heterogeneous 
and may occur with variable reproductive and non-reproductive phenotypes. One such 
characteristic, the sense of smell, differentiates congenital GnRH deficiency into two the 
variants. Some patients exhibit a normal sense of smell while others have impaired olfaction 
with a poor or absent sense of smell (anosmia) – termed Kallmann syndrome (KS). Olfactory 
acuity exists on a spectrum with approximately a third of patients being anosmic (31.5%), 
hyposmic (33.6%), or normosmic (34.9%) (Lewkowitz-Shpuntoff et al., 2012). Interestingly, 
this subtle clinical finding provides clues into the pathopysiology of this rare cause of 
infertility.  
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Pathophysiology of Congenital GnRH Deficiency 
Reproductive fitness is a fundamental component of species survival and puberty is a critical 
developmental process leading to fertility. In higher vertebrates and mammals, reproductive 
capacity is an endocrine function driven by the coordinated action of the hypothalamic-
pituitary-gonadal (HPG) axis. Pulsatile secretion of GnRH from the hypothalamus stimulates 
the release luteinizing hormone (LH) and follicle stimulating hormone (FSH), collectively 
referred to as gonadotropins, from the anterior pituitary (adenohypophysis) which enter the 
bloodstream and circulate peripherally, stimulating sex steroid production and gametogenesis 
in the gonads. The so-called pilot light of reproduction is GnRH, a decapeptide produced by a 
relatively small population of neurons in the hypothalamus (Balasubramanian et al., 2010). 
During embryologic development, these GnRH neurons undergo a remarkable migration from 
the rudimentary nose (olfactory placode) along olfactory nerves across the base of the skull 
(cribriform plate) into the forebrain (arcuate nuceus) where they aggregate and secrete GnRH 
in a coordinated fashion (Wray, 2010). This developmental link between the reproductive and 
olfactory system observed in Kallmann syndrome was first noted in 1856, by Maestre de San 
Juan who documented this association in a patient with absent olfactory bulbs and 
hypogonadism (Maestre de San Juan, 1856). His seminal observation was followed by Franz 
Kallmann in the 1940s, who reported 3 affected families with anosmia and hypogonadism 
(Kallmann, 1944) as well as by noted Swiss anatomist, Georges de Morsier, who reported on 
“dysplasia olfactogenitale” (de Morsier, 1963). 
 
Each of these early investigators noted findings indicating that disruption of GnRH neuron 
ontogeny can underlie problems of puberty and reproduction. Adding further complexity to 
the neuroendocrine control of reproduction is the fact that the activity of the HPG axis varies 
across development (Bianco & Kaiser, 2009). The axis is driven in utero by maternal 
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hormones and then is active in a brief neon-natal window referred to as mini-puberty 
(Grumbach, 2005) prior to falling into a quiescent period during childhood. Then, puberty is 
initiated with a re-activation of the HPG axis. This initially occurs with sleep-entrained GnRH 
pulses (Boyar et al., 1974). As puberty progresses, these nocturnal episodes lengthen into 
daylight hours and ultimately occur around the clock. However, there is wide variation in the 
timing and onset of puberty and it is under the influence of numerous environmental and 
genetic influences (Nathan & Palmert, 2005). Disruption of this developmental of this GnRH 
network can result in congenital hypogonadotropic hypogonadism (CHH) and failure to 
initiate puberty (Bianco & Kaiser, 2009). As such, the term CHH can be used to encompass 
both normosmic and hyposmic/anosmic forms of GnRH deficiency while differentiating it 
from other GnRH deficient states such as functional causes of hypogonadotropic 
hypogonadism or constitutional delay of growth and puberty (Palmert & Dunkel, 2012). 
 
To date more than a dozen different genes have been identified in association with CHH 
(Bouligand et al., 2009; Chan et al., 2011; Y. M. Chan et al., 2009; Clement et al., 1998; Cole 
et al., 2008; de Roux et al., 2003; de Roux et al., 1997; Dode et al., 2003; Dode et al., 2006; 
Falardeau et al., 2008; Fischer-Posovszky et al., 2010; Franco et al., 1991; Gianetti et al., 
2010; Hanchate et al., 2012; Hardelin et al., 1992; Jongmans et al., 2009; Kim et al., 2010; 
Kim et al., 2008; Layman et al., 1998; Legouis et al., 1991; Miura, Acierno, & Seminara, 
2004; Muscatelli et al., 1994; Pitteloud et al., 2006; Pitteloud et al., 2007; Seminara et al., 
2003; Topaloglu et al., 2009; Topaloglu et al., 2012; Tornberg et al., 2011; Trarbach et al., 
2010; Young et al., 2012; Zanaria et al., 1994) (Table 1).   
 
However, despite these advances only approximately 65% of cases can be explained by 
known genetic loci (Sykiotis et al., 2010). 
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Table 1 
Genetic loci associated with CHH 
gene 
year 
identified 
references 
KAL1 1991 Franco et al., 1991; Legouis et al., 1991; 
Hardelin et al., 1992 
NROB1 (DAX1) 1994 Muscatelli et al.,1994; Zanaria et al., 1994 
GNRHR 1997 de Roux et al., 1997; Layman et al., 1998  
LEPR 1998 Clement et al., 1998 
KISS1R (GPR54) 2003 de Roux et al., 2003; Seminara et al., 2003 
FGFR1 2003 Dode et al., 2003; Pitteloud et al., 2006 
NELF 2004 Miura et al., 2004; Pitteloud et al., 2007  
PROK2 2006 Dode et al., 2006; Cole et al., 2008 
PROKR2 2006 Dode et al., 2006; Cole et al., 2008 
FGF8 2008 Falardeau et al., 2008; Trarbach et al., 2010 
CHD7 2008 Kim et al., 2008; Jongmans et al., 2009 
TAC3 2009 Topaloglu et al., 2009; Gianetti et al., 2010 
TAC3R 2009 Topaloglu et al., 2009; Gianetti et al., 2010 
GNRH1 2009 Bouligand et al., 2009; Chan et al., 2009 
LEP 2010 Fischer-Posovszky et al., 2010 
WDR11 2010 Kim et al., 2010 
HS6ST1 2011 Tornberg et al., 2011 
KISS1 2012 Chan et al., 2011; Topaloglu et al., 2012 
SEMA3A 2012 Hanchate et al., 2012; Young et al., 2012 
 
 
Characteristics and Sequelae of CHH 
In addition to being a rare disorder characterized by genetic heterogeneity, CHH is also 
clinically variable in presentation (Table 2). It exists on a spectrum of disease severity from 
the so-called fertile eunuch phenotype (Pitteloud et al., 2001) to cases of  
spontaneous reversal (Raivio et al., 2007) to significant congenital anomalies including cleft 
lip/palate (Molsted, Kjaer, Giwercman, Vesterhauge, & Skakkebaek, 1997) and severe 
syndromic cases (Ballabio et al., 1989). The medical management of CHH primarily focuses 
hormonal therapy to induce secondary sexual characteristics and if desired, fertility. Cases of 
spontaneous reversal in both severe and mild forms of CHH  
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Table 2 
Phenotypes associated with (CHH) 
young looking                                 
(age > appearance) 
anosmia/hyposmia 
cleft lip/cleft palate                     
(also high, arched palate) 
eye anomalies                                     
(i.e. coloboma, 
oculomotor problems) 
ear anomalies                               
(i.e. malformed 
auricles) 
sensorineural                                     
hearing loss 
dental agenesis                  
(hypodontia) 
cryptorchidism                        
(unilateral or bilateral) 
microphallus 
digit anomalies                                
(i.e. clinodactyly, 
syndactyly) 
synkinesia                                 
(mirror movements) 
renal agenesis 
obesity 
skeletal problems                          
(i.e. scoliosis) 
osteopenia/osteoporosis 
Note: Mitchell et al., 2011 
 
have been reported in the literature (Cole et al., 2008; Pitteloud et al., 2005; Raivio et al., 
2007; Raivio et al., 2009; Tornberg et al., 2011). It is estimated that approximately 
 10% of patients will be undergo a reversal (Raivio et al., 2007) yet there are no identified 
predictors to date. Further, as this is a relatively recently reported phenomenon, it not yet well 
understood and we do not know if these patients may revert to hypogonadal states. As such, 
the vast majority of patients diagnosed require lifelong hormone therapy (Han & Bouloux, 
2010; Young, 2012).  
 
Treatment can have clinical importance beyond the reproductive years, as sex steroids (i.e. 
testosterone and estradiol) play important roles in bone mass formation and preservation. 
Because CHH patients lack the surge of gonadotropins and increased sex steroid levels of 
puberty, they lose out on a critical period of bone formation and are at increased risk for 
developing osteoporosis (low bone density). With appropriate long-term hormone treatment 
this heightened risk for fractures can be ameliorated (Dode & Hardelin, 2009; Seminara et al., 
1998; Waldstreicher et al., 1996; Young, 2012). However, if untreated or if treatment is 
stopped, patients rapidly become hypogonadal (with very low sex steroid levels) which is a 
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risk factor for osteoporosis in both men and women (Finkelstein et al., 1987; Potap et al., 
1987; Laitinen et al., 2012).  
 
Additionally, for CHH men, androgen therapy (i.e. testosterone replacement) has well-
documented beneficial effects on maintaining muscle and fat-free (lean) body mass (Bhasin et 
al., 1997; Wang et al., 2004). Further, several meta-analyses have demonstrated an association 
between low serum testosterone levels and the metabolic syndrome and diabetes (Ding et al., 
2006, Coronoa et al., 2011; Brand et al., 2011). Further, acute withdrawal of treatment from 
CHH men induces increased fasting insulin levels and insulin resistance within two weeks 
(Yialamas et al., 2007). Thus, lack of or inadequate androgen replacement may place CHH 
men at increased risk for developing the metabolic syndrome and potential cardiovascular 
morbidity. As such, adequate treatment and close monitoring is warranted to limit these 
potential sequelae (Laitinen et al., 2012)..  
 
Diagnosis and treatment of CHH 
The first issue on treating CHH is obtaining an accurate diagnosis. By definition, CHH 
involves abnormally low levels of serum gonadotropins (LH & FSH) as well as low sex 
steroids (testosterone [T], estradiol [E2]) and may result from either abnormal GnRH release 
from the hypothalamus or by defective responsiveness of the pituitary gonadotpropes (Bianco 
& Kaiser, 2009; Brioude et al., 2010; Mitchell, Dwyer, Pitteloud, & Quinton, 2011). Broadly 
CHH patients fall into three categories, about 51% are normosmic, 39% have disturbed 
olfaction or no sense of smell (KS), and the remaining 10% have syndromic forms of the 
disorder (Young, 2012). Syndromic forms are often identified in pediatric settings as the signs 
are evident prior to pubertal onset and may include other metabolic or endocrinopathies, 
neurologic problems, and/or congenital malformations (Farooqi et al., 2007; L. Lin et al., 
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2006; Netchine et al., 2000; Pinto et al., 2005; Reynaud et al., 2006; Rottembourg et al., 
2008). However, a hallmark characteristic of CHH is incomplete-absent puberty and the 
primary differential diagnosis for this rare disorder is the relatively common diagnosis of 
constitutional delay of puberty, which is simply an extreme variant of the normal timing and 
onset of puberty (Nathan & Palmert, 2005; Palmert & Dunkel, 2012; Sedlmeyer & Palmert, 
2002). As such, many CHH adolescent males presenting with abnormal pubertal development 
(i.e. absent puberty after 14 years of age) may be missed as the clinical presentation is 
assumed to be a variant of pubertal timing or delayed puberty. Indeed, labeling patients as 
“late-bloomers” may be a key reason why the vast majority of CHH patients experience 
delays in diagnosis and frequently present to adult providers as adults with complaints of 
aberrant puberty and hypogonadotropic hypogonadism (Young, 2012). This delay in receiving 
an accurate diagnosis is not uncommon in rare diseases (EURORDIS, 2009) yet the 
consequences can be psychologically and emotionally crippling for patients who are 
essentially adults living in a preadolescent body.  
 
Further complicating the timely and accurate diagnosis is the fact that CHH is a diagnosis of 
exclusion, meaning that the clinician must “rule-out” other potential causes (Table 3) via 
clinical examination, biochemical profiling, radiologic studies, and dynamic endocrine testing 
(Young, 2012). This process can be lengthy and unsettling for patients, yet once the proper 
diagnosis is reached there are a number of effective treatments for CHH. Based on goals for 
treatment, therapeutic options for both male and female CHH patients falls into one of 2 
categories; sex steroid replacement to induce secondary sexual characteristics or hormonal 
treatment to induce fertility. As this project focuses on CHH males, a brief overview of 
available treatment options is provided. 
 
24 
 
 Table 3 
Differential diagnoses and rule-out causes of GnRH deficiency 
Acquired Forms Syndromic Causes 
central nervous system tumor CHARGE syndrome 
Pituitary apoplexy Prader-Willi syndrome 
head trauma Bardet-Biedl syndrome 
Radiation                           
(brain/pituitary) 
combined pituitary                 
hormone deficiency 
medication-induced septo-optic dysplasia 
 leptin deficiency/resistance 
Functional causes Systemic diseases 
malnutrition/malabsorption hemochromatosis 
eating disorders sarcoidosis 
hypothyroidism histiocytosis 
hyperprolactinemia  
diabetes mellitus  
Cushing’s disease  
Note: King & Hayes, 2012: Pallais et al., 2010; Young 2012 
 
Treatment to induce normal changes of puberty 
Inducing secondary sexual characteristics in males is achieved via testosterone replacement 
therapy (TRT) which is available in a variety of forms (Table 4) (T.S. Han & P.M. Bouloux, 
2010). TRT induces a number of changes which are normally evident in puberty including 
increased height, development of muscle mass, deepening of the voice, virilization with 
growth of facial, axillary, and pubic hair as well as an increase in penis size. These body 
changes are accompanied by increased secretion of oil and sweat from the sebaceous glands 
resulting in acne and body odor. The World Health Organization (WHO), U.S. National 
Institutes of Health (NIH), and the U.S. Food and Drug Administration (FDA) all concur that 
the goal of TRT is to replace serum levels as close to physiologic levels as possible in order to 
mirror developmental changes in age-matched peers (Nieschlag et al., 1992).  
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Table 4 
Testosterone preparations 
route of 
administration 
frequency benefits drawbacks 
transdermal                 
(gel) 
daily 
self-administered,    
non-invasive 
local reaction, 
transferability 
transdermal             
(patch) 
daily 
self-administered,    
non-invasive 
local reaction,                
skin irritation 
buccal 
twice                           
daily 
self-administered,    
non-invasive 
local reaction,       
frequency of use 
intramuscular       
injection 
every                            
2-4 weeks 
long-acting, can be 
self-administered 
invasive,           
polycythemia risk 
intramuscular        
injection 
every                           
3 months 
long-acting 
invasive, polycythemia 
risk, requires provider 
injection 
subdermal                      
implant 
every                              
6 months 
long-acting 
invasive, polycythemia 
risk, extrusion, fibrosis, 
requires outpatient 
surgical procedure 
Note: Edelstein & Basaria, 2010; Gooren, 2009; Zitzmann & Nieschlag, 2000 
 
 
 Initially, TRT is a balance between stimulating growth (increased height) and avoiding 
premature epiphyseal closure caused by high serum testosterone levels and resulting in a  
shorter terminal height (Palmert & Dunkel, 2012). Thus, doses are gradually escalated, yet 
this can be a source of frustration for patients as they may be eager to “catch up” to their peers 
or “look normal”. If this is not addressed in appropriately timed anticipatory guidance, the 
patient may have inappropriate expectations for treatment resulting in negative experiences or 
feelings related to the regimen. In addition to developing secondary sexual characteristics, 
TRT also aims to improve bone mineralization and it can have a significant positive impact on 
patients in terms of improved energy levels and developing adequate sexual functioning such 
as increased libido, frequency of erections, morning erections, and capacity for masturbation 
and penetrative intercourse (Han & Bouloux, 2010; Young, 2012). While these changes 
would presumably impact quality of life, few studies have directly examined the impact of 
starting TRT in CHH men.  
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A recent study of 39 young men with CHH demonstrated increased sexual dysfunction, more 
anxiety and depressive symptoms, and lower quality of life scores compared to age matched 
peers (Aydogan et al., 2012). The sexual dysfunction, anxiety, and depression ratings 
improved with TRT and after 6-moths, the CHH men scored no differently than their age 
matched eugonadal peers. Notably, while virtually all subcategories of the quality of life 
measures improved, the HH men on treatment still had significantly lower scores related to 
general health, vitality/energy, and physical and emotional role difficulties. These data 
suggest that normalizing the serum hormone levels does not completely ameliorate the 
biopsychosocial effects the CHH has on patients’ quality of life. Such findings are in line with 
past research demonstrating that psychological morbidity persists in patients successfully 
treated for a number of endocrinopathies (Sonino et al., 2004; Sonino, Ruini, et al., 2007; 
Sonino, Tomba, & Fava, 2007)  
 
Long term TRT is efficacious in maintaining physiologic testosterone levels, energy level, 
proper sexual function, and promoting lean muscle mass and preserving bone density 
(Gooren, 2009; Zitzmann & Nieschlag, 2000). However, TRT has no effect on testicular 
development and the testes will remain small (infantile in some cases) and this can be 
stressful and a source of concern for patients when they become sexually active (Han & 
Bouloux, 2010). Indeed, some authors have noted the atrophic testes and severely diminished 
phallus size (often associated with CHH) can have serious negative effects on self confidence 
and psychosexual development (Bouvattier et al., 2012). Further, as TRT does not induce 
fertility, some have suggested that infertility may have additional deleterious psychological 
and emotional effects on patients (Aydogan et al., 2012). However, patient perceptions of 
these issues have yet to be explored. 
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Treatment to induce fertility 
Treatments to induce testicular development and fertility in CHH men have been available 
since the 1980s. One approach is to replace the absent hypothalamic hormone (GnRH) via 
microinfusion pump to induce physiologic pulses of GnRH which in turn stimulate the release 
of endogenous LH and FSH (Buchter, Behre, Kliesch, & Nieschlag, 1998; Hoffman & 
Crowley, 1982). Alternatively, exogenous gonadotropins in the form of human chorionic 
gonadotropin (hCG) (Finkel, Phillips, & Snyder, 1985; Vicari et al., 1992), or combined 
gonadotropin therapy (FSH+hCG) (Bouloux et al., 2003; Matsumoto et al., 2009) may be 
utilized. Outcomes related to testicular growth and development of fertility (evidence of 
sperm in the ejaculate) are variable, and poorer responses have been noted in patients with 
more severe clinical presentations such as small/prepubertal testicular volume, a history of 
cryptorchidism (undescended testes at birth), and/or low markers of sperm production (serum 
inhibin B levels) (Liu et al., 2009; Miyagawa et al., 2005; Pitteloud et al., 2002; Warne et al., 
2009). Notably, there is no significant advantage of one approach over another as nearly 
equivalent outcomes are observed (Buchter et al., 1998; Liu et al., 2009). While treatment 
may be required for 18-24 months to achieve optimal results (Buchter et al., 1998; Burris, 
Rodbard, Winters, & Sherins, 1988), these are highly effective treatments with approximately 
80% of patients developing a potential for fertility with sperm in the ejaculate (Liu et al., 
2009; Miyagawa et al., 2005; Pitteloud et al., 2002; Warne et al., 2009). Despite the high 
success rates for developing sperm in the ejaculate, many men achieve maximal sperm counts 
that are far below the range which is considered normal by the WHO (Cooper et al., 2010). 
However, this does not preclude fertility as it is known that CHH men can conceive naturally 
despite low sperm counts (Burris, Clark, Vantman, & Sherins, 1988).  
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Potential side effects and monitoring of treatment 
The available TRT and fertility treatments available for CHH men are effective and overall 
very well-tolerated. However, there are potential negative effects of TRT (sleep apnea, 
cardiovascular risk, alteration of lipid profile, fluid retention, benign prostate hypertrophy, 
and risk for prostate cancer). Yet these are typically not of clinical relevance as long as serum 
testosterone levels are maintained within a normal physiologic range (Rhoden & Morgentaler, 
2004). Some adverse effects are related to the mode of delivery, such as higher rate of 
erythrocytosis (elevated levels of red blood cells do to the erythropoetic effect of testosterone) 
in men receiving injections, and higher rates of local reaction in men receiving transdermal 
preparations (patch or gels) (Rhoden & Morgentaler, 2004). Rapid changes in serum hormone 
levels can disrupt the balance of androgens and estrogens resulting in development of 
glandular breast tissue referred to as gynecomastia. This can be a negative side effect of TRT 
and occurs quite frequently with gonadotropin therapy (i.e. hCG injections) to induce fertility 
(Boyar et al., 1973). Other potential drawbacks to fertility inducing treatments include the 
extreme cost, the duration of treatment required to attain fertility, the invasiveness of the 
treatment (requiring either injections given every other day or wearing a microinfusion pump 
attached to a subcutaneous needle), and the limited expertise in treating rare patients with 
these specialized treatments. 
Psychosocial aspects of CHH 
Rare genetic diseases are often associated with psychological burden and negative emotional 
and psychosocial effects (Cohen & Biesecker, 2010; McAllister et al., 2007). Further, roughly 
two-thirds of CHH patients have impaired sense of smell (Lewkowitz-Shpuntoff et al., 2012), 
an impairment that is in and of itself associated with higher ratings of social insecurity and 
depressive symptoms (Croy, Negoias, Novakova, Landis, & Hummel, 2012). While sense of 
smell is something indiscernible to others, the absent pubertal development of CHH is 
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outwardly evident and this visible difference from their peers often lasts throughout their teen 
years. Puberty is a process characterized by numerous physiologic, psychosocial, and 
emotional changes and accompanied by the developing self-concept and disruption of puberty 
can carry a psychological burden (Palmert & Dunkel, 2012). Some of the psychological 
consequences of delayed puberty in late maturing 14-16 year-old boys include body image 
concerns, low self esteem, social isolation and many experience teasing or bullying (Golub et 
al., 2008; Kaplowitz, 2010; Rosen & Foster, 2001). Further, victimization and bullying are 
important and common risks for depression in adolescents (Thapar, Collishaw, Pine, & 
Thapar, 2012) and late maturing boys are more dissatisfied with their body image, more likely 
to engage in binge eating, and less sexually active than boys who underwent an average 
timing of puberty (Michaud, Suris, & Deppen, 2006). This constellation of having a rare 
disease which can induce feelings of isolation and alienation combined with the impact of 
having a very severe form of delayed puberty may contribute to a sense of social isolation, 
low self esteem, and negative psychological outcomes in CHH patients (EURORDIS, 2009).  
 
There is some evidence to suggest that CHH impacts the sexual life of CHH men as the body 
image concerns and low self-esteem arising from pubertal failure and underdeveloped 
genitalia can pose a barrier to engaging in sexual activity (Bouvattier et al., 2012). Further, it 
has been suggested that the lack of rising sex steroid levels of puberty may have long-lasting 
negative effects on psychosexual development in CHH men (Huffer, Scott, Connor, & 
Lovice, 1964). Yet, thorough examination of the impact of these issues of quality of life and 
sexuality is lacking. Indeed there are only small case studies that examine these issues in a 
qualitative manner: a 1971 report of 13 cases from the Johns Hopkins University Hospital 
(Bobrow, Money, & Lewis, 1971) and a 1996 case series describing eight CHH men initiating 
pulsatile GnRH (Huisman, Bosch, & Delemarre vd Waal, 1996). In some instances, the 
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psychological burden of a lagging puberty may be compounded with the initiation of 
treatment as TRT therapy can rapidly normalize sexual function but may not address the 
physical and emotional difficulties in adapting to life as a sexual being (Aydogan et al., 2012). 
Some patients may be challenged to deal with the rapid changes of exogenously induced 
puberty such as acne, body changes, and potentially breast development (gynecomastia). As 
such, patients should receive anticipatory guidance and close monitoring and individual dose 
titration to ensure that physiologic levels are achieved to avoid potential negative side effects 
that may include mood swings related to rapidly changing hormone levels (Han & Bouloux, 
2010). Further, CHH men diagnosed later in their 20s and 30s may face additional challenges 
as they learn to cope with a newfound sexuality and the increased libido and change in sexual 
function is a vast alteration from what they are used to feeling (Huffer et al., 1964). This 
dissonance may pose of barrier for adhering to treatment as the emergence of a sexual identity 
may be psychologically and emotionally challenging for these men.  
 
Several publications mention the psychosocial stress related to CHH and that patients may 
feel self-conscious, awkward, or embarrassed because of their lagging sexual development, 
undeveloped genitalia, and infertility that in some cases is emotionally crippling for patients 
(Huffer et al., 1964; Han & Bouloux, 2010Au, Crowley, & Buck, 2011; Aydogan et al., 
2012;; Bouvattier et al., 2012; Young, 2012). Previous reports from 1964, 1971, and 1996 
describe in a rather anecdotal way issues with confidence, security, and poor views of 
physique (Bobrow et al., 1971; Huffer et al., 1964; Huisman et al., 1996). While this aspect of 
care maybe mentioned in the context of the approach to the patient, the significance of these 
psychosocial implications have not been extensively explored and it is unknown what role 
these may have in relation to adherence to treatment. Despite the benefits of treatment in 
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ameliorating health problems/risks and the availability of effective treatment options, 
adherence to treatment is a significant problem across therapeutic areas (WHO, 2003).  
 
In relation to CHH, several publications make reference to individual patients being “lost to 
follow-up” (Pitteloud et al., 2001; Pitteloud et al., 2007; Quinton et al., 1999; Raivio et al., 
2007), yet there is a notable paucity of data on adherence to treatment in this population. An 
early series reported in the Annals of Internal Medicine in 1964 charts the response of eight 
men during pubertal induction (Huffer et al., 1964). The authors poignantly note, “There is a 
tendency among physicians to assume that a corrigible pathological condition ought to be 
corrected and that the emotional well-being of the patient will improve concomitantly with his 
physical condition” (p. 265). However, the carefully depicted cases suggest otherwise; two 
men (25%) ceased treatment and medical follow up, while the other six men struggled with 
issues of anxiety, depression, and social difficulties as they negotiated the changes of 
adolescence in the 3
rd
 to 5
th
 decade of life. More recently, a report examining bone health in a 
cohort of 26 Finnish CHH patients indicated that nine patients (35%) had long periods of non-
adherence to therapy with treatment pauses exceeding five years (Laitinen et al., 2012). In 
summary, despite the availability of effective treatments, there are seemingly other issues 
diminishing CHH patients’ self-care and health seeking behavior.  
Addressing the Challenges to Health in CHH Patients  
As previously discussed, patients with rare diseases face a multitude of livelong challenges 
which place them within the framework of chronic care and health disparities (Holtzclaw 
Williams, 2011). Patients with rare diseases, including CHH, experience delays in getting an 
accurate diagnosis, and have difficulty identifying providers with expertise in treating their 
condition which can induce feelings of isolation and alienation (EURORDIS, 2009). When 
combined with the psychosocial stressors described above, these factors may impede 
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adherence to treatment which has important health ramifications for patients with chronic 
disorders. Patients with chronic conditions provide approximately 95% of their care (Funnell 
& Anderson, 2000), and the daily decisions people make regarding their health can have a 
huge impact on patient outcomes and quality of life. Activating patients to develop and 
practice self-care is a means to empower patients and facilitate health promoting behaviors 
that are critical for managing chronic conditions (Simmons, 1990). Nurses play a crucial role 
in guiding and teaching patients to perform self-care and in delivering what the WHO terms 
health promotion, the process of enabling people to overcome health challenges and increase 
control over their environment to achieve greater health (WHO, 1986). This definition, is 
intertwined with empowerment, a central theme in health promotion, health equity, and 
chronic disease management which are directly relevant to patients with rare diseases 
(Marmot, 2007).  
 
In the realm of common chronic diseases such as diabetes, the shortfall between what is 
known about managing the condition and its complications and what is actually practiced has 
been well documented (Glasgow, 2003). This has led to the adoption of a number of quality 
improvement initiatives including the implementation of evidence-based practices and a shift 
from a provider-centered compliance approach to a patient-centered empowerment (Glasgow 
& Anderson, 1999; Wagner, Austin, & Von Korff, 1996a, 1996b). One integrated approach, 
the Chronic Care Model (CCM), was developed to facilitate interactions between informed, 
activated patients and a prepared, proactive care team that includes physicians, nurses, social 
workers, dieticians/nutritionists, therapists and others and is now widely used (Bodenheimer, 
Lorig, Holman, & Grumbach, 2002). This collaborative paradigm emphasizes members of the 
care team as health coaches who are critical for helping the patient to gain knowledge and 
develop self-care skills to become confident, active participants in their care. Nurses play a 
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key role in providing self management support, bridging gaps between the patient and 
provider, assisting in the navigation of the healthcare system, and providing continuity of care 
(Bennett, Coleman, Parry, Bodenheimer, & Chen, 2010; Bodenheimer et al., 2005; Ghorob & 
Bodenheimer, 2012). Such nursing sensitive, patient-centered targets for intervention help 
patients become more informed and activated and are effective in improving a number of 
patient outcomes (Wagner et al., 2001). 
 
Interventions aimed at self management support include traditional patient education as well 
as training in problem solving skills and are the component of the CCM most frequently 
associated with improved outcomes (Pearson, Mattke, Shaw, Ridgely, & Wiseman, 2007) . A 
significant amount of CCM literature has focused on diabetes self-care. A meta-analysis of 31 
studies demonstrated that self-management support was associated with improved glycemic 
control (Norris, Lau, Smith, Schmid, & Engelgau, 2002) and a more recent meta analysis of 
group-based programs also improved knowledge as well as glycemic measures (Steinsbekk, 
Rygg, Lisulo, Rise, & Fretheim, 2012). These findings were also supported by Cochrane 
systematic reviews of both individual and group interventions in type-2 diabetes (Deakin, 
McShane, Cade, & Williams, 2005; Duke, Colagiuri, & Colagiuri, 2009). Nurses have also 
demonstrated a key role in planned visits, an aspect of the CCM in which time is dedicated to 
key patient education topics, review medications, and address other patient concerns 
(Bodenheimer, 2005b). A systematic review of 41 studies evaluating the role of planned visits 
demonstrated that they are such interventions are effective in improving glycemic control and 
that nurses play central role in this process and can replace physicians in delivering many 
aspects of diabetes care with the proper training and support (Renders et al., 2001). Notably, 
the common denominator in successful implementation of patient-centered approaches to care 
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includes a central role for nurse care managers within the CCM (Aubert et al., 1998; Glasgow 
et al., 2001; Sadur et al., 1999).  
 
As demonstrated by the systematic reviews and meta-analyses described above, the CCM 
utilizes self management training, planned visits, and case management to develop informed, 
activated patients, achieve sustained continuity of care, and improved health outcomes 
(Bodenheimer, 2005a). Patients’ satisfaction with care and positive patient-provider 
interactions are important determinants for self care that can either promote or undermine 
patient self-management (Flocke, Miller, & Crabtree, 2002; Glasgow et al., 2001; Little et al., 
2001). Recently, there is a growing movement towards a chronic care model for patients with 
rare diseases that is patient centered and includes them as informed, involved and interactive 
partners in the health care team (Burton, Murphy, & Riley, 2010). As such, one might 
anticipate that the benefits of applying the collaborative approach of the CCM to rare disease 
patients would be a patient-centered approach which empowers patients to develop expertise 
in self management as well as enhanced continuity of care.   
Nursing and patient-centered care. 
At the core of the CCM, is the notion of patient-centered care involving an ongoing 
collaborative process between an empowered, activated patient and the care team 
(Bodenheimer, Lorig, et al., 2002; Bodenheimer, Wagner, & Grumbach, 2002). Patient-
focused care integrates elements of patient education, self-care, and evidence-based models of 
practice and distills them into interventions aimed at improving communication and 
developing partnerships with patients, providing physical care, and enabling health promoting 
activities (Bauman, Fardy, & Harris, 2003; Irwin, 2004; Irwin & Richardson, 2006). Nursing 
fits well with patient-focused approaches as they draw on roles that nurses have traditionally 
provided leadership in: patient education, advocacy, developing self-care, enhancing coping 
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skills, enabling empowerment, and promoting self-efficacy in patients. In patient-focused 
care, the role of healthcare provider is no longer that of the professional expert who gives 
instructions and makes the decisions. Rather, they are a coach or a guiding advisor helping the 
patient navigate their health according to personalized goals (Bennett et al., 2010; 
Greenhalgh, 2009). This paradigm shift allows for a shared decision-making process focused 
on informing, assisting, and activating patients towards enhanced self-management their 
condition (Barlow, Wright, Sheasby, Turner, & Hainsworth, 2002; Bodenheimer, Lorig, et al., 
2002).  
 
Patient-centered care dramatically reframes patient involvement, shifts the role of the 
healthcare professional, and redefines successful health outcomes (Greenhalgh, 2009). Nurses 
have been leaders in developing chronic disease self-management training programs that build 
self-efficacy and improve patient outcomes (Marks, Allegrante, & Lorig, 2005a, 2005b). Such 
programs acknowledge patient expertise and redefine expectations related to care and it has 
been posited that this challenge to biomedical superiority has posed barriers to more 
widespread implementation of patient-centered programs (Lawn, McMillan, & Pulvirenti, 
2011; Thorne, Ternulf Nyhlin, & Paterson, 2000). Patients with rare diseases are often forced 
to become their own experts due to the lack of expert care. Indeed, the vast majority of these 
patients seek information on their own, and with time, the relative expertise of the health 
professional diminishes. Further, healthcare providers’ ability to accept patients as informed, 
interactive, and involved partners in the process has significant impact on the patient 
experience (Budych, Helms, & Schultz, 2012). Not surprisingly, information exchange is an 
essential step in meeting the care needs of rare disease patients and knowledge sharing 
improves patient satisfaction (Hannemann-Weber, Kessel, Budych, & Schultz, 2011). One 
way to address the unmet health needs of these patients is through patient-centered 
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empowerment approaches that develop knowledge and expertise enabling self-management 
that is critical for chronic conditions (Ho, Berggren, & Dahlborg-Lyckhage, 2010).  
 
The complexity of rare diseases poses many challenges, yet these hurdles may be overcome 
by creative use of interdisciplinary teams that include patients. Different health care providers 
have different expertise and patients have an intimate and sophisticated understanding of their 
own disease. Therefore, assembling a team with diverse knowledge, abilities, and skills may 
lead to idea generation and implementation of approaches that will enhance patient outcomes 
(van Knippenberg, 2006; Wensing, Wollersheim, & Grol, 2006). Much like the successful 
application of the CCM to diabetes, multidisciplinary teams including medicine, nursing, 
social work, and others have been shown to be effective in providing comprehensive patient-
centered care for a number of genetic disorders (Baker, Crudder, Riske, Bias, & Forsberg, 
2005; Burton et al., 2010; Evatt, 2006; Grosse et al., 2009) and appears to hold relevance for 
rare disease patients.  
Theoretical Foundations for Nursing Practice and Relevance to Rare Disease 
Patients  
Consistent with nursing’s unique contributions to multidisciplinary teams and CCM 
(Bodenheimer et al., 2005), the field of nursing has utilized a number of theoretical 
foundations to better understand health and behavior. Nursing’s integrated and individual 
definition of health is rooted in the philosophy of postmodernism (Reed, 1995). 
Postmodernism is iconoclastic in that it deconstructs the reductionism of empiricism. Rather 
than identifying one objective reality, the focus is on multiple meanings. It is pluralistic in 
that it accepts multiple realities and truths. In the context of health, this is important as it 
places the definition of health not with the professional expert, but rather it includes the 
viewpoint and experiences of the patient through their own subjective lens. This notion is 
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fundamental to a core tenet of nursing, respect. By accepting multiple truths, the nurse 
removes the judgment that one reality is superior to another. This has a leveling effect for the 
power dynamic and facilitates shared decision making as it removes blame and provides 
validity for each participants’ views. The postmodernism appreciation of the absence of one 
objective reality is foundational to developing approaches to patient-centered care as it 
recognizes that the perspective of the professional healthcare provider is not the only valued 
point of view.  
 
Further, given the unique challenges faced by patients with rare diseases, innovative, 
individualized approached to care and patient centered care teams are essential to address the 
complex needs of these patients (Hannemann-Weber et al., 2011). Building on the foundation 
of respect for individuals and the appreciation of different perspectives, nursing places the 
definition of health in the context of the individual and engages in activities with individuals, 
families, and communities to create optimal conditions for improving health and well-being 
and nursing’s unique mix of skills and competencies will inevitably play a key role in 
developing and implementing patient focused approaches to care that are built to value both 
health promotion and patients’ involvement in a context of long lasting disease (Sibbald, 
Shen, & McBride, 2004). Accordingly, it follows that nursing has played an important role in 
implementing the CCM (Bodenheimer et al., 2005) which aims to activate patients for 
enhanced self-management and self-care of their chronic health condition.  
Pender’s Health Promotion Model (HPM)  
One of the nursing models that has been utilized to understand and predict health seeking 
behaviors is the Health Promotion Model (HPM) of Nola Pender (Pender, Murdaugh, & 
Parsons, 2010). The HPM model is based on an earlier model, the Health Belief Model 
(HBM), which was developed to examine patient health behaviors (Janz & Becker, 1984). 
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The HBM incorporated the interrelated concepts of modifying factors, cognitive-behavioral 
factors, and other variables influencing likelihood of action creating a model to understand 
how individuals protected their health. At the core of this model is the idea that the fear or 
threat of a disease is a motivator for positive health behavior, essentially defining it as a 
disease avoidance model (Galloway, 2003). In contrast, Pender’s HPM is not focused merely 
on health protection or disease avoidance, but rather places health within a nursing 
perspective and focuses on achieving higher levels of wellness and self-actualization. 
Pender’s HPM concentrates on the interactions between three broad areas that flow linearly 
towards health promoting behavior: i) individual characteristics and experiences, ii) behavior-
specific cognitions and affect, and iii) behavioral outcomes (Pender, Murdaugh, & Parsons, 
2010. This model is patient-centered and places the definition of health and the importance of 
health within the value scale of the individual (Figure 3). 
 
Figure 3. Pender’s Revised Health Promotion Model. Reprinted from Health Promotion in 
Nursing Practice (p. 45), by Pender, N. J., Murdaugh, C. L., & Parsons, M. A., 2010,  Upper 
Saddle River, NJ: Prentice Hall.   
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Given the holistic and multidimensional view of the individual, the HPM has been used to 
examine numerous biopsychosocial influences impacting health promoting behavior 
(outcomes) and has been used as a model to guide effective nursing interventions (Gillis, 
1993). 
Theoretical underpinnings of the HPM 
The HPM is rooted in the humanistic psychology of Abraham Maslow (Maslow, 1999), the 
expectancy value theory of Normal Feather (Feather, 1982), and in Social Cognitive theory of 
Albert Bandura (Bandura, 1986). Similar to Maslow’s hierarchy of needs, the HPM 
recognizes that basic needs must be met for patients to aspire and move towards higher levels 
of health and self-actualization. Feather proposed that in situations involving a degree of 
choice, action and behavior are strongly influenced by the expectation of being successful and 
the value placed on the desired outcome, meaning that it is something useful or enjoyable 
(Feather, 1982). In terms of understanding and predicting human behavior, the HPM is 
grounded in Bandura’s Social Learning Theory (Social Cognitive Theory). In the Social 
Learning Theory, the locus of control is within the individual. Bandura posited that 
individuals are self organizing and that personal factors (biological, cognitive, and affective), 
behavior, and the environment all interact. From this dynamic interaction, individuals derive a 
personal sense of being able to effectively interact with and transform their environment, the 
concept of self-efficacy (Bandura, 1986).  
 
The HPM posits that individuals will actively seek to regulate their own health behavior and 
that health is the actualization of human potential attained through goal-directed behavior. 
Effective self-care, satisfying relationships, and harmony with the environment are key 
elements of the HPM holistic view of health. Further, the model recognizes the complexity of 
individual characteristics and how both cognitive and affective aspects of experiences can 
40 
 
either enhance self-efficacy, and action towards health promoting behaviors, or alternatively, 
create barriers to action. Such positive/negative factors are the primary motivators for health 
promoting behaviors and include subjective perceptions related to the definition and 
importance of health, perceived control over health, current health status, perceived self-
efficacy related to health, as well as perceived benefits and barriers to health promotion 
behaviors (Pender, Murdaugh & Parsons, 2010) ). The desired outcome in the HPM is action 
and behaviors which improve health and well-being, functional abilities, and ultimately 
improved quality of life. These positive health seeking behaviors are the targets for nursing 
intervention.  
 
How has the HPM been used in nursing research? 
The HPM is multidimensional and recognizes a variety of interrelated factors exerting direct 
and indirect influences on health behavior. A core tenet of the model is the spectrum of 
disease states ranging from disease to well-being which is ever-changing. This fluid state of 
health fits well with the nursing process of assessing, analyzing, planning, implementing, and 
evaluating which is cyclic, dynamic, and goal-oriented (Faust, 2002). And like the nursing 
process, the HPM is flexible as it can be applied to individuals, families, or communities. 
Further, the model is useful as a framework for assessment and as a means to evaluate 
interventions to address an identified need (McClune, 2009; Walker et al., 2009) and has 
demonstrated predictive abilities in a variety of settings (Hong, Lusk, & Ronis, 2005; Lusk, 
Ronis, & Hogan, 1997; Ronis, Hong, & Lusk, 2006; Stuifbergen & Becker, 1994; Weitzel & 
Waller, 1990).  
 
The HPM has been applied to examine specific disease avoidance/health protecting behavior 
such as exercise (Eden, Orleans, Mulrow, Pender, & Teutsch, 2002; Garcia et al., 1995; Shin, 
Yun, Pender, & Jang, 2005; Wu & Pender, 2002; Wu, Pender, & Yang, 2002), smoking 
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cessation (Kelley, 2009; Wynd, 1999), and injury protection (Coppens & McCabe, 1995; 
Hong et al., 2005; Lusk et al., 1997; Lusk, Ronis, Kerr, & Atwood, 1994; McCullagh, Lusk, 
& Ronis, 2002; Ronis et al., 2006). Beyond its application in understanding disease 
avoidance, it has also been useful in identifying attributes and variables associated with health 
promoting behaviors and lifestyles in wide-ranging groups of patients (Ahijevych & 
Bernhard, 1994; Duffy, 1993; Duffy, Rossow, & Herandez, 1996; Eschiti, 2008; Frank-
Stromborg, Pender, Walker, & Sechrist, 1990; Kerr & Ritchey, 1990; Kwong & Kwan, 2007; 
Lusk, Kerr, & Ronis, 1995; May & Rew, 2010; Padula & Sullivan, 2006; Stuifbergen & 
Becker, 1994; Viau, Padula, & Eddy, 2002; Wilson, 2005; N. F. Woods, Lentz, & Mitchell, 
1993).  
 
Further, the HPM has been used to identify barriers to health promoting behavior (Mendias & 
Paar, 2007; Parve, 2004), the association of health promoting behaviors and quality of life 
(Han, Lee, Park, Park, & Cheol, 2005; Stuifbergen, 1995), and to evaluate healthcare 
providers’ attitudes towards health promotion (Conway, McClune, & Nosel, 2007). Notably, 
health promotion activities have been shown to have a positive impact in patients with chronic 
disabling conditions (Stuifbergen, Morris, Jung, Pierini, & Morgan, 2010).  Indeed, the work 
of Stuifbergen and colleagues have demonstrated the applicability and value of the HPM for 
not only understanding barriers to health promoting activities among patients with chronic 
health conditions, but also as a model for delivering wellness interventions to activate patients 
and achieve improved quality of life (Stuifbergen, 2006; Stuifbergen, Becker, Blozis, 
Timmerman, & Kullberg, 2003; Stuifbergen et al., 2012; Stuifbergen, Blozis, et al., 2010; 
Stuifbergen, Morris, et al., 2010; Stuifbergen & Rogers, 1997).  As such, the HPM appears to 
be theoretically coherent with the CCM - wherein the objective is to link proactive healthcare 
teams with informed and activated patients to promote enhanced health outcomes (Wagner et 
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al., 1996b). Further, the HPM has been used as a framework for patient empowerment for 
diabetes (Ho et al., 2010). The demonstrated benefits for patients with chronic conditions and 
the HPM’s theoretical links with concepts of self-actualization, self-efficacy, enhanced 
coping, and empowerment have direct relevance for patients with rare diseases making it an 
appropriate theoretical framework.  
Purpose of Statement 
The purpose of this study is to use the nursing framework of Pender’s HPM in order to 
examine the relationship between illness perception, depressive symptoms, and adherence to 
treatment in male patients living with a rare disease, CHH. This needs assessment will 
identify areas for developing targeted nursing interventions and enhanced patient-centered 
approaches to care. 
Implications, Nursing Significance, and Adaptation of the HPM to this Study 
Nursing has played a key role in providing patient-centered approaches to care in the 
management of chronic conditions. Such nursing interventions are relevant for patients and 
families affected by rare diseases. Therefore, this needs assessment is an initial and critical 
step for identifying targets for nursing interventions and developing rational, empowerment 
based, patient-centered approaches addressing the chronic care needs of patients with rare 
diseases. This study will be nested within the theoretical framework of Pender’s HPM as it 
provides a pragmatic and useful explanatory model for health behavior.  
Specific Aims 
This study proposes to address four specific aims, each relating to specific dimensions of the 
Pender’s HPM in relation to men living with CHH.  
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Specific Aim 1: Individual characteristics and experiences.  
To assess illness perceptions and depressive symptoms in men with CHH.  
Specific Aim 2: Behavior-specific cognitions and affect.  
To explore CHH patients’ perceived barriers related to health promoting behavior.  
Specific Aim 3: Interpersonal influences.  
To describe the type and quality of interactions with healthcare providers.  
 Specific Aim 4: Behavioral outcomes/Health promoting behavior 
To evaluate adherence to treatment in men with CHH. 
 
 
Figure 4. Theorectical schematic for the proposed study.  Pender’s Revised Health Promotion 
Model reprinted from Health Promotion in Nursing Practice (p. 45), by Pender, N. J., 
Murdaugh, C. L., & Parsons, M. A., 2010, Upper Saddle River, NJ: Prentice Hall.   
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Chapter III: Methods 
Design 
First, a descriptive, multivariate correlational needs assessment study utilizing a community 
based participatory research framework was used. This approach has previously been put 
forth as a useful research model for empowering patients and overcoming health inequities 
(Wallerstein & Duran, 2006). As part of a European network focused on CHH (COST Action 
BM1105, www.gnrhnetwork.eu) partnerships were developed with expert patients and online 
patient community leaders (i.e. moderators of online patient support sites) to engage 
stakeholders in the process of study design and conduct. The community partners were 
actively involved in generating ideas as well as providing feedback, comments, and criticism 
in an iterative process to refine the questions and improve the language and clarity of the 
survey, assist in recruiting, and discussing study findings.  
 
This was embedded in a sequential, explanatory mixed-methods approach (Creswell & Plano 
Clark, 2011). In this design (QUANTQual), quantitative data are collected first and 
analyzed, followed by collection of qualitative data in an effort to elucidate mechanism and 
explanations for significant/non-significant findings identified in the quantitative data. In the 
present study, the initial quantitative approach (QUANT) took the form of an online needs 
assessment survey and subsequent patient focus groups were conducted (Qual) to explore 
findings in greater detail, obtain greater insight into the unmet health needs of CHH men, and 
generate working explanatory models.  
 
The rationale for applying this approach is that this mixed method provide a deeper 
exploration of the unmet health needs of CHH men than would be possible by either method 
in isolation (Creswell & Plano Clark, 2011). The quantitative data are used to examine 
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relationships and correlates affecting health promoting behavior while the qualitative data are 
used to provide context and understanding to the quantitative analysis as well as generate 
areas for nursing sensitive interventions.  
 
Sample Size and Power Analysis 
The requisite sample size estimate was based on Cohen’s statistical power analysis for 
correlations. This is one of the most widely used in behavioral sciences for determining 
sample size (Cappelleri & Darlington, 1994). Cohen posits that a medium effect size can 
likely be visible to the naked eye of a careful observer (J. Cohen, 1992). Thus, for this 
descriptive, correlational needs assessment, power calculation was performed using a medium 
effect size (r=0.3, explaining 9% of the variance) with a significance of 0.05 and power of 
0.80 to determine that 85 subjects would be needed to have an 80% chance of detecting a 
difference with 95% confidence (J. Cohen, 1988).  
 
Inclusion and Exclusion Criteria 
Inclusion criteria. 
 Adult males (18-70 years of age).  
 Diagnosed with CHH (i.e. normosmic CHH or Kallmann Syndrome), in order to 
ensure the validity of CHH diagnosis report by patients, a random sample (40%) of 
respondents were contacted to confirm diagnosis. 
 Capable of responding to a written questionnaire in English. 
Exclusion criteria. 
 Men with other forms of hypogonadism (i.e. Klinefelter Syndrome or adult onset 
hypogonadotropic hypogonadism).  
 Incomplete surveys or surveys containing inconsistent or conflicting data. 
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Sampling for the quantitative phase 
The rarity of CHH, approximately one in 4,000-10,000 (Filippi, 1986; Fromantin et al., 1973), 
presents a challenge in terms of recruiting adequate numbers of widely dispersed patients 
(Kruer & Steiner, 2008; Watson et al., 2008). To address this, the convenience sample was 
preferred and potential participants were identified via several recruitment measures in 
collaboration with patient community leaders: i) the international network of clinicians and 
reproductive endocrinologists in the field (COST Action BM1105, GnRH Deficiency: 
Elucidating the Neuroendocrine Control of Human Reproduction, based in Lausanne 
Switzerland at the Center Hospitalier Universitaire Vaudois), ii) the patient-related support 
sites (online support group: Yahoo Kallmannn syndrome support [n= 1,738 members since 
site launch], social networking: Facebook [approximately 400 regular visitors - personal 
communication N. Smith site administrator], weblogs: (Blogspot [n=300 hits/month - 
personal communication N. Smith site host], Wordpress [n=600 hits/month - personal 
communication N. Smith site host]), iii) a link for patient participation on the COST Action 
website (www.gnrhnetwork.eu) and, iv) a link via the clinical trials registry of the U.S. 
National Institutes of health (www.clinicaltrials.gov).  
 
To overcome the dispersed nature of rare disease patients a web-based recruitment (as 
described above) was used combined with web-based data collection (i.e. online survey using 
SurveyGizmo). Previous studies have found the internet (i.e. online web-based 
questionnaires) a useful tool for reaching dispersed populations (Eysenbach & Wyatt, 2002). 
Further, given the anonymity of online information, the internet is considered useful for 
eliciting information that patients may not feel comfortable expressing in face-to-face 
encounters with healthcare providers (Bedgood, Sadurski, & Schade, 2007). The potential 
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sampling bias of internet surveys is of less concern in this mixed-methods approach as the 
goal is to target a specific cohort of patients to explore their situation in depth (Eysenbach & 
Wyatt, 2002).  
Sampling for the qualitative phase 
Subjects participating in the patient focus groups met the following criteria: adult men (18-70 
years of age) diagnosed with CHH and providing written informed consent in English.  
Subjects were recruited among those CHH men actively participating in a patient support 
group meetings jointly organized by patient community leaders and members of COST 
Action BM1105.  Meetings were publicized on the Action website (www.gnrhnetwork.eu) 
and by patient community leaders online.     
Variables and Measures Used in the Quantitative Phase 
The variables and measures selected for this study are largely driven by the HPM. To address 
the four specific aims, data collection include: i) demographic information, ii) established, 
validated instruments (Illness Perception Questionnaire-Revised [IPQR], Zung Self Rating 
Depression Scale [SDS]), and iii) questions developed specifically to address aspects of the 
HPM in the context of the Specific Aims (i.e. personal factors [sexuality and body image], 
past behavior [interactions with health systems] and interpersonal influences [interactions 
healthcare professionals]). These questions include open ended, yes/no, and multiple choice 
formats. Items were formulated for relevance to the HPM and were developed through 
iterative discussions with three expert patients who are members of COST Action BM1105 
Working Group 5: Patient Advocacy. These patient community leaders are actively involved 
in patient support groups and lead online discussions. The patient advocates provided input, 
feedback, comments, and criticism in an iterative process to refine the questions and improve 
the language used in the questionnaire.  
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Specific Aim 1 : Individual characteristics and experiences.  
To assess illness perceptions and depressive symptoms in men with CHH.  
Rationale. Both illness perceptions and depression have been shown to have significant 
impact on adherence to treatment (Ciechanowski, Katon, & Russo, 2000; Kucukarslan, 2012; 
Lin et al., 2004). The HPM recognizes that personal factors play an important role in shaping 
health behavior. Several approaches were used to assess these HPM factors (individual 
characteristics and experiences) and deepen the interpretation of affected illness perceptions 
and depressive symptoms in CHH men.  
 
SA1.1 Prior related behavior (past experiences) was examined in terms of past interactions 
with the healthcare system and collecting information on the age of diagnosis and initiation of 
treatment (Appendix 3) as some authors have suggested that this may be an important area 
impacting the psychosocial effects of CHH (Bouvattier et al., 2012). Additionally subjects 
were asked about past experiences of discrimination in healthcare systems related to CHH 
(Hudelson, Kolly, & Perneger, 2010).  
 
SA1.2 Personal factors  
SA1.2.1 Biologic factors include characteristics such as gender, age, developmental status 
(child, adolescent, or adult), health status, and physical fitness among others. These factors 
were evaluated by demographic information (Appendix 3, 4). The selection of demographic 
variable collected in this study was guided by previous work in men with Klinefelter 
syndrome (Herlihy et al., 2011; Turriff, Levy, & Biesecker, 2011). Klinefelter syndrome 
results from an additional sex chromosome (47XXY) and is the most common chromosomal 
aberration in men occurring in approximately 1 in 500 live births (Turriff et al., 2011). Given 
the paucity of literature on CHH men, the Klinefelter syndrome patient population was 
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considered as a suitable surrogate as these men exhibit many similar phenotypic 
characteristics as CHH (i.e. testosterone deficiency, incomplete or absent puberty, small 
testicular size, infertility) (Herlihy et al., 2011; Turriff et al., 2011). Therefore, the following 
items were collected and analyzed: gender, age, education level, employment status and type 
of work, time since diagnosis, current and past treatments, marital/relationship status, 
children, relationship to children (biological/adopted).  
 
SA1.2.2 Psychological factors include self concept/self-esteem, body image, sexuality, self 
motivation, and perceived health status. These psychological elements were assessed by using 
the Illness Perception Questionnaire - Revised (IPQ-R) (Appendix 5), the Zung Self-rating 
Depression Scale (SDS) (Appendix 8), and several descriptive questions related to body 
image and sexuality (Appendix 6). Problems with body shame and embarrassment associated 
related to CHH have been pointed to by some authors (Au et al., 2011) and so several 
questions were generated in collaboration with patient community leaders and expert patients 
to assess this as part of the survey. Additionally expert patients noted that intimate 
relationships and sexuality were frequently cited topics in online forums and thus questions 
were included to explore these domains. The two main questionnaires IPQ-R and the SDS are 
presented in the next paragraphs. 
 The IPQ-R: An important psychological variable within the HPM is the individual’s 
perception of their health status. Insight into this area has been greatly facilitated by 
the work of Howard Leventhal who developed the Common Sense Model (CSM) of 
self-regulation (Leventhal, Nerenz, & Steele, 1984). The CSM provides a framework 
to understand how patients integrate internal/external stimuli regarding health in the 
form of parallel processing that includes cognitive and affective components. In other 
words, an illness (or symptoms of an illness) stir cognitive interpretations of the nature 
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of the health threat as well as emotional interpretations (i.e. fear) generating a dynamic 
representation of their illness. Leventhal’s model, like Pender’s, is founded on the 
belief that people are active problem solvers who make sense of their experiences and 
health by constructing their own representations or models. Because illness 
representations are subjective, they may appear irrational or incorrect to others. 
However, these representations are derived from core beliefs about illness and 
determine guide patients’ coping and actions in response to illness. Briefly, the five 
dimensions that form an individual’s illness perception include: 
o Identity: the label that the individuals describe their illness and what 
symptoms they believe are associated with the illness.  
o Cause: the individuals’ beliefs about etiology and the associated factors 
which caused the illness.  
o  Consequences: the impact and negative consequences resulting from the 
illness. 
o Timeline: the individuals’ view on the course of the illness (acute, chronic, 
or episodic). 
o Cure/Control: the extent that the individuals believe the illness is amenable 
to being controlled or cured. 
 
Researchers have used the self-regulatory model for instrument development to assess 
illness perceptions (Weinman, Moss-Morris, & Horne, 1996). The original IPQ-R 
includes scales assessing each of the five dimensions and examine cognitive 
representations of illness and has been applied to a number of chronic illnesses 
(Baines & Wittkowski, 2012; Mc Sharry, Moss-Morris, & Kendrick, 2011; J. 
Weinman & Petrie, 1997). The instrument was subsequently revised to improve 
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internal consistency in the cure/control and timeline subscales (Moss-Morris, 2002). 
The Revised instrument - IPQ-R added several elements that have implications for 
coping behavior and outcomes: i) an addition of the concept of cyclicity to the 
timeline dimension, ii) a subscale pertaining to illness coherence to examine how 
individuals make sense of their illness, and iii) an emotional representation of illness 
providing insight into the emotional impact the illness has on a patient’s life.  
 
The revised instrument went through a rigorous validation using a cohort of over 700 
patients across eight different conditions including chronic illness (asthma, diabetes, 
rheumatoid arthritis, chronic pain, multiple sclerosis), infectious disease, myocardial 
infarction, and acute pain (Moss-Morris, 2002). The internal reliability of the seven 
subscales were good with Crohnbach alpha’s ranging from 0.79-0.89 and test-retest 
reliability reflected acceptable stability at both short –term (3 weeks) and long-term (6 
month) retest. The discriminant ability to identify known groups (i.e. acute vs. chronic 
pain patients) was evaluated and all seven dimensions of the IPQ-R and were 
significantly different between groups.   
 
In the 10 years since the introduction and validation of the IPQ-R, the instrument has 
been used to understand illness perception in chronic conditions (Baines & 
Wittkowski, 2012; Bijsterbosch et al., 2009; Chilcot, Wellsted, & Farrington, 2010; 
Fischer et al., 2010; Fowler & Baas, 2006; Mc Sharry et al., 2011; Searle, Norman, 
Thompson, & Vedhara, 2007), endocrine disorders such as acromegaly (Tiemensma et 
al., 2011a) and Cushing’s syndrome (Tiemensma et al., 2011b) and to better 
understand issues relating to adherence to treatment (Aflakseir, 2012; J. C. Chan et al., 
2009; French et al., 2008; Ohm & Aaronson, 2006). Leventhal’s common sense model 
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of self-regulation, and the instruments derived from his work, have been useful in 
relation to nursing as they can be used to both guide care activities as well as 
demonstrate how nursing interventions positively impact measurable patient outcomes 
(Johnson, 1999).  
 
In this proposed study, the IPQ-R affective illness representations dimension is 
utilized to examine the illness perception of CHH patients (Appendix 5). The reasons 
for this are two-fold. The first lies in the theoretical similarities and coherence 
between Leventhal’s CSM and Pender’s HPM. Leventhal poses that internal and 
external stimuli are critical elements in forming illness perceptions, which ultimately 
determine coping. Similarly, within Pender’s individual characteristics and 
experiences axis of the HPM, there is strong co-linearity between external factors i.e. 
prior related behavior and internal stimuli i.e. personal factors including biologic, 
psychological, socio-cultural elements. In the HPM, these interact to create behavior-
specific cognitions and affect while in the CSM, parallel processing occurs to 
determine coping. As such, the IPQ-R is a useful instrument in characterizing the 
individual characteristics and experiences axis of the HPM. Secondly, the IPQ-R is 
highly applicable as it has previously demonstrated utility in relation to chronic 
diseases, endocrine disorders, and adherence to treatment – all of which are relevant to 
the proposed study.  
 
 The SDS: To assess depressive symptoms in the CHH population, the SDS will be 
used (appendix 8). This instrument was developed by William Zung in an effort to 
develop a self-report test to quantify depression severity (Zung, 1965). The instrument 
is a simple and rapidly administered with balanced questions (10 positively worded 
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and 10 negatively worded) examining common symptoms of depression. The SDS 
utility as a screening tool has been demonstrated (Zung, 1990) and has widely been 
used a measure to evaluate treatment effectiveness (Shafer, 2006). This self-report 
instrument scores range from 20-80 which can be translated to four levels of 
depression symptoms: level 0 (normal range) no significant depressive symptoms; 
level 1 (mild) corresponding with significant depressive symptoms yet typically below 
what would normally initiate a referral for treatment; level 2 (moderate) corresponding 
with what might typically be observed among outpatient depression patients or those 
with dysthymia; level 3 (severe) marked symptoms characteristic of major depressive 
disorder. This instrument is internally consistent with split half reliability coefficients 
ranging between 0.73-0.79 (Hedlund & Vieweg, 1979).  Further, evidence of its 
construct validity comes from its relationship with other clinical depression scales 
(Faravelli, Albanesi, & Poli, 1986).  The Zung SDS has demonstrated intercorrelations 
with a wide number of other widely used depression inventories including: Depression 
Scale inventory (0.87) (Zung, 1972), Hamilton Depression Rating Scale (0.80), 
Bunney and Hamburg Rating Scale (0.57) (Faravelli et al., 1986), Wechsler 
Depression Rating Scale (0.54) (Faravelli et al., 1986), as well as global physician 
ratings of clinical depression (0.69) (Biggs, Wylie, & Ziegler, 1978). One advantage 
of using this instrument is that it has been used widely across numerous patient and 
community dwelling population thus providing ample data to estimate community 
base rates of depressive symptoms for comparison. 
 
SA1.2.3 Socio-cultural factors include characteristics like race, ethnicity, education level, 
health literacy and socioeconomic status. Previous work on health literacy has demonstrated a 
self-report method involving a single question corresponds with lengthier gold standard 
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literacy tests (Chew, Bradley, & Boyko, 2004; Chew et al., 2008). Therefore this abbreviated 
approach was used to assess level of healthcare literacy among survey respondents. Socio-
cultural factors were assessed by evaluating independent demographic variables such as 
education level that can be a potentially confounding variable for data interpretation 
(Appendix 3, 4).  
 
Specific Aim 2: Behavior-specific cognitions and affect.  
To explore CHH patients’ perceived barriers related to health promoting behavior 
Rationale: Assessing perceived barriers to health promoting behavior is an initial and 
fundamental step in developing interventions that either remove the barriers or facilitate 
patients’ ability and confidence to overcome them. The individual characteristics (i.e. 
biological, psychological, and socio-cultural elements as described above) interact with a 
number of elements with strong co-linear relationships.  
 
SA2 Perceived benefits to action, Perceived barriers to action, Perceived self-efficacy, 
Activity related affect were explored in patient focus group discussions to gather patient-
reported outcome data. Additionally, as detailed above, the IPQ-R already includes elements 
of personal control and treatment control which are used as additional proxy measures related 
to self-efficacy in terms of adherence to treatment (Appendix 5). The other areas were 
explored in a series of semi-structured patient focus groups. The patient focus group 
discussions were in-person, face-to-face and were led by the investigator. Additionally, an 
expert patient (community leader) also attended to help facilitate the discussion and to help 
the participants feel comfortable with sharing their experiences. Open ended questions 
(Appendix 9) were asked to probe the main thematic elements identified form the online 
survey and assessing aspects of the HPM. The emphasis of the focus group were to stimulate 
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discussion and collect both similar and discordant viewpoints that include both positive and 
negative commentaries to deepen inferences generated from the quantitative analysis and 
generate working explanatory models (Creswell & Plano Clark, 2011). 
Specific Aim 3: Interpersonal influences. 
To describe the type and quality of interactions with healthcare providers  
Rationale: Effective provider-patient communication has long been demonstrated to 
positively impact health (Kaplan, Greenfield, & Ware, 1989). Conversely, poor 
communication can lead to patient perceptions that providers lack empathy or are dismissive 
of their feelings (Bodenheimer, 2005a). Further, discordance between patients and providers 
can negatively impact patient care, adherence to treatment and health-related outcomes 
(Starfield et al., 1981). Within the HPM, healthcare providers as well as friends, peers and 
family provide important interpersonal influences on health promoting behavior. As such 
these influences were examined to deepen the interpretation of adherence (SA4).  
 
SA3.1 Interpersonal influences (healthcare providers) were examined both in the online 
survey as well as in patient focus groups. Aspects regarding healthcare interactions include 
whether or not patients have been seen at specialized academic medical centers and if they 
have had genetic testing/counseling. Subjects were asked about their perception of their 
healthcare provider’s competence (i.e. medical management of CHH) and empathy 
(understanding how patients feel about living with CHH) and if they have ever discussed 
counseling with their healthcare provider or have received a referral for psychological support 
(Appendix 4). Focus group discussions explore interactions with healthcare providers and 
were analyzed to identify types of interactions that support effective coping and those which 
undermine patients’ sense of wellbeing.  
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SA3.2 Interpersonal influences (friends/peers/ family) were explored in the online survey and 
in focus groups discussions. The online survey assessed where patients find information about 
CHH and what sources are deemed the most important (Appendix 4). Patient focus group 
discussions permitted to examine how patients deal with living with CHH with particular 
attention on effective coping strategies and from whom patients draw on for emotional and 
psychological support (Appendix 9).  
Specific Aim 4: Behavioral outcome/Health promoting behavior.  
To evaluate adherence to treatment in men with CHH 
Rationale: Adherence to treatment is a widely-recognized and significant problem in 
healthcare and in particular in chronic disease as an estimated 50% are challenged to meet 
prescribed regimens regardless of disease, prognosis, or setting (Dunbar-Jacob et al., 2000). 
There is a paucity of data on adherence to treatment in CHH and the few reports examining 
this specific question in men living with CHH indicate that anywhere from 25-34% of patients 
have problems with adherence (Huffer et al., 1964; Laitinen et al., 2012a). Further, 
complicating this issue is the fact that there is no single agreed upon standard as to what 
constitutes an adequate level of adherence (Osterberg & Blaschke, 2005). The WHO (2003) 
defines adherence as “the extent to which a person's behaviour - taking medication, following 
a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a 
health care provider” (p. 17).  For the purpose of this study, assessment of non-adherence 
includes activities related to taking prescribed medication and engaging with the healthcare 
system and the following elements were used for the operational definition of non-adherence:  
 Medication related non-adherence: not filling prescriptions or deciding not to take 
prescribed medication, taking medication at different dose or frequency than 
prescribed, or discontinuing/stopping treatment outside of any provider recommended 
treatment washout (Osterberg & Blaschke, 2005). 
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 Healthcare related non-adherence: not scheduling/attending follow-up medical 
appointments, not having recommended diagnostic testing performed, not having 
monitoring tests performed (i.e. blood draws to monitor serum hormone levels and 
treatment effectiveness)(Vermeire, Hearnshaw, Van Royen, & Denekens, 2001). 
To avoid stigmatizing non-adherence, questions relating to adherence were framed with the 
underlying assumption that all patients have difficulty with adherence, and separating 
medication adherence from healthcare adherence.  
 
SA4 Health promoting behavior (adherence) was evaluated by assessing adherence to 
medication and healthcare. Patient-reported medication adherence was evaluated using the 
Morisky Medication Adherence Scale (MMAS) (Morisky, Ang, Krousel-Wood, & Ward, 
2008). The 8-item questionnaire assesses different aspects of medication taking behavior such 
as forgetting to take medication, difficulty with maintaining a treatment plan, missing doses, 
and intentionally stopping medication. Based on these score, patients can be categorized as 
having low (score=1-5), medium (score=6-7), or high adherence (score=8). While not an 
objective measure of medication adherence, self reported measures have the advantages of 
being acceptable to patients, easy to use and reasonably valid (Garfield, Clifford, Eliasson, 
Barber, & Willson, 2011). The MMAS is a widely used, reliable self-report instrument that 
has shown concordance with objective pharmacy refill records (Krousel-Wood et al., 2009; 
Marcum, Handler, Boyce, Gellad, & Hanlon, 2010). It has demonstrated good concurrent and 
predictive validity with 93% sensitivity and 53% specificity among patients taking medication 
for hypertension (Morisky et al., 2008).  
 
Some criticize self-report assessments of medication adherence as an inherently flawed 
method. An alternative approach would be to perform retrospective chart reviews and comb 
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pharmacy refill information, but given the internationally dispersed sample, these are beyond 
the scope of this needs assessment study. Further, there is no gold standard definition of what 
is adherence and what is an acceptable level of adherence and pharmacy refill records only 
indicate what prescriptions have been filled, not what medications have been taken. 
Therefore, this study represents a first pass to obtain general information about adherence 
patterns in this patient population according to patients’ views. In addition to the MMAS, 
patients will be asked their longest duration of non-adherence (both for medication and 
healthcare) (Appendix 7). Aspects of will adherence are addressed in the focus group 
discussions. 
Quantitative Data Analysis Plan 
Quantitative data collected in the online survey are reported using descriptive statistics such 
as mean ± standard deviation, range, median). Pearson product-moment correlation 
coefficients will be used to examine associations between variables and survey responses (i.e. 
depressive symptoms, medication adherence, and selected subscales of the IPQ-R). 
Additionally, comparisons between groups (i.e. based on yes/no response) are made using 
Student’s t-test or Wilcoxon rank-sum test when data are not normally distributed. Other 
statistical approaches include: 
 Chi square: to compare the proportion of respondents who perceive their healthcare 
provider understand the medical aspects of CHH and the proportion of respondents 
who perceive their provider understands the emotional impact of CHH (Appendix 4).  
 Kruskall-Wallace one-way analysis of variance: to assess the relative importance of 
the most frequently used sources of information on CHH (appendix 4). 
 ANOVA with Bonferroni post-hoc correction for multiple comparisons: to compare 
scores of the IPQ-R dimensions between CHH men and reference cohorts. Because 
the general population does not have an illness, there are no normative data for the 
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IPQ-R.  Therefore, several reference groups were used to provide clinical context for 
these data. Literature reference on values in patients with long-term remission of 
acromegaly were obtained (Tiemensma et al., 2011a) as well as acute and chronic 
pain (Moss-Morris, 2002). The reference patients with long-term remission of 
acromegaly included 81 patients (47 men, 34 women, mean age 60 ± 12yrs) All 
patients had long-term biochemical control of acromegaly with a mean duration up 16 
±10 years. Because illness perceptions assess the perceptions of a specific disease, 
there are self-evidently no norm values for the general population, so scores of 
patients with acute and chronic pain have been used instead to provide meaningful 
context (Moss-Morris, 2002). The reference group with acute pain consisted of 35 
subjects who were recruited from a private practice for physical therapy (20 men, 15 
women, mean age of 36±12yr). These patients presented with a first-time peripheral 
painful injury that had been present for less than six weeks. The reference group of 
patients with chronic pain consisted of 63 subjects (26 men and 37 women, with a 
mean age of 54±11yr) who were recruited from hospital-based chronic pain clinics. 
All patients experienced pain for longer than three months which was unexplained by 
medical signs alone. 
  Linear regression: to assess the possible effect of age of diagnosis or duration of 
treatment on medication adherence. 
 Z-score: to assess differences in proportions of CHH men reporting they have never 
been sexually active (Appendix 6) with a reference group. The CHH cohort will be 
compared to a large probability sample (n=2,058) of adults surveyed about sexual 
behavior (Leigh, Temple, & Trocki, 1993). Additionally, the same approach is used to 
compare the proportion of CHH men exhibiting mild, moderate and severe depressive 
symptoms (Appendix 8) compared to a reference group. One advantage of utilizing 
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the SDS is that the wide use of this validated instrument makes reference data 
available (Blumenthal, 1975). The reference group used for the SDS analysis was 
published previously by Barrett and colleagues examining community base rates for 
depressive symptoms (Barrett, Hurst, DiScala, & Rose, 1978). This study collected 
from a group of 292 community-dwelling, healthy, employed men (mean age 36 yrs, 
range 25-49) who underwent monthly administration of the SDS for a full year to 
determine prevalence rates of depressive symptoms among a non-patient, functioning 
population of untreated men. This published community base rate was used as the 
comparator for the CHH cohort.  
Qualitative Data Analysis Plan 
The qualitative data was collected from a series of three semi-structured focus groups 
involving a total of 26 CHH patients. Questions for the focus group included several open 
ended questions to exploring challenges of CHH and impact on quality of life, impact on 
intimate/sex life, coping/support, and adherence (Appendix 9). Focus group questions 
articulate with the 3 components of the HPM: individual characteristics and experiences (i.e. 
psychological profile including body image, sexuality, illness perceptions and depression –
Appendix 9 questions 1 and 2), activity related cognitions and affect (i.e. interpersonal 
influences and support - Appendix 9 question 1), and health promoting behavior (i.e. 
adherence to treatment – Appendix 9, question 3).  The discussions were recorded and digital 
audio files saved on a password protected laptop, anonymized and transcribed verbatim and 
uploaded into QSR NVivo™ (QSR International PTY Ltd, Melbourne, Australia) to facilitate 
thematic analysis (coding).  
 
Thematic analysis was used to examine the qualitative data. A structured, multi-step process 
was used to analyze narrative materials in order to identify and report themes from such 
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qualitative data (Braun & Clarke, 2006). Through this iterative process, text data was reduced 
into summary categories or themes enabling the investigator to make inferences about the data 
(Hsieh & Shannon, 2005). First, transcripts were read several times and elements coded into 
nodes according to: i) respondents actual words/statements and ii) concepts derived from their 
responses and iii) HPM dimensions. The nodes containing words, ideas, concepts, and phrases 
were then organized and sorted into coherent themes and categories. Coding was conducted 
by two separate investigators independently (PhD candidate Dwyer and thesis advisor Morin) 
to generate initial codes from the HPM and to establish new codes from emerging themes. 
Comparisons were made on individual coding and discrepancies were discussed until 
agreement was met on themes and coding. This iterative process occurred until saturation, the 
point at which no new themes emerge and consensus is set. The least coded themes were 
reviewed to see if they related or could be included with more frequently coded themes and 
thus condensing the codebook into a tightly focused, thematic grouping of elements. 
Additionally, connections between coded terms were mapped to examine co-occurring themes 
and connections within and between categories (i.e. whether or not certain themes appear 
together repeatedly) (Saldana, 2009). Additionally, themes arising frequently and expansively 
were given a particular emphasis. Vivid and compelling quotes sere extracted as examples of 
the themes and themes were visually presented and mapped to conceptualize the qualitative 
data. This process was used to analyze patients’ responses, experiences, and perspectives to 
elucidate explanatory mechanisms that help clarify the quantitative findings (Creswell & 
Plano Clark, 2011).  
 
One criticism levied against such an approach to analysis is that pre-set categories can be a 
source of bias leading to an overly deterministic approach (Jackson & M., 2002). Therefore, 
to avoid this potential source of bias, a minimal a priori set of categories was established. 
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Coded responses were reviewed in aggregate to identify recurrent 
consistencies/inconsistencies from which thematic elements emerge and connections between 
coded terms mapped to examine co-occurring themes. Further, themes were ranked on 
relative importance based on the frequency of responses (Priest, Roberts, & Woods, 2002; L. 
Woods, Priest, & Roberts, 2002). Themes and connections were used to provide additional 
context and richness to the discussion of the quantitative results and help elucidate 
explanatory mechanisms for significant findings. This sequential explanatory mixed-methods 
approach was intended to provide the basis for identifying the specific nursing-sensitive 
targets for future web-based interventions. 
Quantitative data collection procedures 
Participants were given the option of completing an online or paper version that can be 
returned by mail. The first page included a detailed description of study aims and an 
explanation that some of the survey questions will be on sensitive matters and that 
participants are not required to responds if they are uncomfortable. However, the rationale for 
these questions was presented to explain that by answering these sensitive questions, 
participants will help better understand the healthcare needs related to CHH. Issues relating to 
confidentiality were explicitly stated with a description of the safeguards in place to protect 
confidentiality (and for online participants - an assurance that cookie tracking is off). Subjects 
opted in by clicking an “I agree” radio button or by completing the questionnaire and 
returning it by mail. Based on the SurveyGizmo algorithms and feedback received from the 
consulting patient community leaders, the entire process took less than 20 minutes to 
complete.  
 
After completing the questions, participants were thanked for their participation and provided 
with contact information for an expert in the field so that they can discuss questions or 
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concerns that may have been raised by participating in the survey and all participants had the 
option to provide their information (phone or email - in a double entry format to avoid errors) 
to be contacted. Per ethics committee requirement, participants in the online survey are not 
obliged to provide contact information. Subsequently, to confirm CHH diagnosis, every other 
respondent providing contact information was contacted. Three attempts were made to reach 
the participant, and if this was unsuccessful as the participant was not able to be contacted 
within three attempts, then the preceding subject (then proceeding subject) was contacted to 
reach a 40% confirmation rate for the overall cohort included in analysis. Survey data was 
downloaded in Excel format statistical analysis. 
Qualitative data collection procedures 
Focus groups were held in concert with patient support meetings that are planned in 
collaboration with the patient advocates/patient community leaders. For example, the support 
groups meetings will be planned for the morning and participating patients will be invited in 
advance for an afternoon focus group discussion and provided with information sheets and 
consent forms to review. Potential participants can then contact the investigator with 
questions and decide whether or not they wish to participate. This approach was used to avoid 
coercion and to recruit highly motivated patients who are eager to share their concerns and 
experiences. All patient focus group discussions were held in the afternoon following a 
morning patient support meeting. Focus group sessions began with a review of the project, the 
nature of the focus group and the confidential nature of the discussion followed by signing of 
written informed consent (with subjects receiving a copy of the signed consent). The 
emphasis was put on fostering discussion among members relating to the open-ended 
questions (Appendix 9). Focus groups lasted approximately 90 minutes.  
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Ethical Considerations 
Although this study is neither interventional nor involved genetic investigations there are still 
relevant ethical considerations and the full proposal was submitted to the Cantonal Ethics 
Commission on Health Research for review and the study began once the ethics approval was 
received.  
 
It is possible that some of the participants may be depressed or have unmet healthcare needs 
(i.e. non-adherence or no access to a provider with expertise in CHH). Because the online 
survey is anonymous (it is not obligatory for patients to provide their contact information) we 
wanted to make sure that participants at risk are directed appropriately to seek care. To 
address these risks, a statement has been added to the written and a pop-up window to the 
online survey stating “Your score on this survey may indicate that you have clinical 
depression. If you are concerned that you may be depressed we strongly encourage you to 
contact your physician/healthcare provider. There are treatments available for depression. 
Please contact the investigator with questions about this”. In this way, if patients do not 
provide contact information they are directed to seek medical care. Lastly, at the conclusion 
of the questionnaire the link for the COST Action is provided (www.gnrhnetwork.eu) with a 
comprehensive listing of providers with expertise in treating CHH and a listing of specialized 
referral centers so that patients can identify expert care in their region. 
 
Focus groups participants provided a written informed consent prior to study participation. 
Some of the data collected in this study will be of a sensitive nature and as such participants 
will be reminded that the discussions remain confidential. For the focus groups, discussions 
were digitally recorded (audio) and immediately downloaded onto an encrypted, password 
protected laptop computer. Transcribed data were coded so it is not directly linked to 
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individuals. Specifically, the coding was assigned during the transcription process to 
anonymize patients. For example, the first participants in the first focus group would be 
assigned P1, P2, P3, P4, and so on. All study data was stored in a limited access, firewall 
protected, secure database. 
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Chapter IV: Results 
 
As explained in the Preface, this chapter is composed of three original articles which present 
the study results. Each article has been submitted to a peer-reviewed journal. It is included in 
the format required by the thesis.  
 
As a reminder, the main objective of this thesis was to examine the unmet health needs in a 
rare disease patient population using the nursing-sensitive Health Promotion Model (HPM) 
(Pender, Murdaugh, & Parsons, 2010) as a theoretical foundation. It was designed to 
specifically pursue four specific aims and the articles were constructed to address these. 
 
Specific Aim 1 concerning individual characteristics and experiences.  
Its objective was to assess illness perceptions and depressive symptoms in men with CHH. 
All three articles included elements within Pender’s individual characteristics and experiences 
domain. More specifically, article n°2 reported illness perceptions and depressive symptoms 
in men with CHH. Further, article °3 reporting the psychosexual impact of CHH relates 
specifically to the individual characteristics and experiences domain of the HPM (i.e. 
psychological traits such as self esteem, body image and sexuality). 
 
Specific Aim 2 concerning behavior-specific cognitions and affect.  
Its objective was to explore CHH patients’ perceived barriers related to health promoting 
behavior. Article n°2 specifically addressed barriers to health promoting behavior and 
examined self-efficacy using the IPQ-R as well focus groups discussions.  
 
Specific Aim 3 concerning Interpersonal Influences.  
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Its main objective was to describe the type and quality of interactions with healthcare 
providers. Within the Pender’s HPM, interpersonal factors are a critical modifiable element 
for enhancing health promoting behavior. As depicted in all three articles, the impact of 
interactions with healthcare professionals was described and areas for enhanced 
communication and shared decision-making were identified. Findings from both the online 
survey and patient focus group discussions revealed that online community is a critical 
support for these men in article n°1. This finding was explored in focus groups and points to 
the acceptability of online interventions and peer-to-peer support as viable avenues for 
meeting some of the unmet health needs in these dispersed patients. 
 
Finally, specific Aim 4 concerned Behavioral outcome, and health promoting behavior. Its 
objective was to evaluate adherence to treatment in men with CHH. The HPM was here again 
utilized to examine CHH men’s health promoting behavior in relation to adherence to 
treatment and healthcare. Both article n°1 and article n°2 depict that these men often struggle 
to adhere to their medication regime and frequently have discontinuities in care which can 
have major health consequences.  
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Abstract 
Background 
Patients with rare diseases such as congenital hypogonadotropic hypogonadism (CHH) are 
dispersed, often challenged to find specialized care and face other health disparities.  The 
internet has the potential to reach a wide audience of rare disease patients and can help 
connect patients and specialists.  Therefore, this study aimed to: (i) determine if web-based 
platforms could be effectively used to conduct an online needs assessment of dispersed CHH 
patients; (ii) identify the unmet health and informational needs of CHH patients and (iii) 
assess patient acceptability regarding patient-centered, web-based interventions to bridge 
shortfalls in care. 
Methods 
A sequential mixed-methods design was used: first, an online survey was conducted to 
evaluate health promoting behavior and identify unmet health and informational needs of 
CHH men.  Subsequently, patient focus groups were held to explore specific patient-identified 
targets for care and to examine the acceptability of possible online interventions.  Descriptive 
statistics and thematic qualitative analyses were used.   
Results 
105 male participants completed the online survey (mean age 37±11, range 19-66 years) 
representing a spectrum of patients across a broad socioeconomic range and all but one 
subject had adequate healthcare literacy.  The survey revealed periods of non-adherence to 
treatment (34/93, 37%) and gaps in healthcare (36/87, 41%) exceeding one year.   Patient 
focus groups identified lasting psychological effects related to feelings of isolation, shame and 
body-image concerns.  Survey respondents were active internet users, nearly all had sought 
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CHH information online (101/105, 96%), and they rated the internet, healthcare providers, 
and online community as equally important CHH information sources.  Focus group 
participants were overwhelmingly positive regarding online interventions/support with links 
to reach expert healthcare providers and for peer-to-peer support.  
Conclusion 
The web-based needs assessment was an effective way to reach dispersed CHH patients.  
These individuals often have long gaps in care and struggle with the psychosocial sequelae of 
CHH. They are highly motivated internet users seeking information and tapping into online 
communities and are receptive to novel web-based interventions addressing their unmet 
needs. 
Keywords 
congenital hypogonadotropic hypogonadism, Kallmann syndrome, community based 
participatory research, internet, e-health, rare diseases, health promotion, patient-centered 
care, nursing 
Background 
Patients affected by rare diseases are dispersed and face a variety of challenges including lack 
of specialized care, delays in diagnosis, negative social consequences and other psychosocial 
burdens.  The European Organization of Rare Diseases has previously reported a variety of 
obstacles these patients face (EURORDIS, 2009). Many of these are critical social 
determinants of health that place rare disease patients in the realm of health disparities 
(Holtzclaw Williams, 2011). Further, beyond disease and symptom burden, the rarity of the 
condition can result in patients and families feeling marginalized.  In addition, the 
psychosocial impact of perceived invisibility, isolation, and feelings of powerlessness can 
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have significant deleterious impact on quality of life  (Cohen & Biesecker, 2101; Huyard, 
2009; Nettleton et al., 2005).  One way that patients and families have overcome this is by 
embracing technology to access information and connect with other patients online (Fox, 
2011; Tozzi et al., 2013). Advances in information technology and communications are 
creating cultural shifts and are changing how people develop expertise. These trends have 
important implications for healthcare systems and particular relevance for empowering 
patients dealing with rare diseases(Ayme et al., 2008). 
 
Congenital hypogonadotropic hypogonadism (CHH, ORPHA174590) is a rare, genetic, 
endocrine disorder which is clinically characterized by incomplete/absent puberty and 
infertility as a result of a deficiency of gonadotropin releasing hormone. When it occurs with 
an absent sense of smell it is termed Kallmann syndrome (KS, ORPHA478). While incidence 
is difficult to assess, it is estimated at one in 4,000-10,000 based on a study of French 
conscripts (Fromantin et al., 1973). Additionally, it is 2-5 times less frequent in females than 
in males though this gender discordance may represent a bias of ascertainment (Hu et al., 
2003; Quinton et al., 2001; Seminara et al., 1998). Most cases are sporadic, consistent with a 
condition which impairs fertility, yet approximately a third of cases display a familial pattern 
of inheritance(Quinton et al., 2001; Seminara et al., 1998). CHH is clinically heterogeneous 
and may occur with variable reproductive (e.g. undescended testes with/without micropenis) 
and non-reproductive phenotypes such as including eye/ear anomalies (including 
sensorineural deafness, cleft lip/palate, skeletal anomalies, osteoporosis, metabolic 
disturbances and renal agenesis (Mitchell et al., 2011).  
As with other rare disorders, CHH patients often experience delays in diagnosis. For these 
individuals, the absent sexual development of CHH becomes increasingly apparent as peers 
and younger siblings advance through puberty while they remain in a preadolescent state. 
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This experience can have significant emotional and psychological consequences - as depicted 
in an early case series (Huffer et al., 1964) and and reiterated in a recent patient account  
(Smith & Quinton, 2012). Indeed, studies of newly diagnosed adolescent males with CHH 
indicate higher levels of anxiety and depressive symptoms compared to peers (Aydogan et al., 
2012b; Lasaite, Ceponis, Preiksa, & Zilaitiene, 2013).  However, the long-term impact on 
CHH patients has not been examined.  Unlike many other orphan diseases, there are effective 
treatments available.  Hormone replacement therapy can induce development of sexual 
characteristics and in most cases, fertility (Pitteloud et al., 2002; Liu et al., 2009; Warne et al., 
2009).  Cases of spontaneous reversal has been documented (Raivio et al., 2007), yet patients 
typically require lifelong therapy.  Importantly, normalizing the serum hormone levels does 
not completely ameliorate the biopsychosocial effects that CHH patients experience.  A study 
of adolescent CHH patients indicated improved mood after 6-months of treatment, yet 
significant physical and emotional role difficulties persisted compared to healthy peers 
(Aydogan et al., 2012).  These factors may impede adherence to treatment which is a widely-
recognized and significant problem in healthcare, particularly in chronic disease, as an 
estimated 50% find it challenging to meet prescribed regimens regardless of disease, 
prognosis, or setting (Dunbar-Jacob et al., 2000).   Patients with chronic conditions provide 
approximately 95% of their care (Funnell & Anderson, 2000) and thus, adherence problems 
can have important health ramifications. Non-adherence in men with CHH causes hormone 
levels plummet and patients become hypogonadal, placing them at risk for osteoporosis, 
anemia and metabolic problems such as insulin resistance (Brand et al., 2011; Corona, 
Monami, Rastrelli, Aversa, Sforza, et al., 2011; Ding et al., 2006; Finkelstein et al., 1987; 
Popat et al., 2009; Yialamas et al., 2007).   A study examining bone health of a cohort of 26 
Finnish patients indicated 35% of patients had non-adherence periods exceeding 5 years 
(Laitinen et al., 2010).  So despite the availability of effective treatments, there are seemingly 
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other issues diminishing CHH patients’ self-care practices.  However, we do not know the 
extent of problems with adherence among the general population of CHH men nor do we 
understand patients’ perceived barriers to adherence and health promoting behavior.  
 
Therefore, the aim of this study was threefold. First, to examine the utility of web-based 
platforms for reaching dispersed CHH patients and conducting an online needs assessment.  
Second, to better define patterns of adherence to treatment and unmet health and 
informational needs of CHH patients.  Third, to identify specific patient-reported targets for 
care and assess the acceptability of launching patient-centered e-health interventions to 
enhance self-care and health promoting behavior.  
Methods  
This study utilized a community based participatory research framework.  This approach has 
previously been put forth as a useful research model for empowering patients and overcoming 
health inequities (N. B. Wallerstein & Duran, 2006).   As part of a European network focused 
on CHH (COST Action BM1105), partnerships with online patient community leaders (i.e. 
moderators of online patient support sites) were developed to contribute to the study design, 
recruitment, and conduct of the study.  We recognized patients as experts and these partners 
were actively involved in generating ideas as well as providing feedback, comments, and 
criticism in an iterative process to refine the questions and improve the language and clarity of 
the survey and focus group questions.  This descriptive, multivariate correlational needs 
assessment study employed a sequential mixed-methods design. This approach (QUANT-
Qual) started with an online survey and statistical analysis of the quantitative data (Figure 1).  
Subsequently, patient focus groups were conducted and discussions were analyzed using a 
qualitative data analysis.  The intention behind employing this mixed-methods approach was 
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to provide a deeper exploration of the unmet health needs of CHH men than would be 
possible by either method in isolation.  
 
Men were targeted for recruitment as CHH is rare and male cases are 2-5 times more common 
than female cases Seminara et al., 1998, Mitchell et al., 2011).  Men 18-70 years of age 
diagnosed with CHH (Young, 2012) were included in the study.  A random sampling (40% of 
subjects) were contacted to confirm diagnosis and those outside of the age range or who had  
other causes of hypogonadism were excluded from analyses. The study was publicized online 
via a closed/private CHH social media group (Facebook), CHH forum (chat room), a clinical 
trials registry (www.clinicaltrials.gov), and the COST Action website (www.gnrhnetwork.eu). 
Focus groups were held in concert with patient-support meetings that were planned jointly by 
patient community leaders and study investigators. 
 
First, the quantitative arm included an online survey to collect demographic information and 
to assess healthcare literacy, health information seeking patterns, interactions with healthcare 
system/providers, and self-reported adherence to treatment/healthcare (supplemental 
materials).  To assess healthcare literacy we used a self-report method previously shown to 
correspond with lengthier gold standard literacy tests (Chew et al., 2004; Chew et al., 2008).   
Descriptive statistics, Chi square and Pearson product moment coefficients of correlation 
were performed on survey results.  To evaluate the relative importance of the most frequently 
used sources of CHH information we performed Kruskall-Wallace one-way analysis of 
variance on ranks.  SigmaStat (Systat Software Inc., San Jose, California, USA) was used for 
statistical analyses and a p<0.05 was considered significant.  
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Second, the qualitative arm involved patient focus groups discussing issues and challenges 
related to living with CHH, patient-reported coping strategies and the acceptability of possible 
online interventions. Questions were derived from Pender’s Health Promotion Model (Pender, 
Murdaugh, & Parsons, 2010) and developed with input from patient community leaders.  
Focus group transcripts were analyzed using NVivo10 (QSR International PSY Ltd., 
Melbourne Australia).  Briefly, thematic analysis (coding) was conducted by two separate 
investigators (AD:DM) to identify categories of responses and themes emerging from the 
focus group discussions and discrepancies in coding as well as emergent categories were 
discussed until resolution was achieved.  Iterative coding occurred until no further themes are 
identified, suggesting a saturation point has been reached.  Additionally, connections between 
coded terms were mapped to examine connections within and between categories (i.e. 
whether or not certain themes appear together repeatedly) and those arising frequently and 
expansively were given particular emphasis (Saladana, 2009).   
 
The study was approved by the University of Lausanne ethics committee and informed 
consent was obtained from all participants.  Participants in the online survey provided an 
electronic, opt-in format consent while focus group members provided written consent.  All 
participants received investigator contact information to address questions/concerns and were 
given the option to provide an email address if they agreed to be contacted by the 
investigators for follow-up clarification.  
 
RESULTS AND DISCUSSION  
Web-based platforms combined with community partnerships are effective for conducting 
needs assessment survey in dispersed patients 
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The survey was online for 7-months and received a total of 230 hits.  Of these, 105 (46%) 
were CHH men who completed the survey and met inclusion criteria.  To provide context, if 
one takes the incidence of CHH as 1/10,000, then recruiting 100 subjects would provide an 
equivalent denominator of 1 million people.  Thus, the web-based recruitment was an 
effective way to reach this dispersed population of CHH men. The sociodemographic 
information of the men responding to the web-based survey is provided in Table 1.  These 
participants varied in age from 19-66 years (mean 37±11, median 36), two thirds had received 
education beyond high school/vocational training (69/105, 66%) and the majority were 
employed (79/104, 76%) across a broad spectrum of fields (supplemental materials).  From 
the relatively advanced age of survey respondents we suspect that younger men with CHH 
may be lurking online to gather information but may not yet feel emotionally secure enough 
to discuss issues regarding their lack of sexual development.  A review of the email addresses 
voluntarily provided by participants included email service providers from North and South 
America, Europe, and Australasia underscoring the global reach of online recruiting via social 
media for rapidly reaching dispersed patients.  
 
Studying orphan diseases presents a challenge in terms of recruiting adequate numbers of 
widely dispersed patients (Kruer & Steiner, 2008; Watson et al., 2008).  Previously, online 
web-based questionnaires have proven a useful tool for reaching dispersed populations 
(Eysenbach & Wyatt, 2002) and advertising on social media platforms can enhance patient 
recruitment efforts (Close et al., 2013, Ramo & Prochaska, 2012).  Instead of using online 
advertising, herein we developed partnerships with online patient community leaders to reach 
dispersed rare disease patients and utilized web-based platforms for both recruitment and data 
collection. This was an effective way to reach a large audience and conduct an online CHH 
needs assessment.  Further, such patient community partnerships may provide multiple bi-
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directional benefits including connecting patients with expert care and enhancing recruitment 
for research/clinical trials.  
 
CHH patients have long gaps in care 
Nearly all the men (99/105, 94%) in the online survey responded that they had received 
testosterone therapy for CHH.  Six men reported never having received testosterone; three 
men stated they had never been on treatment (2/3 had been recently diagnosed) and the other 
3 men had only received gonadotropin injections.  In total, only 24/93 (26%) of men reported 
never having a lapse or gap in treatment (Figure 2).  However, 37% (34/93) reported having 
been off treatment for more than a year.  Survey respondents reported similar the periods 
when asked about the longest duration without healthcare (supplemental materials).  No 
correlation was observed between medication/healthcare adherence and either age of 
diagnosis or lifetime duration of treatment.  Importantly, these gaps in treatment and care can 
have major health impacts on patients.  Hypogonadism causes decreased libido,  impaired 
sexual function and  anemia and can have profound effects on bone density placing patients at 
increased risk for osteoporosis and fracture (Finkelstein et al., 1987; Laitinen et al., 2012).  
Further, several meta-analyses point to an association between low serum testosterone levels 
and the metabolic syndrome and diabetes (Ding et al., 2006; Corona et al., 2011; Brand et al., 
2011).  Even acute withdrawal of treatment in these men induces increased fasting insulin 
levels and insulin resistance within two weeks (Yialamas et al., 2007) while long-term 
hypogonadism carries heightened prevalence of hyperinsulinemia, metabolic syndrome and 
diabetes (Shahani et al., 2008).  Thus, lack of or inadequate androgen replacement may 
heighten further health risks for CHH men such as cardiovascular morbidity. Accordingly, 
these represent meaningful targets for interventions to enhance adherence to treatment and 
self-management.  
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CHH patients have unmet psychosocial health needs 
The online survey included several questions that were developed to examine past interactions 
with healthcare systems (supplemental materials) including experiences with discrimination 
related to their condition (Hudelson, Kolly, & Perneger, 2010).  Fewer than one in five 
(16/105, 15%) of men reported that they had faced this type of discrimination.  Notably, 
approximately half of the respondents (54/105, 51%) had been seen at a specialized/academic 
medical center.   As healthcare providers exert important interpersonal influences on health 
promoting behavior, we queried patients about their experiences with healthcare 
professionals.  In total, 70/105 (67%) stated that their healthcare provider understood the 
medical aspects of their condition.  However, significantly fewer (39/104, 38%, p<0.001) 
perceived that their provider understood the emotional impact of CHH.  Having a provider 
who comprehended the medical aspects of CHH correlated positively with being seen at a 
specialized center (R=0.40, p<0.001) while having a provider who understood patients’ 
feelings about having CHH was positively correlated with having been referred for 
psychological counseling (R=0.22, p<0.05).  The patient perspectives identified in the survey 
suggest that while many CHH patients are able to find and obtain specialized 
care/consultation with expertise in handling the medical aspects of their care, the emotional 
and psychological aspects of CHH are underappreciated.   
 
Based on the survey findings we conducted three patient focus groups (n=26 total 
participants, mean age 37±13, range 18-66, median 36 years) to explore the challenges 
patients face in living with CHH and identify facilitators of adaptive coping strategies that 
could be leveraged for potential online interventions.  What emerged from these discussions 
were consistent, pervasive psychological and emotional issues related to feelings of isolation 
and shame (Figure 3).  The mean age at diagnosis was 18±5 years (range 10-27, median 17 
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years) and spending teenage years and young adulthood in a prepubertal body was 
emotionally traumatic for many.  Indeed, many patients commented on their frustration with 
what they perceived to be a late diagnosis or a delay in initiating treatment as well as 
significant concerns related to underdeveloped genitalia.  These experiences were linked to 4 
coherent themes: i) body image concerns, ii) low self-esteem, iii)  anxiety/depression, and iv) 
a sense of being left-behind as their peers developed into adult bodies (and adult roles) 
(Figure 3, Table 2). These themes were frequent and their co-occurrence within and across 
groups suggest that a saturation point had been reached.  Thus, these unmet psychosocial 
health needs indicate the need for psychological support and represent targets for much-
needed intervention. Notably, differences were observed across different national health 
systems.  For instance, patients with nationalized health systems reported better continuity in 
care (i.e. better transitions) and fewer gaps when changing healthcare providers.  In contrast, 
patients in individual payer systems reported significant transition problems as well as 
medication coverage issues both of which undermined adherence to treatment. 
 
CHH patients have unmet health information needs 
During focus group discussions, participants indicated that healthcare providers (physicians, 
nurses and pharmacists) played both positive and negative roles in helping them adapt to 
living with CHH (Table 2).  Providers who were not forthcoming with information about 
CHH, disregarded patient concerns/feelings, did not set appropriate expectations for treatment 
outcomes, and did not engage patients in decisions, were sources of frustration for patients 
and undermined patients’ sense of wellbeing.  Healthcare professionals could also be 
powerful promoters of adaptive coping.  Patients reported feeling supported by providers who 
expressed empathy, facilitated self-management techniques (i.e. self-injecting medications) 
and involved them in decision making. As such, efforts to promote patient participation in 
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treatment decisions and providing patient information and anticipatory guidance in lay 
language appear to be avenues for meeting patients’ informational needs, and potentially 
improving patient satisfaction with care and adherence. 
 
CHH patients rely on the internet for CHH information and peer-to-peer support 
The survey participants were active users of the internet for issues related to their condition.  
Nearly all participants (101/105, 96%) stated they had sought information from online sources 
(i.e. Wikipedia).  This may be related to the fact that the manifestations of CHH (sexual 
immaturity and infertility) are very private and personal matters and thus may contribute the 
high rate of anonymous information seeking that the internet provides.  Less than half of 
survey respondents (49/105, 47%) used the medical literature as a resource for finding out 
about CHH.  This was interesting as these men have relatively high levels of education (Table 
1), yet preferred to seek information from other online resources, paralleling the increase in 
such practices among physicians (Kritz et al., 2013).  Because the number of years of formal 
education may not be the best predictor of facility with medical information, we also used a 
previously validated self-report question “How confident are you filling out medical forms by 
yourself?” to screen those participants with inadequate healthcare literacy (Chew et al., 2004; 
chew et al., 2008).  By this standard, all but one of participants had adequate healthcare 
literacy.  Therefore, despite adequate education, appropriate healthcare literacy and access to 
the literature (i.e. PubMed Central), it seems that patients are much more likely to seek out 
information from online sources that are not part of the medical literature.  Therefore, 
providing expert-reviewed information in lay language online could be an effective way to 
disseminate CHH-related health information to these dispersed patients.  
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The survey also revealed that patients seek information from healthcare providers and the 
online community in equal proportions (74/105, 70% and 81/105, 77% respectively).  Further, 
when asked to rate the importance of healthcare professionals, online community and the 
internet as sources for information, all rated similarly (p=0.58).  These data support the notion 
that for CHH patients, information from healthcare providers and members of the online 
community who share their condition are equally important and complementary.  The 
importance of connecting with other patients via the online community was echoed in the 
patient focus groups.  Participants stated that connecting with other patients online and 
finding out they were not alone was an important aspect of coming to terms with CHH, 
finding meaning in their condition, and being able to not let CHH dominate their life.  
Further, face-to-face encounters with other patients were often regarded as a pivotal and life-
changing event (Table 3).   
 
The data from the present study are in line with the findings of a 2011 report from the Pew 
Foundation that identified patients with rare diseases as the most likely group to draw upon 
online peer support network, even more so than those with other, more common chronic 
health conditions (Fox, 2011).  Patient knowledge is different from that of professional 
healthcare providers.  Patient expertise grows from a personal day-to-day experience of living 
with a condition and as such, patients can provide critical informational support for coping 
and managing one’s health (Hartzler & Pratt, 2011).  These complementary realms of 
expertise present an opportunity for collaborative efforts for health promotion and improving 
quality of life for patients dealing with chronic conditions (Lorig et al., 2013; Archambault, 
2011, Gepta et al., 2011).  Connecting with other patients is critical for CHH because it can 
diminish the isolation of living with a rare condition. Further, such peer-to-peer support may 
hold important promise for very practical and concrete benefits such as promoting adherence 
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to treatment and continuity with healthcare and encouraging peers to seek mental health 
services when needed.    
 
CHH patients are receptive to online interventions 
Focus group participants were unanimously open to and in support of utilizing online 
approaches to help develop coping and self-management skills. The only concern raised 
regarding this was the issue of confidentiality that perhaps is not surprising given the very 
private nature of the sexual immaturity and infertility of CHH. This mixed-methods study 
identified a variety of unmet health needs of CHH men.  Importantly, the focus groups 
revealed positive examples of patients overcoming challenges, finding meaning in their 
condition and becoming empowered, activated patients (Table 3). As these men are active 
internet users and receptive to the idea of online interventions, we propose several patient-
centered approaches for health promotion in these dispersed patients.  
 
Developing online interventions to address the needs of CHH patients  
Interventions addressing the identified shortfalls in care for CHH patients are intended to 
enhance wellness and improve coping and quality of life for these individuals.  This is the 
fundamental objective of health promotion – the  process of enabling people to overcome 
health challenges and increase control over their situation to achieve greater health (World 
Health Organization (WHO), 1986).  Indeed, the Health Promotion Model (Pender, 
Murdaugh, & Parsons, 2010) has been used as a model to develop patient-centered 
approaches to activate and empower patients for self-management (Ho, Berggren, & 
Dahlborg-Lyckhage, 2010) and thus seems fit the needs of CHH patients. This approach 
acknowledges patient expertise and dramatically reframes patient involvement as well as  the 
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role of the healthcare professionals to redefine successful health outcomes (Greenhalgh, 
2009).  Herein we identify three main targets for health promoting interventions (Table 2, 3).  
 
First, CHH patients have unmet informational needs related to their condition. Given their 
active internet use, it seems logical to launch web-based information resources for patients 
and providers alike.  For patients, this could include information in lay language about CHH, 
treatment options, and anticipatory guidance related to treatment (i.e. what to expect from 
treatment and in what timeframe).  Further, we propose to develop materials (i.e. fact sheet of 
discussion points) for healthcare professionals, written by expert clinicians and available 
online for patients to use in order to initiate discussions with their healthcare provider on the 
psychological and emotional aspects of the condition and to promote shared decision-making.  
These materials would help contribute to create a virtual online empowerment toolkit for 
patients to learn about their condition, find expert care, and become empowered to take 
control of their health.  Further, these resources could be provided in multiple languages via 
the European network studying GnRH deficiency (www.gnrhnetwork.eu) encompassing  
patient information in lay language, listings of specialized referral centers, genetic testing 
resources, clinical trial listings, and web-based platforms for contacting expert clinicians as 
well as links with peer-to-peer support. 
 
Second, enhancing online peer-to-peer support to diminish the sense of isolation, share coping 
strategies and encourage peers to seek mental health services when needed to address issues 
of anxiety/depression.  The synergy of online connectivity and patient expertise facilitates 
crowdsourcing for the rare disease community.  Crowdsourcing is the process of tapping into 
the collective knowledge and problem solving abilities of a group (such as patients with a 
shared medical condition) to generate ideas and solutions (Howe, 2006).  Importantly, online 
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patient communities are not intended to replace existing healthcare infrastructures, rather their 
expertise differs from healthcare professionals and can be valuable for peer-to-peer support 
and learning how to deal with issues on a daily basis (Hartzler & Pratt, 2011).  Further, this 
pool of knowledge/experience not only impacts health management, but is also beginning to 
change approaches to research (Swan, 2012).   
 
Third, to help patients address their feelings of shame, body image concerns and low self-
esteem there is an opportunity to utilize online cognitive-behavioral interventions. Indeed, 
online education combined with peer-to-peer coaching has been successful in enhancing self-
management and adherence to treatment for bipolar disorder and diabetes (Proudfoot et al., 
2012; van der Wulp et al., 2012).  A similar approach combining online patient education, 
cognitive behavioral interventions, and peer coaching could be adapted to address the specific 
body-image and self-esteem issues related to CHH.  Further, technology may enable contact 
with otherwise difficult to reach patients and potentially surmount barriers that exist for face-
to-face mental health treatment.   
   
Limitations 
Like other studies of this kind, this needs assessment has limitations.  First, the inferences 
drawn from the survey findings could be strengthened by a larger sample size.  Indeed, 
recruiting adequate numbers of rare disease patients can pose a challenge.  This is why we 
utilized a web-based approach, yet this is not without bias as not everyone has internet access 
and is perhaps reflected in the fact that respondents  were highly educated.  Further, an online 
survey in English may introduce a potential Anglophone bias.   Importantly, the longstanding 
critique of online research (access) is beginning to fade as the number of individuals lacking 
internet access rapidly shrinks.  As of 2011, 73% of European Union households had internet 
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access (2/3 of which have broadband).  Further, more than half of Europeans use the internet 
daily and just one quarter (24%) have never used the internet (Seybert, 2011) and many 
developing countries have “leapfrogged” straight into mobile handsets for multimodal 
communication and connectivity (Napoli, 2013).  
 
Second, there are potential biases in the sampling of subjects.  Participants were recruited via 
expert clinicians as well as among patient support groups.  As medical record review was not 
part of this study, we recontacted 40% of respondents to confirm diagnosis.  As such, we 
cannot be sure that every respondent met all hormonal and clinical criteria of a CHH 
diagnosis.  However, the fact that the findings of the survey were mirrored in the focus groups 
(where all participants had confirmed CHH diagnosis) contributes to the validity of the study.  
Additionally, engaging patients in the study development and conducting an internet survey 
introduces sources of potential bias as these patients are the ones who seek out forums and 
web-based support.  Similarly, those participating in patient support groups could represent  
men who are struggling most to deal with their condition and thus may overestimate the 
difficulties experienced by men with CHH.  However, these issues may be less of a concern 
for such a needs assessment as the intent was precisely to identify a specific cohort of patients 
to explore their situation and perspectives in depth.  While not a random sampling of patients, 
targeting internet users was necessary to assess the acceptability of delivering web-based 
interventions to patients who use the internet as a resource for health information and support.  
In addition, the anonymity of online information can be an asset for eliciting information that 
patients may not feel comfortable expressing in face-to-face encounters with healthcare 
providers (Bedgood, Sadurski, & Schade, 2007).  
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Third, the evaluation of adherence is often debated as there is no gold standard definition, no 
clear consensus on what is an acceptable level of adherence and self-report is subjective and 
an inherently flawed method.  An alternative approach would be to perform retrospective 
chart reviews and comb pharmacy refill information, but these are beyond the scope of this 
needs assessment study.  Rather, this survey was intended to capture a global picture 
adherence patterns in this patient population.  The rationale for using a self-report measure 
was based on the fact that CHH is a chronic condition and as such, patients are responsible for 
the bulk of their care.  Therefore, understanding patient perceptions and perspectives is a 
critical first step in developing patient-centered approaches to activate individuals and 
enhance self-management of their chronic condition. 
 
CONCLUSIONS  
Patients with CHH often have long gaps in care and struggle with significant psychosocial 
sequelae that are often unrecognized by the healthcare community.  These patients are active 
internet users who draw on social media and online communities for support and to 
complement the information received from healthcare professionals.  Patients are receptive to 
online interventions aimed at addressing their unmet needs.  Peer-to-peer support can help 
enhance coping and patients should be encouraged to utilize these online communities.  
Drawing upon patient expertise and developing partnerships with online patient communities 
may provide new opportunities for health promotion and improved quality of life for these 
patients. 
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Illustrations and Figures 
 
 
Figure 1. Study schema 
Figure Legend:  
Schematic depicting the sequential explanatory mixed-methods design.  (A) First, a 
quantitative online survey was conducted and statistical analysis performed.  (B) 
Subsequently, qualitative focus groups were conducted to explore the survey findings in detail 
and identify potential explanatory mechanisms.  Asterisks note study stages involving 
participation of patient community leaders.    
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Figure 2. Adherence to treatment among CHH men 
Figure Legend: Patient-reported longest duration off treatment (n=93). All men had been on 
treatment for at least 12 months. Only 26% (24/93) of men reported never having a gap in 
treatment (white bar).  In total, 37% (34/93) had a lapse in treatment of more than1 year. 
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Figure 3. Patient-reported challenges of CHH 
Figure Legend: Patient-reported challenges represent targets for interventions.  Focus group 
discussions revealed two dominant themes relating to feelings of isolation and shame 
(depicted by circles).  These themes encompassed 4 consistent, inter-related psychosocial 
challenges related to CHH low self-esteem, body image concerns, feeling left behind by their 
lack of sexual development, and issues related to anxiety and depression (depicted by 
diamonds).  The shapes are sized according to the frequency of patient comments and 
overlaps and connected shapes identify co-occurring themes.   
ISOLATION SHAME
anxiety &
depression
body image
concerns
low 
self-esteem
feeling
“left behind”
95 
 
Tables and Captions 
Table 1. 
Sociodemographics of the CHH men completing the online survey (n=105) 
 
Age (n=105) n (%) 
   19-29  32 (30%) 
   30-39 39 (37%) 
   40-49  19 (18%) 
   50-59  11 (10%) 
   60+  4 (4%) 
Education (n=105)  
   High school/vocational 36 (34%) 
   University 38 (36%) 
   Post-Graduate 31 (30%) 
Employment (n=104)  
   Working full-time 70 (67%) 
   Working part-time 9 (9%) 
   Unemployed 10 (10%) 
   Retired 6 (6%) 
   Student 9 (9%) 
Relationship Status (n=104)  
   Married 38 (36%) 
   In a relationship 16 (15%) 
   Single 25 (24%) 
   Never been in a relationship 24 (23%) 
   Divorced 1 (1%) 
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Table 2.  
Table of themes emerging from focus group discussions, representative quotes, and targets 
for interventions 
 
Table Legend: The first column identifies thematic elements from the focus groups 
discussions across 2 topic areas (shaded in gray): patient-reported challenges and negative 
healthcare interactions.  The middle column presents representative quotes for the emergent 
themes.  The third column lists the related targets for interventions to address the unmet 
health and informational needs of the CHH men.  
 
 
 
 
 
 
 
 
 
 
 
 
Theme Representative quotes Targets for interventions 
Patient-Reported Challenges 
Isolation 
 "I was on the outside of any social group or gathering and on the inside, I was very alone and depressed 
and isolated and very frightened" 
 
 "I realized that something was “wrong” with me, and didn’t know what, and it looked like nobody knew. 
I more or less expected to have a unique disease which would have my name." 
 
 "I’ve pretty much been in exile for the past ten years" 
 
Connecting with others & 
online peer-to-peer  support 
Shame  
Cognitive-behavioral 
interventions 
  i. body image 
 (the hardest part of CHH) "The body image problems really... I will have that until the day I die" 
  
 "I can’t get undressed... I haven’t been swimming in many years. I can’t even pull my sleeves up... I 
can’t sit there like you with your sleeves rolled up...I’ve got to keep covered." 
 
ii.  self-esteem 
 
 "I have a tough time engaging with people, talking with people.  Usually, when I am out in public I tend 
to look down at the ground, because you know... I feel so ashamed" 
 
 "I always thought there was a big spotlight on me all the time.  Just... self-conscious... absolutely. I got a 
lot of bullying and being pushed around and abused when I was young" 
 
iii. left behind 
 
 “I’m 40 years old and should be at the prime of my career and I don’t see myself…I don’t know, it’s a 
psychological barrier that I can’t progress, I’m stuck " 
 
 "For Kallmann’s (CHH), it’s sort of a crucial sort of time you know, we say the psychological and 
emotional things are equally as big as the medical forms of treatment for it.  That big, big thing (absent 
puberty) carries on for the rest of your life" 
 
iv. depression & 
anxiety 
 
 "I have depression, definitely. I have noticed a common denominator with depression and self 
medication... myself included" 
 
 "…and my family, they weren’t supportive.  They didn’t help me. So, I got depressed and I tried to take 
my own life and then um…I left to seek help on my own" 
 
* Quotes referencing the term "Kallmann's" refers to Kallmann syndrome - the association of CHH with the inability to smell (anosmia) 
 
 (Table 2 continued)  
Negative Healthcare Interactions 
lack of 
information 
• "The professor (doctor) who diagnosed my condition didn't even touch on the psychological side of 
things" 
 
• ""For the first few years after it (CHH) was mentioned to me, there was nothing at all coming back from 
the doctors.  They didn’t really tell me what I was being treated for.  So it was kind of…they diagnosed 
me but didn’t tell me and anything" 
 
• "The doctors weren’t… it was just nothing.  There was no real after-care at all after the diagnosis.  It was 
just ‘you need to take these injections’ and that was that…you know, for the rest of your life.  There was 
no kind of…nothing.  It was a lack of communication really" 
 
online information & 
resources 
disregard for 
feelings 
 
• "I felt like I wasn’t considered intelligent enough to understand what I was being treated for.  It was like 
‘oh, you won’t understand, it's complicated’.  That’s it…yeah, it’s not nice to be made to feel that way." 
 
• "Somebody once said something to me, actually it was an endocrinologist, and I said ‘but I’m not normal’ 
you know?  And this was several years ago, and I think he was trying to say ‘look, everything will be 
alright, keep taking your medication and all the rest of it’ and I said ‘I don’t know what normal is’...and 
that didn’t seem to faze him at all. I sat here saying to this professional , educated, intelligent man - he’s a 
professor - and I was saying ‘I don’t know what normal is’ and he didn’t respond. Nothing…he didn’t 
even look at me." 
 
• "There’s no sense from anyone... about them trying to understand or even that it crosses their mind that 
you are going through anything.  You know, that it’s painful. They are just ‘Mr. fix-it’ - give you a 
prescription and you are gone" 
 
promoting                      
patient-centered approaches 
& developing a                    
"talking sheet" to                   
initiate discussions      with 
providers 
lack of shared 
decision-making 
 
• "He (doctor) didn’t give me any treatment options.  He just said 'take this gel'.  We didn’t discuss what 
was the best treatment. I don’t know if it was just the physician that I went to…maybe there are better 
ones out there who would have given me the option(s)". 
  
• "The first doctor I saw he said just take these and you’ll be ok" 
 
discordant 
expectations     
for treatment 
outcome 
 
• "No one really explained to me…I thought that if I took the  testosterone…I didn’t understand that…I 
thought that if I just took the testosterone that I would go through puberty and I would be normal." 
 
• "I said no, I can’t smell a thing adn he said, 'Ah, you’ve got Kallmann's (CHH)!'  I thought wow that’s 
great, give me the injections and I can smell the roses and all that and well of course it didn’t happen.  My 
sense of smell never came." 
 
online anticipatory 
guidance information 
* Quotes referencing the term "Kallmann's" refers to Kallmann syndrome - the association of CHH with the inability to smell (anosmia) 
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Table 3.  
Patient reported facilitators of coping 
 
Table Legend: The first column identifies thematic elements from the focus groups 
discussions across 2 topic areas (shaded in gray): patient-reported challenges and negative 
healthcare interactions.  The middle column presents representative quotes for the emergent 
themes.  The third column lists the related targets for interventions to address the unmet 
health and informational needs of the CHH men.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Theme Representative quotes 
Targets for 
interventions 
Meeting others & 
online support 
• "Though I have a loving family I had spent most of my life feeling depressed, confused, lonely, alone, 
isolated, and frequently in despair. In just a couple of hours at the meeting 3 years ago... those feelings 
decreased. For the first time ever I was with a group of people with whom I felt normal and at ease, 
valued and respected. This has made a tremendous difference in my life.” 
 
• "It wasn’t until I found other people like (patient community leader) that I kind of filled in the blanks a 
bit. It was quite isolating for me and I had no one to talk to and I felt like I was the only person in the 
world to have this problem" 
 
• "I’ve really felt alone.  So I went online, on Facebook just to see if there was something or a meeting and 
I found this group and it was the best thing I ever did because I found out there are other people and I 
thought I was alone.  But I found others... which is really good" 
 
• "Going to my first Kallmann (CHH) meeting about 6 years ago… and until then, I was totally in the 
dark. And when I met up with fellow patients, I realized I’m not on my own" 
Online peer-to-peer 
support 
Coming to terms 
with CHH 
• “Get over it, take matters into your own hands… you will get help.  All you have to do is ask for it.  (To 
the moderator) in your research, you are searching for ways that would help me… a toolkit, a fact sheet 
‘living with Kallmann (CHH)’ that kind of thing…it also involves emotional things.  If you can give that 
to a doctor so then that is the trigger to start a conversation.  Then you can take matters into your own 
hands”.  
  
• "So it was a change in mentality, being taunted as a child then I realized that I had to do certain things to 
get my life back" 
 
• "It was just the things that I would have to find out about myself that no one could tell me... and like I 
said, (patient community leader) has helped…  Both on a personal level and for the research into the 
condition itself.  But, being able to live with it is a very personal thing that I think you need to find out 
for yourself…and I think I’m coming along pretty nicely... I’m not letting it rule my life quite so much 
as I used to." 
Patient 
empowerment 
Positive 
Healthcare 
interactions 
• "All the medical professionals I have been working with…I’ve been very lucky because they have 
always been very helpful and considerate about it. So, I guess I have been fortunate that way" 
 
• "Definitely, self-injecting (helped).  Learning about the syndrome made me feel that Kallmann (CHH) is 
not such a big deal.  But in my case, it was not enough... and the psychotherapy aspect helped a lot" 
 
• "I first heard about Kallmann's (CHH) at 25 when I moved in a new city and changed endocrinologists. 
That made a huge difference, suddenly she made it sounds like it was not such a big deal. In my 
experience female doctors are more easy to talk with, tend to ask more about how it works in the 
everyday life, and involve us in our prescriptions" 
promoting                      
patient-centered 
approaches & 
developing a                    
"talking sheet" to                   
initiate discussions      
with providers 
* Quotes referencing the term "Kallmann's" refers to Kallmann syndrome - the association of CHH with the inability to smell (anosmia) 
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Additional Files: A1  
A1 - Supplemental materials. 
Identifying the unmet health needs of patients with congenital hypogonadotropic 
hypogonadism using a web-based needs assessment: Implications for online interventions and 
peer-to-peer support 
1.Summary of online survey results  
1A. Sociodemographic information 
Age: [open ended response] 
19-29 yrs: 32/105 (30%) 
30-39 yrs: 39/105 (37%) 
40-49 yrs: 19/105 (18%) 
50-59 yrs: 11/105 (10%) 
60+ yrs: 4/105 (4%)  
 
Relationship status: [multiple choice] 
Never been in a relationship: 24/104 (23%)   
Single: 25/104 (24%)   
In a relationship: 16/104 (15%)   
Married: 38/104 (36%)  
Divorced: 1/104 (1%)  
 
Religion: [open-ended question]  
Christian (protestant & evangelical): 25/90 (28%) 
Roman Catholicism: 17/90 (19%) 
Orthodox Christianity: 3/90 (3%)  
 (Eastern & Russian)  
Islam:  5/90 (6%) 
Judaism: 2/90 (2%) 
Buddhism: 1/90 (1%) 
Hinduism: 1/90 (1%) 
 Other: 10/90 (11%) 
 (Paganism, Mormonism, Jehovah's Witness, secular humanist, personal faith)
 Atheism: 10/90 (11%) 
None: 16/90 (18%) 
 
Highest level of education: [multiple choice] 
Elementary: 0/105 (0%) 
High school/vocational: 36/105 (34%)   
University: 38/105 (36%)   
Post-graduate: 31/105 (30%)  
102 
 
 
Employment: [multiple choice] 
Student: 9/104 (9%)  
Working part-time: 9/104 (9%)  
Working full-time: 70/104 (67%)  
Retired: 6/104 (6%)  
Unemployed: 10/104 (10%) 
 
Type of employment: [open ended question - responses included]  
Business & Finance 
Business analyst/consultant 
Economist 
Finance 
Teaching & Education 
Teacher 
Professor 
School administrator 
Law & Legal Services 
Attorney 
Legal assistant 
Legislative consultant  
Psychology & social Work 
School Counselor 
Counselor/mediator 
Healthcare & Science 
Dentist 
Physician 
Nurse 
Pharmacist 
Ambulance staff 
Patient care assistant 
Translation services 
Biomedical scientist 
Chemist/Lab Technician 
Hospital finance/administration 
Engineering & Information Technology 
(IT) 
Engineer 
Electrical Engineer 
Applications engineer 
Network Engineer 
Computer systems management 
Software developer 
Computer programming 
IT technician 
Service & retail 
Clerk 
Sales/Retail 
Personal trainer 
Call center/customer services 
Management & supervisors 
Manager - small business 
Manager – manufacturing 
warehouse supervisor 
Purchasing manager 
Laborer & Manufacturing 
Construction 
Lawn care 
Airline baggage 
Warehouse 
Milling machine operator 
Quality control technician 
Transportation 
Public transportation driver 
Limousine Service 
Truck driver 
 
Civil Service 
civil servant 
Postal worker 
Juvenile services 
Arts & Entertainment 
Composer 
Performing arts 
Graphic design 
Religious clergy 
clergy 
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Buddhist monk 
 
1B. Healthcare literacy 
How confident are you filling out medical forms by yourself? 
Extremely: 45/105 (43%)    
Quite a bit: 34/105 (32%)    
Somewhat: 25/105 (24%)    
A little bit: 1/105 (1%)    
Not at all: 0/105 (0%)   
   
1C. Health information seeking patterns: 
Where have you searched for information to learn about CHH? (check all that apply) 
Internet (i.e. Wikipedia): 101/105 (96%)     
Online community (social media/chat): 81/105 (77%) 
Healthcare professionals: 74/105 (70%)          
Medical literature: 49/105 (47%)          
Family/friends: 12/105 (11%)                
Other: 0/105 (0%) 
 
From your experience, please rank the 3 most important sources:  
Healthcare professionals: weighted score 166 
Internet (i.e.Widkipedia): weighted score 150  
Online community (social media/chat): weighted score 146 
Medical literature: weighted score 93 
Family/friends: weighted score 18 
 
 
 
1D. Interactions with healthcare system/providers  
Within the healthcare system, have you ever experienced discrimination because of CHH? 
  No: 89/105 (85%) 
Yes: 16/105 (15%) 
 
Have you ever had a consultation or received treatment at an academic health center (such as 
a teaching hospital or research center)?  
No: 51/105 (49%) 
Yes: 54/105 (51%)  
 
Is there a healthcare provider (i.e. doctor or nurse) who you feel really understands the 
medical aspects of your CHH?  
No: 35/105 (33%) 
Yes: 70/105 (67%) 
 
Is there a healthcare provider (i.e. doctor or nurse) who you feel understands your feelings 
about having CHH? 
No: 65/104 (62.5%) 
Yes: 39/104 (37.5%) 
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Has a healthcare provider (either general practitioner or specialist) ever offered you 
counseling or a referral for professional counseling? 
  No: 79/105 (75%) 
Yes: 26/105 (25%) 
 
1E. Diagnosis, treatment & adherence 
At what age were you diagnosed with CHH? [open ended question] 
Mean±SD: 18±6 years 
Range: neonatal – 32 years 
Median: 18 years 
 
Lifetime duration of treatment [calculated from start of treatment] 
Mean±SD: 18±12 years 
Range: 0 – 46 years 
Median: 16 years 
 
What treatments have you had for CHH? (check all that apply) 
Testosterone (injections, pellets, patches, or gel): 99/105  
Gonadotropin/fertility injections: 37/105   
None: 3/105 (two recently diagnosed patients) 
  
What is the longest period of time that you have gone without medical care (not under the 
care of a doctor or healthcare provider for your CHH): [open-ended] 
Never: 24/93 (26%) 
<6 months: 27/93 (29%) 
6-12 months: 7/93 (8%) 
13-24 months: 15/93 (16%) 
25-36 months: 8/93 (9%) 
36+ months: 12/93 (12%) 
 
What is the longest period of time that you have been off your CHH medication (not at the 
instruction of your doctor or healthcare provider): [open-ended] 
  Never: 28/87 (32%) 
<6 months: 20/87 (23%) 
6-12 months: 3/87 (3%) 
13-24 months: 17/87 (20%) 
25-36 months: 6/87 (7%)  
36+ months: 13/87 (15%) 
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Figure S1. Patient-reported longest duration without healthcare among CHH men. 
 
Figure Legend: Healthcare continuity as assessed by patient-reported longest period without 
contact with a healthcare professional (n=87).  In total, 32% of CHH men reported never 
having a break in their continuity of healthcare while 41% had gaps in care exceeding 1 year. 
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interventions promoting self-management may help bridge these unmet health needs. 
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Abstract  
Context: Congenital hypogonadotropic hypogonadism (CHH) is a rare endocrine disorder 
characterized by absent puberty and infertility.  Hormonal treatments are available to induce 
puberty and fertility in most these patients, yet little is known about patterns of adherence to 
treatment and the psychosocial impact of CHH. 
Objective: To examine patterns of adherence to treatment, depressive symptoms, and illness 
perceptions of men with CHH.  A secondary objective was to assess patient-reported barriers 
to adherence.  
Design, Setting, and Subjects: A sequential, explanatory mixed-methods study involving 
both an online survey and three patient focus groups in an ambulatory setting.   
Main Outcome Measures: Morisky medication adherence scale, Zung self-rating depression 
scale, revised illness perception questionnaire and patient-reported factors related to 
adherence.  Comparisons were made with reference groups of community dwelling adults and 
other chronic conditions.  
Results: A total of 101 men participated in the online patient survey (mean age 37±11 yrs).  
In total 58/101 had low medication adherence and 21/101 had moderate levels of adherence.  
Rates of mild, moderate and severe depressive symptoms (27%, 17%, 20% respectively) were 
significantly elevated compared to the reference population (all p<0.001).  Illness perceptions 
indicated that CHH has significant negative psychosocial consequences on patients.  Focus 
group participants (n=26) cited healthcare system, interpersonal, and personal factors as 
barriers to adherence.   
Conclusions: CHH men are challenged to adhere to long-term medication regimes.  They also 
face significant psychosocial morbidity that is often underappreciated by healthcare providers.  
Further work is needed to determine if patient-centered approaches can enhance self-
management and coping.   
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Introduction 
Congenital hypogonadotropic hypogonadism (CHH) is a congenital reproductive endocrine 
disorder resulting from deficiency of gonadotropin releasing hormone (GnRH) (Bianco & 
Kaiser, 2009).  Hallmark clinical characteristics of this condition include incomplete-absent 
puberty and infertility.  Additionally, there are a number of CHH-associated phenotypes that 
occur at variable frequencies including anosmia, eunuchoidal proportions, cleft lip/palate, and 
micropenis among others.   Those patients with an impaired or absent sense of smell 
(anosmia) are termed as having Kallmann syndrome. CHH is a rare genetic condition thus 
making incidence difficult to accurately assess yet it is generally estimated at 1/4,000-10,000 
(Fromantin et al., 1973).  Further, the reported 2-5-fold male excess has no known genetic 
underpinning and likely represents a bias of ascertainment as women often present to 
gynecology rather than endocrinology practices.  In most cases, CHH presents sporadically 
yet approximately one-third of cases display familial inheritance (Seminara et al., 1998).   
 
Testosterone replacement for males (and estrogen for females) is commonly used to treat 
patients with CHH and to induce secondary sexual characteristics.  From a provider point of 
view, testosterone gels, patches, and injections are safe, well tolerated, and highly effective 
for inducing virilization and normalizing sexual function yet they do not induce fertility (Han 
& Bouloux, 2010).  However, specialized hormone treatment with  pulsatile GnRH or 
exogenous gonadotropin therapy can induce sperm development in approximately 80% of 
men (Liu et al., 2009; Pitteloud et al., 2002).  Notably, cases of spontaneous reversal have 
been reported in approximately 10% of cases (Raivio et al., 2007) but the vast majority of 
patients require lifelong hormone therapy.  For chronic conditions like CHH, adhering to 
treatment and ongoing medical care can be problematic (Osterberg & Blaschke, 2005).  
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Indeed, a recent analysis of prescription claims for transdermal testosterone gels across 
multiple hypogonadism diagnostic codes indicates high discontinuation rates (Schoenfeld, 
Shortridge, Cui, & Muram, 2013).  However, little is known about adherence patterns in men 
with CHH, who have severe testosterone deficiency resulting in absent sexual development 
and who have an absolute requirement for lifelong replacement. 
 
Among chronic disease populations, both depression and patients’ illness perceptions play 
important roles in adherence to treatment (Kucukarslan, 2012; Lin et al., 2004).  Further, 
previous studies have shown that negative illness perceptions of patients with Cushing 
syndrome and acromegaly dramatically impact quality of life (QoL) (Tiemensma et al., 
2011a, 2011b).   However, as CHH is congenital, we do not know how patient perceptions 
may differ or not from other rare endocrine disorders.  Two studies of treatment-naïve CHH 
adolescents have demonstrated increased levels of anxiety and depression compared to age-
matched peers (Aydogan et al., 2012; Lasaite et al., 2013).  These significantly impacted QoL 
measures (Lasaite et al., 2013), not all of which improved following 6-months of testosterone 
treatment (Aydogan et al., 2012).  Thus, in the short-term at least, it appears that normalizing 
serum testosterone levels does not fully alleviate the psychosocial impact of the disrupted 
puberty of CHH. However, there are no available data on the psychosocial effects of CHH 
patients receiving long-term of treatment, how CHH patients perceive their condition, and 
how these aspects may relate to adherence to treatment.   
 
Therefore, we aimed to examine adherence to treatment, depressive symptoms, and affective 
illness representations of men with CHH on long-term treatment.  Further, we set out to 
identify the patient-reported barriers to treatment in order to develop interdisciplinary 
interventions to bridge the identified shortfalls and gaps in care. 
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Subjects and Methods 
The Pender Health Promotion model  was used as a guiding framework for understanding 
adherence among CHH men  (Pender, Murdaugh, & Parsons, 2010).  This study employed a 
sequential, explanatory mixed methods approach (QUANT-Qual) (Creswell, 2008).  First, we 
conducted an online survey (QUANT) which included several previously validated 
instruments to assess adherence to treatment, depressive symptoms and illness perceptions.  
Subsequently, qualitative focus groups (Qual) were used to elaborate on the survey findings 
and to identify patient-reported barriers to adherence. The study was approved by the 
Cantonal Human Research Ethics Committee (Canton Vaud).  Participants in the online 
survey provided an opt-in electronic consent while focus group participants provided written 
informed consent.  
  
Subjects 
CHH participants were recruited via the international network of clinicians and investigators 
studying GnRH deficiency (COST Action BM1105, www.gnrhnetwork.eu) and from existing 
patient support groups.  As CHH is rare and affected male are 2-5 times more common than 
female cases (Seminara et al., 1998), men with CHH were targeted for recruitment.  Adult 
males (18-70 years of age) who had at least one year of CHH treatment were included in the 
analysis of the online survey.  A random sampling (40%) of participants were contacted to 
confirm CHH diagnosis and respondents with other forms of hypogonadism (i.e. Klinefelter 
syndrome or adult-onset hypogonadism), and those with less than one year of treatment were 
excluded.  Focus groups were conducted in concert with CHH patient support meetings 
jointly coordinated by the investigators and patient community leaders.  
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Procedures 
The online survey included collection of sociodemographics and questions regarding 
treatment and prior interactions with healthcare system/providers.  Additionally, participants 
completed three validated questionnaires. 
 
Morisky Medication Adherence Scale (MMAS): Patient reported medication-adherence was 
evaluated using the Morisky Medication Adherence Scale (MMAS) (Morisky et al., 2008).  
The 8-item questionnaire assesses different aspects of medication taking behavior such as 
forgetting to take medication, difficulty with maintaining a treatment plan, missing doses, 
intentionally stopping medication, etc.  Scores can be categorized as low, medium, or high 
medication adherence.  The MMAS is a widely used, reliable self-report instrument that has 
shown concordance with objective pharmacy refill records (Krousel-Wood et al., 2009) and 
has demonstrated good concurrent and predictive validity with 93% sensitivity and 53% 
specificity among patients taking medication for hypertension (Morisky et al., 2008).  Unlike 
pharmacy refill records, MMAS captures events when medication has been dispensed yet not 
actually taken. 
Zung Self-Rating Depression Scale (SDS) 
This is a 20-item self-report instrument used to quantify severity of depressive symptoms 
across four distinct categories (affective, somatic, psychomotor, and psychological)(Zung, 
1965).   The SDS has been used extensively in healthy community dwelling adults and within 
patient populations, providing extensive validation data. It has been used to assess community 
base rates for depressive symptoms and as a rapid screening tool as well as a metric for 
evaluating treatment effectiveness (Blumenthal, 1975; Zung, 1990).  The SDS is quickly 
administered and scores can be translated to four levels of depression symptoms: level 0 (no 
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significant symptoms), 1, 2 and 3 (mild, moderate and severe depressive symptoms 
respectively).     
 
Illness Perception Questionnaire - Revised (IPQ-R)  
The Illness Perception Questionnaire-Revised (IPQ-R) was used to assess both emotional and 
cognitive representations of illness (Moss-Morris, 2002). The IPQ-R includes 38 statements 
concerning views on the illness, scored on a 5-point Likert scale (from strongly disagree to 
strongly agree). The questions are transformed to seven illness perception dimensions: 
timeline acute/chronic (beliefs about the chronic nature of the condition), timeline cyclical 
(beliefs regarding the cyclical nature of the condition), consequences (negative consequences 
of the disease), personal control (perceived personal controllability of the disease), treatment 
control (perceived treatment controllability of the disease), emotional representations (the 
emotional responses generated by the illness), and illness coherence (personal understanding 
of the disease). A higher score indicates a stronger belief in that particular dimension.  
 
Reference populations  
Depressive symptoms (SDS) among CHH men were compared to community base rates for 
depressive symptoms previously reported in the literature.  For the present study we utilized 
data collected from a group of 292 community-dwelling, healthy, employed men (mean age 
36 yrs, range 25-49) (Barrett et al., 1978).   This cohort of men underwent monthly 
administration of the SDS for a full year to determine prevalence rates of depressive 
symptoms among a non-patient, functioning population of untreated men. 
 
As there are no normative scores for the IPQ-R for the general population, several reference 
groups were selected to provide clinical context for these data.  We obtained reference values 
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in patients with long-term remission of acromegaly (Tiemensma et al., 2011a) as well as acute 
and chronic pain (Moss-Morris, 2002). The reference patients with long-term remission of 
acromegaly included 81 patients (47 men, 34 women, mean age 60 ± 12yrs). All patients had 
long-term biochemical control of acromegaly with a mean duration up 16 ±10 years. Because 
illness perceptions assess the perceptions of a specific disease, there are self-evidently no 
norm values for the general population, so scores of patients with acute and chronic pain have 
been used instead to provide meaningful context (Moss-Morris, 2002). The reference group 
with acute pain consisted of 35 subjects who were recruited from a private practice for 
physical therapy (20 men, 15 women, mean age of 36±12yr). These patients presented with a 
first-time peripheral painful injury that had been present for less than six weeks. The reference 
group of patients with chronic pain consisted of 63 subjects (26 men and 37 women, with a 
mean age of 54±11yr) who were recruited from hospital-based chronic pain clinics. All 
patients experienced pain for longer than three months which was unexplained by medical 
signs alone. 
 
Patient Focus Groups 
Focus groups were conducted to identify patient-reported barriers to health promoting 
behavior (adherence) among CHH men.  We proposed the Health Promotion Model as a 
useful construct to explore adherence.  It posits that thoughts, behavior, and environment must 
be considered as background factors that influence health behavior and that  individuals 
engage in purposeful action if they value the outcome and perceive it as possible (Pender, 
Murdaugh, & Parsons, 2010).  Focus group questions were formulated to stimulate discussion 
among the patients to elicit barriers to adherence to treatment (supplemental materials).  
Recordings of group discussions were transcribed, checked for accuracy and analyzed using 
NVivo10 (QSR International PSY Ltd., Melbourne Australia).  Briefly, thematic analysis 
115 
 
(coding) was conducted by two separate investigators (AD:DM) to independently identify 
categories of responses and themes emerging from the focus group discussions to form a 
codebook. Discrepancies were discussed until resolution was achieved and iterative coding 
occurred until no further themes were identified, suggesting a saturation point had been 
reached. Additionally, connections between coded terms were mapped to examine 
connections within and between categories (i.e. whether or not certain themes appear together 
repeatedly) and those arising frequently and expansively were given particular emphasis 
(Saldana, 2009).   
  
Analysis 
Survey data are presented using descriptive statistics and comparisons between groups were 
performed using Student’s t-test or Mann-Whitney rank sum test when not distributed 
normally.  Linear regression was used to examine the possible effect of age at diagnosis or 
duration of treatment on medication adherence (MMAS).  Z-Scores were used to assess 
differences in the proportion of CHH men exhibiting depressive symptoms (levels 1, 2, 3) 
compared to the reference group.  Pearson product-moment correlations were performed to 
assess the associations between depressive symptoms (SDS), medication adherence (MMAS) 
and select illness-perception subscales (IPQ-R).  The IPQ-R subscales were compared across 
the CHH and reference groups using ANOVA with Bonferroni post-hoc correction for 
multiple comparisons. Survey data were analyzed using PASW Statistics version 17.0.2 
(SPSS Inc., Chicago, IL).  All data are presented as mean ± SD and the level of significance 
for these analyses was set at p ≤ 0.05.   
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Results 
The web-based survey was online for 7-months and received 230 hits.  In total, 101 men 
(mean age 37±11yrs, range 19-66, median 36) who completed the survey met the inclusion 
criteria and were retained for analysis.  The sociodemographic information of the survey 
respondents is presented in Table 1.  The age of meaningful diagnosis was variable ranging 
from neonatal diagnosis (n=4) to 32 years (mean 18+6, median 18 yrs).  Notably, men with a 
familial pattern of inheritance (14/101, 14%) were not diagnosed earlier than sporadic 
counterparts (p=0.1) (Figure 1).  Half the men had been seen at a specialized or academic 
medical center (52/101, 51%) and similar number had genetic testing performed (43/100, 
43%) yet only 13% (13/101) had ever received genetic counseling.  For pubertal induction, 
the age of initiating treatment ranged from 11-32 (mean 19±5, median 18 years).  All men had 
been on long-term treatment (mean 18±12 yrs, range 1-46, median 16 years) and virtually all 
men (98/101) had reported having been on a form of testosterone treatment (injection, pellets, 
or gel) at some point.  More than a third (37/101, 37%) reported having had fertility inducing 
treatment with either exogenous gonadotropins or pulsatile GnRH therapy with variable 
outcomes (Table 1).       
 
CHH men are challenged to adhere to treatment  
Results of the Morisky Medication Adherence Scale (MMAS) revealed a high percentage of 
men with poor medication-adherence.  More than half (58/101, 57%) of the men had low 
levels of adherence, 21% (21/101) had moderate and a similar percentage (22/101) had high 
(exemplary) medication-adherence.  A total of 93 men provided a self-reported longest-
duration-off-treatment and responses ranged widely from never (n=24, 26%) to 15 years.  
Notably, 35/93 (38%) respondents reported being off treatment for more than one year.  No 
associations were identified between longest duration off treatment and either age of 
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diagnosis (r=0.02, p=0.8), or the time since starting treatment (r=0.06, p=0.6).  These data 
suggest that, despite notional availability of effective treatments and providers, men with 
CHH are challenged to stick with their medication regime. 
 
CHH men exhibit high rates of depressive symptoms 
One hundred CHH men completed the Zung Self-rating Depression Scale (SDS) and 
comparisons were made with the reference group of  292 similarly aged community-dwelling, 
employed  men (mean age 36 years, range 25-49) (Barrett et al., 1978). The CHH patient 
population exhibited significantly higher rates of depressive symptoms (all p<0.001) (Figure 
2).  Twenty seven percent of CHH men had mild depressive symptoms, 17% moderate (i.e. 
dysthymia), and one in five (20%) exhibited the highest level of symptomatology (akin to 
major depressive disorder). Having more severe depressive symptoms was moderately 
correlated with poorer medication adherence (R=0.35, p<0.001).  This is consistent with 
previous reports demonstrating that depression negatively affects adherence to treatment in 
chronic conditions like diabetes (E. H. Lin et al., 2004) yet it may also reflect the contrary - 
that patients with poorer adherence exhibit more depressive symptoms.  Interestingly, while a 
high proportion of CHH men exhibit significant depressive symptoms, only one quarter 
(25/101) stated that their healthcare provider had ever discussed counseling services or had 
given them a psychological or psychiatric referral.  Cumulatively, these data suggest that the 
psychological aspects of CHH are underappreciated and warrant renewed attention and 
assessment.   
 
CHH men’s illness perceptions reveal significant psychosocial consequences  
Compared to reference groups, CHH patients viewed their illness as being more chronic (all 
p<0.001) and that their condition changes little over time, which is in contrast to chronic pain 
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which often has periodic flares (p<0.001)(Table 2).  Furthermore, CHH men experience 
negative consequences impeding physical, psychological, and social well-being that were 
significantly greater than patients with acute pain and acromegaly (both p<0.01).  Notably, 
this impact was positively correlated with depressive symptoms (r=0.43, p<0.001) and poorer 
medication adherence (r=0.40, p>0.001).  The negative emotional impact (emotional 
representations) of CHH was not significantly different from patients with chronic pain, but 
significantly greater than patients with either acute pain or acromegaly (both p<0.01). These 
emotional representations were positively correlated with depressive symptoms (r=0.64, 
p<0.001) and weakly correlated with diminished adherence (r=0.27, p>0.01). Compared with 
patients in long-term remission of acromegaly, men with CHH perceived a higher level of 
personal control (perceived personal controllability of CHH) (p<0.01) yet treatment control 
(perceived treatment controllability of CHH) was perceived to be lower (p<0.001).  Compared 
with patients with acute pain men with CHH perceived less personal and treatment control 
(both p<0.001).  Lastly, men with CHH exhibited the highest scores on illness coherence 
(how they make sense of their condition) which may in fact be related to the congenital nature 
of CHH and that these men have lived with it since adolescence. However, illness coherence 
scores were negatively correlated with severity of depressive symptoms (r=-0.37, p<0.001) 
and thus may represent a protective or ameliorating factor for depression.   
 
Healthcare systems, interpersonal influences, and individual factors pose barriers to 
adherence 
Three focus groups were used to explore patient-reported barriers to health promoting 
behavior (medication adherence).  Twenty six men participated (mean age 37±13yrs, range 
18-66, median 36 years) and discussions revealed three, consistent, interrelated aspects of 
adherence including personal factors, interpersonal influences, and structural factors (i.e. 
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healthcare system) (Figure 3) .  The most frequently reported facilitators of medication 
adherence included having a strong personal preference for a particular treatment modality, 
capacity for self-management (i.e. learning to self-inject medication), establishing a routine, 
having supportive family/peers, and understanding the importance of treatment for improving 
mood and limiting comorbidities.  Commonly cited barriers to adherence included fractured 
healthcare transitions (i.e. changing providers and gaps in care) and pharmacy problems (i.e. 
difficulty obtaining syringes/needles and pharmacist concerns regarding anabolic abuse).  
Focus group participants reported that cognitive and affective factors such as depression, 
increased fatigue when off treatment and not having a good understanding of CHH, also 
negatively impacted their adherence.  An additional theme emerging from discussions related 
to the initial treatment period of pubertal induction.  Patients who did not understand the 
treatment plan (i.e. rationale for the timing of increasing the dose) or who had inappropriate 
expectations for treatment outcome (i.e. that testosterone would induce testicular growth) 
were less committed to adhering to treatment.  These patient-reported outcomes underscore 
the importance of effective communication between healthcare providers and patients (Kovac 
et al., 2014) as well as the critical importance of anticipatory guidance during pubertal 
induction. 
 
Discussion 
Herein we report that men with CHH struggle with long-term adherence to treatment, exhibit 
increased incidence of depressive symptoms and have significant physical, psychological, and 
social consequences related to their GnRH deficiency.  Psychological aspects such as 
depression and illness perceptions play important roles in how patients manage chronic health 
conditions (Kucukarslan, 2012; E. H. Lin et al., 2004).  While there is no wide-reaching 
consensus on what is an acceptable or adequate level of adherence (Osterberg & Blaschke, 
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2005), these data indicate that only about one-quarter of CHH patients have excellent 
adherence (22% via MMAS and 26% reporting never having been off treatment).  As 
testosterone replacement has potent effects on mood, libido and sexual function (Wang et al., 
2004) we presumed that treatment pauses would result in a potent trigger for CHH men to 
resume treatment, yet this was surprisingly not the case.  Further, non-adherence is relevant 
because, but for the rare cases of reversal (Raivio et al., 2007), patients require lifelong 
hormone replacement.  In the present study, nearly 40% of men reported treatment pauses of a 
year or longer that not only diminish sexual function but can also cause anemia and increases 
the risk for developing osteoporosis (Finkelstein et al., 1987).  Indeed, a report examining 
bone health in a cohort of Finnish CHH patients indicated that 9/26 (35%) had treatment 
pauses exceeding 5 years and exhibited significantly lower bone mineral density than those 
without gaps (Laitinen, Hero, Vaaralahti, Tommiska, & Raivio, 2012b).  Further, meta-
analyses demonstrate an association between low serum testosterone and the metabolic 
syndrome and diabetes (Corona, Monami, Rastrelli, Aversa, Tishova, et al., 2011; Ding et al., 
2006).  Thus, gaps in treatment may incur additional metabolic health risks.  Indeed, acute 
withdrawal of treatment in CHH men induces increased fasting insulin levels and insulin 
resistance within two weeks (Yialamas et al., 2007) and men undergoing GnRH-analog 
induced androgen-deprivation therapy have increased rates of the metabolic syndrome and 
diabetes (Shahani et al., 2008).  Thus, lack of androgen treatment or even inadequate 
replacement, appears to place CHH men at increased metabolic risk and potentially increased 
cardiovascular morbidity.   
 
Beyond adherence problems, the CHH men in this study also exhibit significantly increased 
rates of mild, moderate, and severe depressive symptoms.  These symptoms were correlated 
with poorer adherence which could reflect a bi-directional interaction.  For instance, previous 
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studies of chronic disease patients support that depression negatively impacts adherence and 
health promoting behaviors (E. H. Lin et al., 2004).  Conversely, given the potent impact of 
testosterone on mood (Wang et al., 1996), non-adherent CHH men may trigger depressive 
symptoms when they stop treatment.  These interacting factors could perpetuate a vicious 
cycle of depression and non-adherence.  While testosterone replacement seems to have an 
antidepressant effect in select subpopulations such as hypogonadal men with HIV/AIDS 
(Zarrouf, Artz, Griffith, Sirbu, & Kommor, 2009), the relationship between low testosterone 
and depression remains unclear.  Concerning the psychological aspects of CHH, there is 
surprisingly limited literature with only three case series from 1964, 1971, and 1996.  These 
studies reported on few subjects and describe issues related to anxiety, depression, and social 
difficulties among CHH patients, albeit in a rather ad hoc manner (Bobrow et al., 1971; 
Huffer et al., 1964; Huisman et al., 1996).  These observations were reiterated in a recent 
patient narrative depicting ongoing struggles with lingering psychological aspects of CHH 
(Smith & Quinton, 2012).  In the present study, we demonstrate the pervasive and lasting 
impact on mental health and quality of life in a large CHH cohort despite long-term treatment, 
albeit with variable adherence.  Importantly, this largely goes under-recognized as only a 
quarter of men had a healthcare provider to discuss counseling or psychological/psychiatric 
support.  Thus, this finding begs heightened attention and further studies investigating clinical 
depression and anxiety on a larger scale seem warranted.  
 
The under-appreciation of psychosocial aspects of CHH may represent a clinician bias 
towards treating the physical signs of CHH.  For instance, growth spurt, deepening of the 
voice and appearance of secondary sexual characteristics are easily observed and treated.  
These signs can serve as a rapid clinical barometer of response to treatment, whereas 
assessing emotional development and psychological adaptation are less easily quantified.  
122 
 
Further, providers may have limited availability of psychological referral sources. Regardless, 
it seems that CHH men have lasting psychological, emotional, and psychosexual aspects of 
their care that are largely unmet, a finding that is also supported by the affective illness 
representations of these patients. Importantly, illness coherence scores are inversely related to 
depressive symptoms suggesting that enhanced understanding of CHH could be protective 
factor for depression in these men and thus represents a target for interventions to enhance 
patient resilience.  These patients perceive themselves to have a high level of personal control 
over their condition yet they have much lower ratings of treatment-control (how effectively 
their treatment controls their condition). This is in contrast to the prevailing opinion of 
healthcare providers and specialists, who see testosterone replacement in CHH patients as 
being highly-effective. When this was explored in the context of the patient focus groups, 
several themes consistently emerged as potential modifiable targets to enhance adherence 
including: improving anticipatory guidance (what to expect from endocrine treatment and 
during what timeframe), partnering for decisions on treatment modality (individual 
preferences), enhanced self-management (auto-injection), and sealing gaps in care (transitions 
between providers).  These data support the utility of the Health Promotion Model as a 
theoretical framework for examining issues of adherence. 
 
Along with all studies of this kind, this study has several limitations, including that the 
convenience sample for the internet survey may not be truly representative.  However, 
studying rare disease populations is always challenging and, while this may not be a random 
sampling, it examines a relatively large cohort of such patients.  Additionally, we assessed 
depressive symptoms and did not explicitly evaluate the actual incidence of clinical 
depression among this patient population.  Moreover, the psychological aspects of chronic 
disease are complex and this study was not designed to delineate the relative contributions of 
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late diagnosis or body image problems related to CHH-associated phenotypes such as 
micropenis which are likely contributing variables.  Self-report measures are not objective 
metrics, yet there has been a growing recognition and appreciation of their importance for 
managing chronic conditions (Bayliss et al., 2012).  The objective of this study was to identify 
a group of CHH patients and explore their perspectives in detail to understand their health 
promoting behavior and perspectives in order to develop more-patient-centered approaches to 
care for these patients.  Patients with CHH, like other chronic conditions, are responsible for 
the vast majority of their care.  They decide whether to take medication or not, are the first to 
be able to identify changes in health status, and are the decision makers for making and 
keeping appointments with healthcare providers.  Thus, understanding their unmet health 
needs, motivations, and perceptions regarding their condition are critical for developing 
approaches to enhance self-management.  
 
In summary, patients with CHH are challenged to adhere to their long-term medication 
regimens and many have extended periods without treatment.  In addition, these patients 
exhibit significant depressive symptoms and have long-lasting psychosocial effects that are 
often unappreciated by healthcare professionals.  These mixed-methods findings underscore 
the likely benefit of early diagnosis, maintaining continuity of care through healthcare 
transitions, providing appropriate psychological support, and the need for patient education 
and anticipatory guidance related to testosterone treatment and possibility for developing 
fertility. These unmet health and informational needs warrant clinical attention and further 
work is needed to determine if patient-centered interventions can ameliorate these shortfalls in 
care. 
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Tables and Figures 
Table 1 
Sociodemographic and treatment history of CHH men completing the online survey (n=101) 
 
Age                                                             n  
   19-29 yrs 30 
   30-39 yrs 38 
   40-49 yrs 19 
   50-59 yrs 11 
   60+ yrs 3 
Education  
   High school/vocational 35 
   University 35 
   Post-Graduate 31 
Employment  
   Working full-time 67 
   Working part-time 9 
   Unemployed 10 
   Retired 5 
   Student 9 
   No response given 1 
Relationship Status  
   Married 36 
   In a relationship 16 
   Single 24 
   Never been in a relationship 23 
   Divorced 1 
   No response given 1 
Children 
     none 75 
     biologic children 8 
     adopted children 18 
Treatment  
testosterone (ever) 98 
fertility treatment* 37 
     no children 22 (59%) 
     adopted children 7 (19%) 
     biological children 8 (22%) 
*gonadotropin therapy or pulsatile GnRH 
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Table 2.  
Comparison of IPQ-R scores between CHH patients and other patient groups  
 
 
IPQ-R 
CHH 
n=101 
Acute pain  
n=35 
Chronic pain 
n=63 
Acromegaly 
n=81 
Timeline (acute/chronic) 26.7 (3) 13.4 (5)** 23.1 (4)** 22.9 (6)** 
Timeline (cyclical) 9.7 (4) 9.4 (3) 12.9 (4)** 10.1 (4) 
Consequences 21.3 (4) 14.2 (4)** 23.5 (4)* 16.9 (5)** 
Emotional 
representations 
19.2 (6) 16.1 (4)* 19.8 (4) 12.6 (4)** 
Personal control 19.9 (5) 22.9 (4)** 18.4 (4) 17.5 (5)* 
Treatment control 15.5 (4) 19.4 (3)** 14.2 (3) 18.1 (3)** 
Illness coherence 18.1 (4) 9.3 (3)** 13.4 (5)** 17.5 (3) 
Data are mean (SD), * p<0.01 vs. CHH, ** p<0.001 vs. CHH 
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Figure 1. Age at CHH diagnosis 
Figure Legend: Age of diagnosis of CHH among sporadic (n=87) and familial cases (n=14). 
The box depicts the 25-75th percentile and the horizontal line is the median. The error bars 
depict the 10th and 90th percentiles respectively. Age at diagnosis was not different between 
groups (p=0.1). 
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Figure 2. Severity of depressive symptoms in CHH men  
Figure Legend: Depressive symptoms were assessed using the Zung Self-Rating Depression 
Scale. 27% of CHH men had mild symptoms (meaningful yet normally less than what would 
ordinarily initiate an evaluation or referral); 17% exhibited moderate symptoms (what one 
would expect to see among outpatient depression patients, or among patients with dysthymia) 
and 20% reported severe symptoms (characteristic of major depressive disorder). * p<0.001 
vs. reference group (Barrett et al., 1978).  
Severity of Depressive Symptoms
none mild moderate severe
P
e
rc
e
n
t
0
5
10
15
20
25
30
35
40
90
95
100
0.2%
1.9%
* * *
7%
reference group (n=292)
CHH men (n=100)
131 
 
 
Figure 3. Patient-reported promoters and barriers to adherence to treatment 
Figure Legend: Focus group participants identified three interrelated themes impacting 
adherence to treatment: interpersonal factors, structural factors (healthcare systems) and 
personal factors (cognitive and affective).  
  
Ineffective healthcare 
provider communication
Barriers (-)
Supportive family,
peers or spouse
Promoters (+)
Barriers (-)
Healthcare transitions
Medication supply 
& pharmacy-related 
issues
Promoters (+)
Continuity of care
Depression/anxiety
Fatigue/lack of motivation off treatment
Change in mood/feelings on treatment
(key: anticipatory guidance)
Poor understanding of CHH 
Barriers (-)
Personal preference for 
a particular treatment modality
Feeling ‘good’ on treatment
Understanding how treatment 
can limit comorbidities
Promoters (+)
Cognitive & Affective
factors
ADHERENCE
Interpersonal
factors 
Structural
factors
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Supplemental Materials  
Focus Group questions addressing promoter s and barriers to treatment adherence. As 
described in the Methods, focus group questions were derived from the Pender Health 
Promotion Model (17) and refined with input from patient community leaders.  
 
1. CHH is a chronic condition and it is often hard to stick with treatment and keep 
appointments over time. Have you had periods when you were off treatment? 
2. How do you feel when you are on/off treatment? 
3. What do you think are the 3 most important things you need to do for your health related 
to CHH? What things prevent you from doing those things?  
4. What do you think the benefits are to you in treating your CHH? 
5. What are the things that keep you from sticking with your medication? 
6. What are the things which help you staying on treatment?  
7. Do you feel in control of your CHH medication? 
8. Do you administer your own CHH medication? Would you like to? Are there things that 
prevent you from self-administering your CHH medication?  
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Abstract  
Introduction. Congenital hypogonadotropic hypogonadism (CHH) is a rare, genetic, 
reproductive endocrine disorder characterized by absent puberty and infertility.  Limited 
information is available on the psychosocial impact of CHH and psychosexual development 
in these patients.   
Aims. To determine impact of CHH on psychosexual development in men on long-term 
treatment. 
Methods. A sequential mixed-methods explanatory design.  First, an online survey 
(quantitative) was used to quantify the frequency of psychosexual problems among CHH 
men.  Second, patient focus groups (qualitative) were conducted to explore survey findings in 
detail and develop a working model to guide potential nursing and interdisciplinary 
interventions. 
Main outcome measures. Patient characteristics, frequency of body shame, difficulty with 
intimate relationships and never having been sexually active were assessed.  Additionally, we 
collected subjective patient-reported outcomes regarding the impact of CHH on 
psychological/emotional well-being, intimate relationships and sexual activity. 
Results. A total of 101 CHH men on long-term treatment (>1 year) were included for the 
analysis of the online survey (mean age 37±11yrs, range 19-66, median 36).  Half (52/101, 
51%) of men had been seen at a specialized academic center and 37/101 (37%) reported 
having had fertility-inducing treatment. A high percentage of CHH men experience 
psychosexual problems including difficulty with intimate relationships (70%), body image 
concerns/body shame (94/101, 93%), and the percentage of men never having been sexually 
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active is 5-times the rate in a reference group (26% vs. 5.4%, p<0.001). Focus groups 
revealed persisting body shame and low self-esteem despite long-term treatment that has 
lasting impact on psychosexual functioning.   
Conclusions. CHH men frequently experience psychosexual problems that pose barriers to 
intimate relationships and initiating sexual activity.  These lingering effects cause significant 
distress and are not ameliorated by long-term treatment.  Psychosexual assessment in CHH 
men with appropriate psychological support and treatment should be warranted in these 
patients.     
 
Keywords 
Kallmann syndrome, psychosocial factors, body image, self-esteem, psychosexual outcome, 
nursing, mixed methods, congenital hypogonadotropic hypogonadism 
 
Introduction 
Congenital deficiency of hypogoandotropic hypogonadism (CHH) is an endocrine disorder 
resulting from gonadotropin-releasing hormone deficiency (GnRH).  This genetic condition is 
clinically characterized by absent puberty and infertility and may be accompanied by a variety 
of associated phenotypes including cryptorchidism, micropenis and anosmia (termed 
Kallmann syndrome) (Bianco & Kaiser, 2009). CHH is rare with incidence estimated at 1 in 
4,000-10,000 (Fromantin et al., 1973) and has a striking gender discordance (approximately 
2-5 males for each female case) (Quinton et al., 2001; Seminara et al., 1998).  This gender 
difference remains genetically unexplained and may well represent an ascertainment bias as 
amenorrheic women presenting for gynecologic evaluation may likely receive empiric 
treatment, as opposed to being referred for an endocrine evaluation (Mitchell et al., 2011).  
Importantly, CHH patients cannot initiate puberty spontaneously and require hormonal 
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treatment to develop secondary sexual characteristics (Han & Bouloux, 2010). It is a treatable 
form of infertility with approximately 80% of men able to develop sperm with either pulsatile 
GnRH or exogenous gonatropin therapy (Liu et al., 2009; Pitteloud et al., 2002). 
 
CHH patients typically present to medical attention with failure to undergo spontaneous 
puberty; the challenge being to differentiate this rare condition from more frequent variants in 
the timing and onset of puberty such as constitutional delay of growth and puberty(Harrington 
& Palmert, 2012; Palmert & Dunkel, 2012).  CHH adolescent males presenting with absent 
puberty after 14 years of age, may be inaccurately defined as “late bloomers” and their 
treatment unnecessarily delayed; the “watchful waiting” approach finally ending with the 
patients re-presenting as apubertal young adults with frank hypogonadotropic hypogonadism 
(Young, 2012).  As captured in a recent patient report, such delays in diagnosis can have 
lasting psychological and emotional effects on patients (Smith & Quinton, 2012). 
 
Puberty is a developmental process characterized by numerous physiologic, psychosocial, and 
emotional changes culminating in reproductive capacity.  While timing of onset of pubertal 
development is variable, late sexual development can carry a psychological burden.  Delayed 
puberty can result in body image concerns, low self-esteem and social isolation and later 
sexual activity (Golub et al., 2008; Michaud et al., 2006; Waylen & Wolke, 2004).  Further, 
many late maturers experience victimization or bullying, which are important and common 
risk factors for developing depression (Thapar et al., 2012).  For CHH men, who represent the 
most extreme form of delayed puberty, data on psychological aspects are limited to a handful 
of descriptive case series with few patients (Bobrow et al., 1971; Huffer et al., 1964; Huisman 
et al., 1996).  Prior to starting treatment, adolescents with CHH exhibit impaired quality of 
life and increased anxiety and depression compared to peers (Aydogan et al., 2012; Lasaite et 
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al., 2013).  However, the existing literature has solely focused on the time of diagnosis or 
during the initial pubertal induction and therefore, data regarding the psychosocial impact of 
CHH in men on long-term treatment are lacking.  Accordingly, we do not know whether long-
term sex steroid treatment and/or fertility-inducing treatments mitigate the impact on 
psychosexual development of CHH men.   
 
Aims 
This study aimed to examine patient characteristics, sexual activity and frequency of body 
image concerns among men with CHH.  Further, we aimed to explore the psychosocial impact 
of CHH on body image and psychosexual development in CHH men on long-term treatment.     
 
Methods 
A community based participatory research framework (N. B. Wallerstein & Duran, 2006) was 
utilized for developing and conducting this sequential, explanatory mixed-method study 
(Creswell, 2008).  In the context of a European network focused on CHH/KS (COST Action 
BM1105), partnerships with patient community leaders (i.e. moderators of online patient 
support sites) were developed to include patient perspectives into the process.  Patient leaders 
participated in developing and improving the language and clarity of the survey, facilitated 
recruitment efforts, and provided feedback on study findings at each stage of anlaysis.  First, a 
quantitative online survey was used to collect patient characteristics and information on 
diagnosis/treatment as well as body image, relationship status and sexual activity.  
Subsequently, qualitative patient focus groups were conducted to explore the survey findings 
in greater detail.  Focus groups were held in concert with CHH patient support meetings 
jointly planned by patient community leaders and study investigators. The psychosexual 
assessment of men with CHH was part of a larger research project examining health 
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promoting behavior (Pender, Murdaugh, & Parsons, 2010) and factors affecting quality of life 
among CHH men. The ultimate goal of this study is to design innovative nursing and 
interdisciplinary interventions to address unmet health needs in these dispersed rare disease 
patients. The study was approved by the Health Research Ethics Committee (Canton Vaud) 
and all participants provided informed consent prior to the initiation of study-related 
activities.  For the online survey, an opt-in electronic consent was used while focus group 
participants provided written informed consent.  
 
Subjects 
As male patients outnumber female patients in this rare disorder (Seminara et al., 1998) we 
focused our attention on male subjects.  Adult CHH men (18-70 years) on treatment for at 
least 1 year were recruited for the study.  A random sampling (40%) of online survey 
respondents were contacted and interviewed to confirm diagnosis.  Those men with other 
causes of hypogonadism (i.e. Klinefelter syndrome, adult-onset hypogonadism) were 
excluded and surveys with multiple incomplete or conflicting responses were excluded. The 
study was publicized online via a closed/private CHH/KS social media group (Facebook), 
CHH/KS forum (chat room), a clinical trials registry, and the COST Action website.  Data 
from the American National Survey of Sexual Health and Behavior was used as a comparison 
reference group (Leigh et al., 1993).   
 
Statistics 
Survey results were analyzed using descriptive statistics (mean ± standard deviation, range, 
median), Student’s t-test (Wilcoxon rank-sum test for data not normally distributed) to 
evaluate differences between groups, and Z score to assess differences in proportions between 
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the CHH and the reference group. SigmaStat (Systat Software Inc., San Jose, California, 
USA) was used for statistical analyses and a p<0.05 was considered significant.  
 
Qualitative Analysis 
Thematic analysis (coding) of focus group transcripts was performed by two separate 
investigators (AD:DM) using NVivo10 (QSR International PSY Ltd., Melbourne Australia).  
Categories of responses and themes were first classified on the basis of the Health Promotion 
Model (Pender, Murdaugh, & Parsons, 2010. Iterative coding occurred until no further themes 
were identified, suggesting a saturation point had been reached.  Additionally, connections 
between coded terms were mapped to examine connections both within and between 
categories (i.e. whether or not certain themes appear together repeatedly) and those themes 
arising frequently and expansively were given particular emphasis (Saldana, 2009).   
 
Main outcome measures 
For the online survey, patient characteristics, frequency of body shame, difficulty with 
intimate relationships and never having been sexually active were the main outcome 
measures.  For patient focus group discussions, subjective patient-reported outcomes 
regarding the impact of CHH on psychological/emotional well-being, intimate relationships 
and sexual activity were recorded. 
Results 
The survey was online for 7 months and received a total of 230 hits of which 101 surveys 
(44%) were retained for analysis.  The men (mean age 37±11yrs, range 19-66, median 36) had 
all been on long-term treatment (>1 year) and half (52/101, 51%) had been seen at a 
specialized or academic medical center.   Participant characteristics and treatment information 
are presented in Table 1. In this cohort, CHH was diagnosed neonatally in four men and as 
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late as 32 years (mean 18±6, median 18 years).  The age of initiating treatment to develop 
secondary sexual characteristics ranged from 11-32 years (mean 19±4, median 18 years) and 
nearly all men (98/101) had been on some form of testosterone replacement (injection, 
implanted pellets, patches, or gel).  Over a third of men (37/101, 37%) reported having had 
fertility inducing treatment (exogenous gonadotropins or pulsatile GnRH therapy) with 
variable outcomes (Table 1).  Nearly a quarter of the men receiving fertility-inducing 
treatment (8/37, 22%) were single or had never been in a relationship, suggesting a motivation 
for pursuing these time and resource-intensive programs extended beyond an immediate 
desire to achieve fertility. 
 
Despite long-term treatment, a high proportion of CHH men have psychosexual 
problems 
As no data are available on the sex lives of men on long-term treatment, we asked participants 
if they had ever been sexually active.  Notably, 26/101 (26%) of men reported they had never 
been sexually active.  This is nearly 5-times the rate (26% vs. 5.4%, p<0.001) observed in 
adult men (18+ years) in a large (n>2,000) probability survey examining sexual activity 
(Leigh et al., 1993).  During survey development, discussions with patient community leaders 
suggested that traumatic experiences, body image concerns, and difficulty with intimate 
relationships were frequently raised in private, online discussions.  When we inquired about 
these points 72% (73/101) stated that they had been teased or ridiculed because of CHH and 
93% (94/101) reported that they had felt embarrassed or ashamed of their body and avoided 
undressing in public such as at the gym or beach.  Further, 70% (69/99) men agreed that 
intimate relationships were difficult because of CHH.  Neither age of diagnosis nor age of 
treatment initiation were significantly related to any of these results.  We hypothesized that 
concerns about testicular size could be a factor in these findings, yet no differences were 
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observed between those men who had received fertility-inducing treatment (inducing 
testicular growth) and those men on testosterone only (no testicular development). These data 
point to a significant impact of CHH on the psychosexual development.  To explore this in 
greater detail, we conducted three patient focus groups. These discussions provided further 
insight into the survey findings and helped explain the lasting psychosexual impact of CHH 
that pose barriers to dating, developing intimate relationships and initiating sexual activity.   
 
CHH-related body shame has lasting impact on psychosexual functioning 
Patient focus group discussions grew from two questions: “What has been the most difficult 
part of living with CHH?” and “How has CHH affected your sex life and intimate 
relationships?”.  Twenty six men participated in the focus groups (mean age 37±13yrs, range 
18-66, median 36 years) revealing consistent, overarching themes of shame and isolation 
related to CHH.  More specifically, patients reported their sense of isolation resulted from 
their absent sexual development and feeling “left behind” as peers developed physically, 
became sexual active, and assumed adult roles (Figure 1, Table 2).  This marginalization fed 
fears of being exposed and many (20/26) attempted to hide their lack of puberty by avoiding 
situations possibly involving nudity and in some cases avoiding social events.  Problems with 
body image dominated focus group discussions both in terms of the number of comments and 
the proportion of participants (23/26) reporting body shame (Figure 1, Table 2).  
 
Similar to the literature on late maturing adolescent boys (Golub et al., 2008; Michaud et al., 
2006; Thapar et al., 2012; Waylen & Wolke, 2004) and the online survey results, men in the 
focus groups reported traumatic experiences including teasing, victimization and bullying 
related to their youthful appearance, under-developed genitalia and in some cases 
gynecomastia resulting from CHH.  Notably, despite virilization on long-term hormone 
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treatment, these men struggled to overcome a self image of the undeveloped, youthful 
adolescent of their past.  These negative thoughts persisted well into adulthood - even though 
many realized that these thoughts were not rational.  Discussions revealed a cycle of isolation 
and shame wherein hiding and removing oneself from social situations only worsened the 
body image and self-esteem issues (Figure 1, Table 2).   
 
Importantly, patients reported ameliorating factors that helped them cope with their disrupted 
psychosexual development including meeting other patients with CHH (Table 2).  In total, 
15/26 men provided unsolicited comments stating that this was a life-changing event enabling 
them to overcome some of their feelings of shame and isolation. Half of the men (13/26) 
shared that coping with the psychosexual aspects of CHH became easier with age and that this 
was often related to finding someone who accepted them as they are (i.e. an understanding 
healthcare provider, therapist, partner, or spouse).  These highlight potential interventions 
such as connecting patients for peer-to-peer support. 
 
Limitations 
This type of study has inherent limitations.  First, studying rare disease populations pose 
challenges for recruiting patients (Kruer & Steiner, 2008; Watson et al., 2008), which tends to 
limit sample size.  We attempted to overcome this by using web-based data collection via an 
online survey.  This approach introduces potential bias as not everyone has internet access, so 
this convenience sample may be enriched with well-educated men and may reflect a response 
bias of more proactive and/or more severely affected patients.  Second, as no validated 
questionnaire is available for CHH men to assess health related quality of life or sexual 
function (Langham, Maggi, Schulman, Quinton, & Uhl-Hochgraeber, 2008), we developed 
our own questionnaire. Face validity was sought with input from patient advocates, but a full 
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validation process was not performed. While validity and reliability in self-report responses 
are important, there is a growing acceptability of using patient-reported outcomes for 
managing chronic conditions (Bayliss et al., 2012).  Further, using focus groups with expert 
patients to explore these is an added value to the validity of the results. 
 
Discussion 
We report evidence of persisting psychosexual impact of CHH that is not ameliorated by 
long-term hormone replacement therapy.  CHH is a rare disorder that has been previously 
been used as a unique human disease model providing important insights into the hormonal 
control of the hypothalamic-pituitary-gonadal axis (Pitteloud et al., 2008a, 2008b).  Further, 
genetic studies on this extreme form of delayed puberty have informed our understanding of 
the molecular control of human puberty and reproduction (Balasubramanian et al., 2010; 
Bianco & Kaiser, 2009).  However, there are scant data on how the severe disruption of 
puberty impacts psychosexual development in CHH men.  
 
Previous reports on the psychosocial aspects of CHH include several descriptive case series of 
small cohorts CHH men during initial treatment.  The 1964 report of 8 cases of so-called 
‘sexual infantilism’ (including 3 CHH men 20-47 years of age) commented on embarrassment 
because of youthful appearance and feelings of sexual inadequacy (Huffer et al., 1964).    A 
subsequent 1971 report documenting 13 cases from the Johns Hopkins University Hospital 
added observations on insecurity, decreased confidence and low interest in dating among 13 
CHH men (19-44 years old) after starting treatment (Bobrow et al., 1971).   Another study 
published in 1996 followed 8 CHH men initiating pulsatile GnRH therapy for pubertal 
induction noting diminished social interactions and poorer views of their physique compared 
to controls (Huisman et al., 1996).  In the present study, we examined these issues in a 
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relatively large cohort of CHH men (n=101) providing data on the prevalence of these issues.  
We then conducted focus groups to develop an explanatory model for these observations, thus 
enhancing our understanding of the unmet psychological and psychosexual needs of CHH 
men in order to better direct therapy and interventions. 
 
In contrast to prior studies, we focused exclusively on men receiving long-term treatment to 
see if psychosocial and psychosexual issues are corrected by a longer period with a 
normalized sex steroid milieu.  Testosterone replacement therapy has long been shown to be 
effective for inducing secondary sexual characteristics and normalizing sexual function (Han 
& Bouloux, 2010)and has well-documented beneficial effects on muscle and fat-free (lean) 
body mass (Bhasin et al., 1997) as well as mood (Wang et al., 1996).  Importantly, the data 
presented herein suggest that normalizing serum hormone levels does not ameliorate the 
psychosocial consequences of CHH.   Moreover, focus group discussions revealed CHH men 
are challenged to perceive themselves as a normal-appearing virilized men.  This may relate 
to a form of body dysmorphic disorder (BDD) wherein individuals develop an altered view of 
personal appearance (Kaplan, Rossell, Enticott, & Castle, 2013).  BDD has been linked with 
early traumatic life events (Buhlmann, Marques, & Wilhelm, 2012) and can have significant 
impact on quality of life (IsHak et al., 2012).  As BDD appears to be responsive to cognitive-
behavioral interventions, similar approaches may be warranted for CHH men to address their 
significant body image concerns. 
 
A surprising finding was that fertility was never raised as a major concern within focus group 
discussions.  Rather, attention centered on body shame and lack of genital development.  
Testosterone replacement induces secondary sexual characteristics and normalizes sexual 
function yet has no effect on testicular development and testis volume remains small (infantile 
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in some cases).  We found that 22% of men who had received fertility-inducing treatment had 
never been in a relationship.  This observation suggests that these treatments were pursued to 
augment testicular volume and thus normalize genital appearance.  Indeed, it would be 
interesting to utilize the recently developed  genital self-image scale (Herbenick, Schick, 
Reece, Sanders, & Fortenberry, 2013) to better understand how these factors may contribute 
to these men’s sexual experiences and why they are 5-times more likely to never have been 
sexually active.  Some have speculated that the atrophic testes and/or severely diminished 
phallus size sometimes associated with CHH as can have serious negative effects on self-
confidence and the sexual life of CHH men (Han & Bouloux, 2010; Bouvattier, et al, 2012; 
Young, 2012).  Herein, we provide direct evidence supporting these assertions.   
 
Micropenis (with or without cryptorchidism) can be associated with CHH.  We did not assess 
how many men were born with micropenis as this can difficult to ascertain in the absence of 
medical documentation.  However, outcome studies of patients with micropenis indicate 
diminished penis size persisting into adult life can have negative consequences on sexual 
quality of life (Callens et al., 2013).  Related to this, concern about penis size was pervasive 
and a frequently occurring topic in focus group discussions.  Indeed, in every focus group 
patients made spontaneous inquiries regarding normative ranges for penis size among CHH 
men.  While population-based normative data are available on penis size (Herbenick, Reece, 
Schick, & Sanders, 2014) corresponding data on a large cohort of CHH is lacking.  CHH men 
experience significant preoccupation and shame regarding penis size.  Accordingly, it could 
be useful to evaluate this using a validated instrument (Veale et al., 2014) before and after 
providing reference ranges for this patient population along with targeted cognitive-
behavioral interventions to address these body shame issues.  Such an approach could be a 
possible avenue for alleviating this distressing problem for CHH men. The ultimate goal of 
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this study was assess impact of CHH on psychosexual development in order to identify 
patient needs and design innovative nursing and interdisciplinary interventions for these 
dispersed patients.  Importantly, one result of this study was that conducting patient focus 
groups brought together isolated patients and provided them with an opportunity to discuss 
these problems, share experiences and seek support – which in and of itself was an important 
and empowering intervention for these patients.        
 
Conclusions 
This mixed-methods study presents data demonstrating the pervasive psychosexual 
difficulties experienced by CHH men on long-term treatment.  The CHH-related absent sexual 
development has lasting effects that pose barriers to intimate relationships and initiating 
sexual activity.  Further, the psychosocial distress experienced by CHH men is not 
ameliorated by long-term treatment.  These findings underscore the importance of 
psychosexual assessment of CHH men and the need for psychological support and 
interdisciplinary care for this patient population.  
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Tables  
Table 1 
Sociodemographic and treatment information of CHH men (n=101) 
 
Age                                                            n 
   19-29 yrs 30 
   30-39 yrs 38 
   40-49 yrs 19 
   50-59 yrs 11 
   60+ yrs 3 
Education  
   High school/vocational 35 
   University 35 
   Post-Graduate 31 
Employment  
   Working full-time 67 
   Working part-time 9 
   Unemployed 10 
   Retired 5 
   Student 9 
   No response given 1 
Relationship Status  
   Married 36 
   In a relationship 16 
   Single 24 
   Never been in a relationship 23 
   Divorced 1 
   No response given 1 
Children 
     none 75 
     biologic children 8 
     adopted children 18 
Treatment n (%) 
testosterone (ever) 98 
fertility treatment* 37 
     single/never been in a   
        relationship 
8/37 (22%) 
     no children 14/29 (48%) 
     adopted children 7/29 (24%) 
     biological children 8/29 (28%) 
*gonadotropin therapy or pulsatile GnRH  
 
 
 
 
 
Table 2.  
Themes and representative quotes arising from focus group discussions 
  
Theme Representative quotes 
Feeling left 
behind (isolation) 
 
• "I was diagnosed at 23.  So, that’s why I say I 'missed out' on that 17-20 (years of age) physical and emotional development. I think that 
is where people miss-out on a lot... and not being able to catch up" 
 
• "...watching your sisters, your younger sisters and younger cousins and watching them pass you while you are left behind right now is 
still emotionally traumatic.  It’s just the little stuff like that... it all builds" 
 
• "I was dependent on a nurse who injected my treatment twice a week, and people all around  me experiencing their young adult 
life...independence from parents, sentimental and sexual relationships, a night out... all that discovery was out of reach for me for unfair 
reasons" 
 
Fear of being 
exposed 
 
• "Fear of exposure was the biggest thing for me… especially when I was younger in middle school and through high school.  I was afraid 
to go into the bathroom and pee in the urinal" 
  
• "(around 15 years-old) I was forced to take gym class and I feared that I would be noticed. I knew I would be ridiculed mercilessly if 
anyone found out. I vowed that I would not use the shower after gym class no matter what" 
 
• "(communal showers) it was like doing anything to get out of a shower... I would try anything.  In fact, I would just come out of the gym 
and just not shower.  You know, just put my clothes on over my gym shorts and stuff like that. But it’s that…fear of exposure" 
 
• "I would purposefully forget (gym clothes) so I wouldn’t have to take physical education so I wouldn’t have to shower.  And the teacher 
would go to the lost property and find a spare  and try to force me to wear it so that I could take part. So, I would be in detention…god 
knows how many times" 
 
Hiding 
 
• "(during teen years) I was doing my best to remain as inconspicuous as possible and not have my condition discovered… nothing else 
mattered" 
 
• "You spend so much of your adolescence and your late teens, 20s hiding stuff. You are hiding the fact that you can’t smell, you are kind 
of covering over that, you are hiding that you don’t want to shower, it’s just so much hiding that there’s almost an emotional reticence.  
And, I think that translates into relationships too" 
 
• "For me it has been shame. Yeah, that has been the hardest part. And so... I kind of isolated myself, staying indoors, and that has led to a 
kind of social anxiety. So, I don’t really have any friends really…that’s given the most impact on my life" 
 
Body shame/ 
poor body image 
 
• "I haven’t been intimate with anyone in over 10 years.  I don’t have any friends, I don’t have a girlfriend…I have kind of accepted that I 
won’t have any girlfriends or friends.  I’m just ashamed of my body" 
 
• "(regarding dating) you think down the road and wonder if this eventually goes anywhere... I don’t want to undress in front of this 
person" 
 
 
 
  
Body shame/ 
poor body image 
 
• "My biggest thing was about having Kallmann’s (CHH) was genital size. That’s the only thing that was affected…and been an issue.  
Which I know is very superficial and is probably a bit silly, but that’s me.  It’s always sort of there, you’re always sort of consciously  
 
• aware of it" 
 
• "There’s extreme shame about having small genitalia…it’s just extreme for me"   
• "we are probably hung a bit less-well than most people.  It can be a bit…you know, if a woman…if you drop your trousers and a woman 
bursts out laughing, it’s just devastating.  What do you do?" 
 
• "I was always ashamed of that stuff (body & gynecomastia).  It was insidious, sometimes I was seen as a girl…you know, is that a boy 
or a girl?" 
 
Low self-esteem 
 
• "I felt ashamed really… I withdrew from it, from everything really.  So, it’s the same I don’t really have any friends really, not a lot of 
social contact or anything like that" 
 
• "It (CHH) is always with me... very, very low self-esteem, massively low confidence…you know, I have done all the educational stuff, 
I’ve got a good job.  Even after 20+ years with the same company, my confidence level at my work is still very, very low.  I tend to 
mask it sometimes, in that sort of situation but in reality, I’m in quite a fragile state…it doesn’t take much to sort of push me down" 
 
• "For a long time even after starting treatment,I knew I was physically as normal as a man can be...(but) I was unable to seduce a 
woman... very difficult to deal with the potential rejection... still thinking she would see a kid who should not do what he is doing. I had 
a total lack of confidence in this aspect of my life" 
 
Lingering effects 
 
• "All of those things are seeds for psychological damage. I mean the stuff occurring at that stage builds up and builds up and builds up 
over the years…it lingers for sure" 
 
• "You may have all the outward appearances (of puberty), but here (pointing to head)… as far as I’m concerned, I’m still different.  It’s 
almost as though one day, someone is going to see right through it, and they’ll know…it’s that fear." 
 
• "Basically as a Kallmann (CHH) patient I spent most of my early adult life building barriers and walls to others to avoid being 
emotionally hurt and keep mental sanity.  It worked... but later on in my life, these survival skills were totally irrelevant and became the 
main problem" 
 
• "I still have a hard time with public nudity... I wouldn’t join a gym that had an open shower... so like there are even these lingering 
psychological that affect me even today but they are not as severe as when I was younger" 
 
• "I’m wondering is if we have some overlap with a PTSD (post traumatic stress disorder), there might be some things that are still things 
that will trigger flashbacks" 
 
• "I was forever looking back at as far as I could see... a lost 16 years. As I’ve grown older, it’s not just the 16 years. There’s actually a lot, 
lot more than that. The older I get, the focus is perhaps not on looking back but looking forward. And that…is just as negative for me 
sometimes as it is looking back. As far as I’m concerned, it never, ever leaves me…" 
 
  
Mediating factors 
 
• "I have found the groups on Facebook and that, you know... starting to talk to people.  That’s the only thing that has really helped me so 
far for coming to terms with it (CHH)" 
 
• "It wasn’t until I found other people like (patient community leader) and such that I kind of filled in the blanks a bit. It was quite 
isolating for me and I had no one to talk to and I felt like I was the only person in the world to have this problem you know?" 
 
• "The two major things for me have been having somebody love me and not see as no different from any other man…and this, meeting 
other people face to face, being able to talk and email people and just... you know…(other patient) has been exceptionally caring to me" 
 
• "When I was in my teens and 20s it was harder... it does get a little easier, but still there’s a lot of emotional scars" 
 
• "It’s like, you can answer those questions(for young CHH patients) and say: look, it’s going to be tough for a couple of years…but, you 
know, it’s going to get better" 
 
• "Learning about it (CHH) made me feel that Kallmann (CHH) is not such a big deal.  But in my case, it was not enough and the 
psychotherapy aspect helped a lot... I’m not sure I’d be as satisfied without" 
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Figure 1. Focus group themes related to the impact of disrupted sexual maturation on 
psychosexual development and intimate relationships. 
Figure Legend: (A) focus group participants reported feeling isolated and “left behind” as 
peers underwent sexual development, started dating, and began taking on more adult roles. 
(B) patients often developed fear and anxiety about being exposed and tried to hide their lack 
of sexual development as a coping response. (C) body shame and body image concerns were 
the most frequently cited issues which co-occurred with low self-esteem. These issues 
interacted with existing fears/anxiety creating a cyclic pattern with effects lasting far after 
treatment initiation. Circles depict themes from focus group discussions, circles are sized 
proportionally with the number of references, overlapping circles depict co-occurring themes 
and interactions are noted by arrows.  
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Chapter V: Discussion 
Rare diseases can be characterized as conditions with low prevalence and high complexity.  
And while individually infrequent, collectively the estimated 5,000-8,000 rare diseases have a 
large cumulative effect - impacting approximately 30 million Europeans (van Weely & 
Leufkens, 2004). As described in the EURORDIS report (EURORDIS, 2009), patients with 
rare diseases face a number of challenges that place them in the realm of health inequities 
(Holtzclaw Williams, 2011).  These so called orphan diseases are often neglected and thus, 
there was little available data on adherence in CHH patient populations, the psychosocial 
impact of this rare endocrine disorder, or the unmet health and informational needs of this 
patient population. This was the impetus for this nursing needs assessment study with the 
ultimate goal of identifying targets for nursing and interdisciplinary interventions to meet 
shortfalls in care for these patients. The three publications presented in the results chapter 
address each of the four specific aims. However, that does not capture the full picture of this 
project as this thesis contributes to nursing knowledge in several important ways.  
 
Identifying unmet health and informational needs of CHH men 
Rare diseases such as CHH are chronic health conditions and require lifelong treatment.  
However, adherence to treatment is a significant challenge for managing chronic diseases 
(Osterberg & Blaschke, 2005) yet combing the CHH literature identified only two reports 
with a combined 41 subjects suggesting that one quarter to one third of CHH patients have 
problems with adherence (Huffer et al., 1964; Laitinen et al. 2012).  Herein, this study 
demonstrates the extent of adherence problems is much larger - only approximately 25% of 
CHH men have high levels of adherence and the vast majority struggle with adherence to 
long-term treatment.  These data identify adherence as a significant barrier for effective long-
term disease management.  Subsequently, we conducted focus groups (utilizing the HPM 
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framework as a guiding theory) and identified modifiable patient-reported barriers to 
adherence that are targets for nursing interventions. 
 
It has been documented in the literature that both depression and patients’ perceptions of their 
condition can have significant impact on adherence (Ciechanowski et al., 2000; Kucukarslan, 
2012; Lin et al., 2004).  Accordingly, we examined these characteristics as correlates of 
adherence and show that CHH men have significant negative 
psychosocial/psychological/psychosexual consequences from CHH.  These data should spark 
renewed attention as they provide evidence of persisting psychological impact that is not 
ameliorated by long-term hormone replacement therapy.  CHH has been previously been used 
as a unique human disease model providing important insights into the hormonal control of 
the hypothalamic-pituitary-gonadal axis (Pitteloud et al., 2008a, 2008b) as well as the 
molecular control of human puberty and reproduction (Balasubramanian et al., 2010; Bianco 
& Kaiser, 2009; Sykiotis, Pitteloud, Seminara, Kaiser, & Crowley, 2010).  However, there are 
scant data on how the severe disruption of puberty impacts patients and how they cope with 
CHH. Indeed the 3 descriptive reports from the past 50 years (Bobrow et al., 1971; Huffer et 
al., 1964; Huisman et al., 1996) have included few patients (8, 13, and 8 respectively) and 
lacked validated measures.  Two reports utilizing previously validated instruments focused 
exclusively on patient at the time of diagnosis (Aydogan et al, 2012; Lasaite et al., 2013).  
Therefore, this study contributes a nursing perspective to a gap in the literature that has direct 
relevance for developing interventions aimed at improving health outcomes and quality of life 
for these dispersed rare disease patients.   
 
158 
 
New application of the Health Promotion Model  
This project, and the resulting manuscripts, point to possibilities for using Pender’s HPM 
model for understanding medication adherence in chronic disease. Indeed, the only link 
between adherence and the HPM comes from a single report (case study) from 1997 that 
pointed to Pender’s model as a possible framework for understanding adherence to 
anticonvulsant therapy among patients with epilepsy (Lannon, 1997). We demonstrate how 
the HPM can be used to dissect factors mediating medication adherence in chronic conditions 
and identifying targets for nursing sensitive interventions (Aims 1-4, see above Article n°2). 
Thus, the present study adds to the theoretical base of nursing practice by expanding the use 
of Pender’s HPM. 
 
The HPM has not previously been applied to rare disease patients - yet is has been put forth as 
a model for patient empowerment in diabetes (Ho et al., 2010).  As delineated in the 
background, empowerment is a critical issue for rare disease communities (Ayme et al., 
2008).  Accordingly, these points suggested that the HPM could hold relevance for examining 
CHH men. Herein we provide supporting evidence that the HPM is indeed a useful middle-
range theory that can be applied to a rare disease patient population - thus expanding 
applicability and adding to its theoretical robustness as a model for nursing. Future directions 
for this project will include drafting a manuscript focusing on the theoretical aspects of the 
HPM and novel applications for nursing research.  
 
Innovative partnerships to reach dispersed and isolated patients 
Another contribution of this thesis is that it adds to the evolving ways in which nursing 
research engages with patients, families, and promotes action for improved health and 
wellness within communities. Patients with rare diseases such as CHH, face a variety of 
159 
 
challenges that place them in the realm of heath inequities (Holtzclaw Williams, 2011) and 
empowerment is a critical factor for such patients (Ayme et al., 2008). We recognized patient 
expertise and developed partnerships with key patient advocates/community leaders to engage 
them as stakeholders in the research process. Indeed, such a community based participatory 
framework has previously been useful for empowering patients to overcome health inequities 
(Wallerstein & Duran, 2006). These partnerships included these expert patients as true 
collaborators in the process who made integral contributions throughout: from planning and 
development, to recruitment and conduct, to discussion of results and implications for future 
directions. As such, it is an example of how community engagement can be used not only as a 
research approach but also as a nursing intervention enabling participants to surmount health 
inequities. 
 
Using technology to extend the reach of nursing care 
By definition, patients with rare diseases are dispersed. However, advances in information and 
communication technology now make it possible to reach such dispersed individuals. Further, 
rare disease patients, such as the CHH described herein are highly active internet users. This 
interconnectivity provides new opportunities for healthcare delivery to connect patients with 
specialists as well as for peer-to-peer support. Such patient expertise and communities of 
knowledge can be drawn upon for crowdsourcing solutions in managing and coping with rare 
conditions.  
 
This study demonstrates how nursing can leverage technology to extend its reach. This is 
particularly relevant and timely as demographic changes are challenging nursing to meet 
patient needs in an evolving and increasingly complex healthcare delivery system (Institute of 
Medicine (IOM), 2101). Technology will likely become increasingly important for nursing to 
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meet the needs of ever-growing numbers of chronic disease patients in the face of nursing 
shortages. This may result in technology being employed to monitor and treat patients. As this 
“high-tech” trend continues, there is a need to maintain what has been a critical aspect of 
nursing since the era of Florence Nightingale, i.e. care. It will be increasingly important for 
nursing to identify ways to combine the high-tech with the “high-touch” that has been so 
closely connected with nursing’s role.  
 
This study serves as a proof of principle to demonstrate how partnerships with stakeholders 
(expert patients) and leveraging technology can be combined to reach a large cohort of widely 
dispersed rare disease patients. In this mixed methods study we collected survey information 
from a large cohort of CHH men using a high-tech approach while qualitative focus groups 
(held in concert with patient support meetings) contributed a high-touch element. This mixed-
methods approach grew from an initial patient support meeting three years ago organized by 
patient advocate Mr. Neil Smith. The stories shared that afternoon and the resulting positive 
patient responses following the meeting was the seed from which this high tech-touch project 
grew. Importantly, beyond the scientific impact of any resulting publications, this project and 
the patient support meeting/patient focus groups have had significant impact on human capital 
of the participants.  
Though I have a loving family I had spent 64 years of my life feeling depressed, 
confused, lonely, alone, isolated, and frequently in despair. In just a couple of 
hours at the meeting 3 years ago in London those feelings decreased. For the 
first time ever I was with a group of people with whom I felt normal and at 
ease, valued and respected. This has made a tremendous difference in my life 
and I am very grateful. I am indebted to you. Thank you. 
 
This project therefore supports the notion that nursing can take a leading role in developing 
innovative healthcare delivery models to bridge existing shortfalls in care. Future directions 
and application of these nursing research findings include developing tailored online (e-
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health) interventions. These nursing interventions combined with peer-to-peer support will 
focus on patient empowerment and activating individuals for enhanced self-care and wellness. 
 
 Conclusion 
This thesis demonstrates that partnerships with patient community leader and utilizing web-
based recruitment and data collection was an effective means to reach a large audience of 
dispersed rare disease (CHH) patients. Such an approach introduces potential bias as not 
everyone has internet access, and indeed this approach appears to be enriched with well-
educated men.  Further, one must account for a response bias of more proactive and/or more 
severely affected patients and take into account that as the online survey was in English 
responses may reflect a cultural Anglophone bias.  For example, in discussing the results with 
the community leaders one online group moderators reflected that from their experience, 
fertility is a more frequent concern among those from Latin cultures.  Therefore, these study 
findings should be interpreted in light of these limitations and should not be viewed as 
universal truths that can be generalized to all men with CHH.   
 
The validity of the study findings were strengthened by several factors.  First, for the 
qualitative survey, healthcare literacy, illness perceptions, depressive symptoms and 
medication adherence were assessed using previously validated instruments.  For some 
aspects of hypogonadism (such as sexual/intimate life) where no CHH-validated instrument 
exists (Langham et al., 2008), we developed our own questions. Importantly, involving expert 
patients and utilizing a mixed-methods approach both helped contribute to the external 
validity of the study findings.  First we sought face validity via input from patient advocates, 
yet a full validation process was not performed. Secondly, survey findings were explored in 
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the context of the patient focus group discussions corroborating the survey findings.  Thus, 
one may be reasonably confident in the validity of the results.  
 
A critical aspect of the nursing research process is the translational step of applying research 
findings (Chesla, 2008).  Barriers to implementation slow this process and impede the transfer 
of findings and their application to improve healthcare (Crowley & Gusella, 2009).  The next 
steps for this project will focus on this translational process.  First, as pointed to in article °1 
and °2, there is a need for patients to have access to information about their condition, 
treatment options, anticipatory guidance regarding treatment and links to reach clinical 
experts as well as for peer-to-peer support.  As part of an international network of clinical 
investigators, basic researchers, geneticists, bioinformaticians, clinicians, nurses and patient 
advocates (COST Action BM1105), launching such information on the Action website seems 
like a logical, practical, and achievable translational objective.  Second, as described in article 
°1, developing a talking sheet for patients to discuss concerns with their healthcare provider is 
a tangible patient-centered nursing intervention promoting shared decision-making.  
Providing such information openly on web-based platforms in multiple languages will help 
overcome some of the implementation based roadblocks.  Third, subsequent steps for practice 
include reaching out to nursing colleagues and sharing this approach as a means by which 
nursing, or even an individual nurse, can impact the health and wellness of a dispersed rare 
disease patient population. 
Future research directions could include several follow up projects.  First, it would be 
interesting to evaluate a similarly sized cohort of female CHH subjects to see how similar or 
differently results are across gender.  Presumably altered puberty would affect males and 
females differently, yet this is hypothetical at this point and examining similar questions 
among female patients could point to   specific gender-based needs. Second, I believe it will 
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be important to move beyond the descriptive aspects of the present study to develop an 
interventional study.  Some have described nursing as a complex intervention (Richards & 
Borglin, 2011) and I envision a subsequent step would be to develop an interventional study 
for CHH patients that would draw upon expertise from complementary fields including 
nursing, psychology and medicine.  More specifically, one could imagine  delivering complex 
interventions  such as online tailored cognitive behavioral therapy (CBT) interventions 
(Andersson, Ljotsson, & Weise, 2011) paired with professional and/or peer-to-peer support.  
Such online CBT interventions have proven effective for treating anxiety and depression 
(Andersson & Titov, 2014; Mayo-Wilson & Montgomery, 2013).  Such complex, web-based 
interventions could hold promise for addressing the depressive symptoms, low self-esteem, 
and body image concerns in these dispersed CHH men. 
 
These next steps and future directions in both the clinical and research domains underscore 
that nursing is not solely focused on alleviating illness and suffering but is also focused on the 
patient’s reaction to illness. This holistic, patient-centered view is a central aspect of nursing’s 
contribution to healthcare.   
I believe that to meet the emerging healthcare challenges, nurses at all level must move 
beyond health education activities and work collaboratively in interdisciplinary teams to 
develop complex interventions for behavior change to promote enhanced health outcomes, 
wellness, and quality of life for patients.  
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Appendix 3: Questions relating to demographics and past experiences with healthcare 
Please answer the following questions about yourself: 
1. Gender:  Male  Female 
2. Age: ____ years 
3. Highest level of education:  
  elementary    high school/vocational    university    post-graduate  
4. How confident are you filling out medical forms by yourself? 
   extremely    quite a bit    somewhat    a little bit    not at all      
5. Employment:  
   student   working part-time   working full-time   retired   unemployed 
6. Type of employment: ______________________ 
7. Religion:_____________________________  none   
8. What is your relationship status?  
   single   in a relationship   married   divorced  
9. Do you have children?  
   no   yes, biologic children   yes, adopted children  
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Appendix 4: Questions relating to experiences with healthcare 
 
We would like to know a little about when you were diagnosed with hypogonadotropic 
hypogonadism or Kallmann syndrome (we will call this CHH for congenital 
hypogonadotropic hypogonadism) and your past experiences with the healthcare system. 
Please answer the following questions:  
  
1. How old were you when you were diagnosed with CHH? ______ years 
 
2. Is there anyone else with CHH in your family?  
  No   Yes If yes, how are they related to you?_________________________ 
 
3. How old were you when you started treatment (i.e. testosterone or gonadotropin/fertility 
injections)  
  to induce puberty? ______ years 
 
4. What treatments have you had for this (please check all that apply)?  
   none      testosterone (injections, patches or gel)   
   other _____________  gonadotropin/fertility injections   
 
5. Have you ever had a consultation or received treatment at an academic health center (such 
as a teaching hospital or research center)?   No   Yes 
 
6. Have you ever had genetic testing?  No   Yes 
 
7. Have you ever had genetic counseling?  No   Yes 
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8. Where have you searched for information to learn about CHH? (check all that apply) 
 internet (i.e. Wikipedia)       online community (social media/chat)   
 family/friends                   medical literature          
 healthcare professionals            Other:______________ 
 
9. From your experience, please rate the 3 most important sources:  
  __ internet (i.e. widkipedia)   
__ medical literature   
__ online community (social media/chat)  
   __ healthcare professionals   
__ family/friends     
__ other:__________  
 
10.Within the healthcare system, have you ever experienced discrimination because of CHH?   
No   Yes 
 
11. Is there a healthcare provider (i.e. doctor or nurse) who you feel really understands the 
medical aspects of your CHH?  No  Yes 
 
12. Is there a healthcare provider (i.e. doctor or nurse) who you feel understands your feelings 
about  having CHH?   No   Yes 
 
13. Have you ever sought professional counseling or therapy for issues related to CHH? 
  No   Yes 
 
14. Has a healthcare provider (either general practitioner or specialist) ever offered you 
counseling or a referral for professional counseling?   No   Yes 
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Appendix 5: Illness Perception Questionnaire- Revised  
 
We are interested in your personal views about CHH. Please indicate how much you agree or 
disagree with the following statements about CHH.  
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  strongly 
disagree 
disagree neither 
agree nor 
disagree 
agree strongly 
agree 
IP1 My CHH will last a short time      
IP2 My CHH is likely to be permanent rather than 
temporary 
     
IP3 My CHH will last for a long time      
IP4 My CHH will pass quickly      
IP5 I expect to have CHH for the rest of my life      
IP6 CHH is a serious condition      
IP7 CHH has major consequences on my life      
IP8 CHH does not have much effect on my life      
IP9 My CHH strongly affects the way others see me      
IP10 My CHH has serious financial consequences      
IP11 My CHH causes difficulties for those who                       
are close to me 
     
IP12 There is a lot that I can do to control my symptoms      
IP13 What I do can determine if my CHH gets                      
better or worse 
     
IP14 The course of my CHH depends on me      
IP15 Nothing I do will affect my illness      
IP16 I have the power to affect my CHH      
IP17 My actions will have no effect on the outcome                   
of my CHH 
     
IP18 My CHH will improve with time      
IP19 There is little that can be done to improve my CHH      
IP20 My treatment will be effective in curing my CHH      
IP21 The negative effects of CHH can be 
prevented/avoided by my treatment 
     
IP22 My treatment can control my illness       
IP23 There is nothing which can help my condition      
IP24 The symptoms of my CHH are puzzling to me      
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  strongly 
disagree 
disagree neither 
agree nor 
disagree 
agree strongly 
agree 
IP25 My CHH is a mystery to me      
IP26 I don't understand my CHH      
IP27 My CHH doesn't make any sense to me      
IP28 I have a clear picture/understanding of my CHH      
IP29 My CHH  symptoms change a great deal from                     
day to day 
     
IP30 My symptoms come and go in cycles      
IP31 My CHH is very unpredictable      
IP32 I go through cycles in which my CHH gets                                    
better and worse 
     
IP33 I get depressed when I think about my CHH      
IP34 When I think about my CHH I get upset      
IP35 My CHH makes me angry      
IP36 My CHH does not worry me      
IP37 Having CHH makes me feel anxious      
IP38 My CHH makes me feel afraid      
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Appendix 6: Questions regarding body image and sexuality 
 
We would like to ask you a few questions to better understand how your CHH has affected 
your body image and your sexuality. This confidential information will help us better 
understand how we can help patients in these parts of their lives. If you are uncomfortable 
answering these questions you may skip to the next section. 
 
1. Are you, or have you ever been concerned, embarrassed or ashamed of your body?  
 (i.e. avoiding situations that involve undressing in public places such as the gym or beach) 
    No   Yes   prefer not to respond 
 
2. Have you ever been teased or ridiculed because of CHH? 
    No   Yes   prefer not to respond 
 
3. Are intimate relationships difficult because of CHH?  
    No   Yes   prefer not to respond 
 
 4. Have you ever been sexually active?  
    No   Yes   prefer not to respond 
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Appendix 7: Questions regarding adherence (Morisky Medication Adherence Scale) 
Many people have difficulty taking their medication. We are interested in your experiences. 
There is no right or wrong answer. Please answer each question based on your personal 
experience with your medication for CHH. 
            
1. Do you sometimes forget to take your CHH medication?     NO      YES   
 
2. People sometimes miss taking their medications for reasons other than forgetting. Thinking 
over the past two weeks, were there any times when you did not take your CHH medicine?     
NO      YES   
 
3. Have you ever cut back or stopped taking your medication without telling your doctor, 
because you felt worse when you took it?     NO      YES   
 
4. When you travel or leave home, do you sometimes forget to bring along your CHH 
medication?     NO      YES   
 
5. Did you take your CHH medicine yesterday (or the last time you were due to take it)?  
     NO      YES   
 
6. When you feel like your CHH is under control, do you sometimes stop taking your 
medicine?     NO      YES   
 
7. Taking medication is a real inconvenience for some people. Do you ever feel hassled about 
sticking to your CHH treatment plan?     NO      YES   
 
8. How often do you have difficulty remembering to take all your medications?  
  Never/Rarely     Once in a while      Sometimes      Usually      All the time 
 
9. Please estimate the longest period of time that you have gone without medical care (not 
under the care of a doctor or healthcare provider for your CHH): 
 __________  months   years  
 
10. Please estimate the longest period of time that you have been off your CHH medication 
(not at the instruction of your doctor or healthcare provider): 
  __________  months   years  
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Appendix 8: Questions regarding depressive symptoms (Zung Self-Rating Depressive Scale) 
For each item please choose the response that best describes how often you felt of behaved 
this way during the past several days.             
                                                                        A little of     Some of     Good part     Most of  
                                                                          the time       the time    of the time     the time 
1. I feel down-hearted and blue.          
    
2. Morning is when I feel best.           
3. I have crying spells or feel like it.              
4. I have trouble sleeping at night.              
5. I eat as much as I used to.              
6. I still enjoy sex.              
7. I notice that I am losing weight.              
8. I have trouble with constipations.              
9. My heart beats faster than usual.              
10. I get tired for no reason.              
11. My mind is as clear as it used to be.              
12. I find it easy to do the things I used to do.              
13. I am restless and can’t keep still.              
14. I am hopeful for the future.              
15. I am more irritable than usual.               
16. I find it easy to make decisions.              
17. I feel that I am useful and needed.              
18. My life is pretty full.               
19. I feel that others would be better off 
      if I were dead.                
20. I still enjoy the things I used to do.                 
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Appendix 9: Questions for patient focus group discussions 
The online survey and discussions with patient community leaders identified 3 main areas that 
were explored during focus group discussions within the construct of the Pender HPM:  
1. Challenges of living with CHH and aspects of coping and support: 
• What has been the most difficult part of living with CHH? Are there positive aspects 
to having CHH?  
• How has CHH impacted your life? What helps you cope with having CHH?  
• Who do you get support form for dealing with your CHH? Do you find it difficult to 
talk to people about CHH? Who have you told about your CHH? 
• What words of advice and encouragement would you give to a young man who has 
just found out he has CHH? What do you wish someone would have told you? 
2. Impact of CHH on intimate and sexual life: 
• How has CHH affected your sex life and intimate relationships?  
3. Aspects related to adherence to treatment: 
• CHH is a chronic condition and it is often hard to stick with treatment and keep 
appointments over time. Have you had periods when you were off treatment? 
• How do you feel when you are on/off treatment? 
• What do you think are the 3 most important things you need to do for your health 
related to CHH? What things prevent you from doing those things?  
• What do you think the benefits are to you in treating your CHH? 
• What are the things that keep you from sticking with your medication?  What are the 
things which help you staying on treatment?  
• Do you feel in control of your CHH medication? Do you administer your own CHH 
medication? Would you like to? Are there things that prevent you from self-
administering your CHH medication? 
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